

BMJ Open

Placebo effects in trials evaluating 12 selected minimally invasive interventions: a systematic review and meta-analysis.

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-007331
Article Type:	Research
Date Submitted by the Author:	29-Nov-2014
Complete List of Authors:	HOLTEDAHL, ROBIN; Fram Rehabilitation Centre, Tjomsland, Ole; South-Eastern Norway Regional Health Authority, Division of Quality and Specialist Areas Brox, Jens; Oslo University Hospital, Orthopaedic
Primary Subject Heading:	Evidence based practice
Secondary Subject Heading:	Evidence based practice, Ethics, Research methods, Surgery
Keywords:	Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Health economics < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Clinical trials < THERAPEUTICS, MEDICAL ETHICS, PAIN MANAGEMENT

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8 **Placebo effects in trials evaluating 12 selected minimally**
9 **invasive interventions: a systematic review and meta-**
10 **analysis.**

11 Robin Holtedahl, Jens Ivar Brox, Ole Tjomsland

12
13
14 Fram Rehabilitation Centre, Rykkinveien 100, 1349 Rykkin,
15 Norway Robin Holtedahl Consultant Department of Physical
16 Medicine and Rehabilitation, Oslo University Hospital, Box
17 4956 Nydalen, 0424 Oslo, Norway Jens Ivar Brox Professor
18 South-Eastern Norway Regional Health Authority,
19 PB 404, 2303 Hamar, Norway Ole Tjomsland Director of Quality
20 and Specialist Areas

21
22 Correspondence to: Dr Robin Holtedahl; robi-hol@online,
23 telephone +4790248973

24 **Key words:**

25 Placebo effects
26 Invasive procedures
27 Biomedical ethics
28 Evidence based health care
29

30 **Word count:** 3783
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Objectives To analyse the impact of placebo effects on outcome in trials of selected minimally invasive procedures, and to assess reported adverse events in both trial arms.

Design A systematic review and meta-analysis.

Data Sources and Study Selection We searched MEDLINE and Cochrane library to identify systematic reviews of musculoskeletal, neurological and cardiac conditions published between January 2009 and January 2014 comparing selected minimally invasive with placebo (sham) procedures. We searched MEDLINE for additional randomised controlled trials published between January 2000 and January 2014.

Data synthesis Effect sizes (ES) in the active and placebo arms in the trials' primary and pooled secondary endpoints were calculated. Linear regression was used to analyse the association between endpoints in the active and sham groups. Reported adverse events in both trial arms were registered.

Results We included 21 trials involving 2519 adult participants. For primary endpoints, there was a large clinical effect ($ES \geq 0.8$) after active treatment in 12 trials and after sham procedures in 11 trials. For secondary endpoints, seven and five trials showed a large clinical effect, respectively. Three trials showed a moderate difference in ES between active treatment and sham on primary endpoints ($ES \geq 0.5$) but no trials reported a large difference. No trials showed large or moderate differences in ES on pooled secondary endpoints. Regression analysis of endpoints in active treatment and sham arms estimated an R^2 of 0.78 for primary and 0.84 for secondary endpoints. Adverse events after sham were in most cases minor and of short duration.

Conclusion The generally small differences in effect size between active treatment and sham suggest that non-specific mechanisms, including placebo, are major predictors of the observed effects. Adverse events related to sham procedures were mainly minor and short-lived. Ethical arguments frequently raised against sham-controlled trials were generally not substantiated.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

3

SUMMARY

Key messages

- The magnitude of change in the active treatment- and placebo arms varied greatly, but about 80% of the variance in effect size of active treatment could be predicted by placebo effects, regression to the mean or spontaneous improvement.
- Adverse events related to sham procedures were mainly minor and short-lived, and frequently outweighed by positive placebo effects.

Strengths and limitations

- Selection of trials with low risk of bias
- Calculation of effect sizes on primary and pooled secondary endpoints in both active treatment and sham arms.
- Heterogeneous interventions, outcome measures and timing of assessment.

1

INTRODUCTION

It is normally assumed that medical practices are based on firm clinical evidence, and that new practices or techniques are introduced when superiority, or at least non-inferiority, has been demonstrated compared to established treatments. However, medical history reveals numerous examples contradicting this assumption. Forty-two percent of 146 medical practices were found to be reversed in a recent review analysing 10 years of publication in a high-impact medical journal.¹ Large effects of an intervention in initial reports are often spurious findings, while the vast majority may represent substantial overestimations.²

Even though surgical and other invasive techniques generally have reached a high degree of sophistication through the last decades, not all invasive procedures have lived up to expectations. Promising results in initial observational studies have in some cases led to widespread clinical implementation, in spite of lack of documented effectiveness.³ The reluctance to abandon contradicted medical practice is commonly ascribed to both culturally embedded medical practices and different forms of vested interests.^{4,5} The continuation of unnecessary and potentially harmful interventions leads to major costs for both patients and society.

The randomised placebo-controlled trial is considered the gold standard for evaluating the effects of pharmacological treatments. However, there are relatively few controlled studies in peer-reviewed surgical journals, and even fewer placebo (sham)-controlled studies.⁶⁻⁸ Ethical concerns raised by the potential for harm to participants are usually cited as the main obstacle to sham-controlled studies.⁹ Problems of a practical nature relate to patient blinding, differing technical expertise, the heterogeneity of the interventional techniques and variable outcome specifications, making standardisation difficult to achieve.¹⁰

A meaningful effect in clinical trials may result from a large effect in the active treatment group, a small effect in the placebo group, or a combination. Even though a placebo effect has been documented in a range of clinical conditions, there are few studies assessing the magnitude of the placebo effect in surgical procedures. In the present study, we analysed placebo-controlled trials of minimally invasive interventions in musculoskeletal, neurological and cardiac conditions. The aims were threefold: (a) to assess the magnitude of change in outcome from baseline to trial endpoint in both the active treatment and placebo (sham) arms, (b) to explore the contribution of non-specific factors, including placebo, to the outcome of active treatment, and (c) to assess the level of reported adverse effects in both trial arms.

METHODS

Search strategy and selection criteria

We first conducted electronic searches for randomised placebo-controlled trials of minimally invasive interventions for cardiac, neurological and selected musculoskeletal conditions, using MEDLINE and Cochrane library to identify systematic reviews published between January 2009 and January 2014. We defined minimally invasive procedures as interventions involving the introduction of a medical device, substance or other foreign material into the body through a cannula, catheter or arthroscope, thereby minimising damage to biological tissues at the point of entrance. We excluded open surgical and laparoscopic interventions. Where applicable, we used the “core clinical journals” filter in PubMed, which is an index of journals particularly relevant to practicing physicians. From the reviews, we selected randomised placebo-controlled trials published from January 2000 to January 2014 that according to the review fulfilled at least four of the following methodological criteria: random allocation, allocation concealment, blinding of participant, blinding of assessor and intention-to-treat analysis. We chose these criteria both because they were the most commonly used in the selected reviews, and because use of scales for assessing quality or risk of bias is explicitly discouraged in Cochrane reviews¹¹. Two of the authors (RH and JIB) independently assessed the five methodological criteria in the RCTs included from systematic reviews.

We next searched MEDLINE for additional randomised placebo-controlled trials published between January 2000 and January 2014. Two of the reviewers (OT and JIB) independently assessed the five criteria mentioned above in the additional RCTs that were identified from this search.

Only English language journals were included. We excluded crossover trials, trials that did not report results as means, standard deviation, standard error or confidence intervals in both active and sham-groups, as well as trials with only graphic representation of data. Details of the search strategy are shown in web appendix table 1 and web appendix figure 1. We give a short description of each procedure’s introduction, therapeutic rationale and history in web appendix table 2. This review is reported in accordance with the PRISMA statement.¹²

Data extraction

We registered all continuous primary endpoints. In trials without continuous primary endpoints, with multiple endpoints or no defined primary endpoint, we selected an outcome related to pain or condition-specific endpoint. The heterogeneity of trials did not allow for use of pain as a primary outcome. We used the

RCTs' defined primary outcome to avoid bias introduced by choosing our own endpoint. We also registered secondary endpoints in order to avoid potential bias from selective reporting in the included trials. The included and excluded secondary endpoints are shown in web appendix table 3. Endpoints describing medication, radiographic or physiological variables, social or psychological function, were not included. For the Parkinson-trials, only endpoints in the off-medication state were registered. Results from the last follow-up until 12 months were extracted. The trials' protocol registration, funding source, description of sham intervention, sample size, disease duration, length of follow-up and reported adverse events in both trial arms were registered (tables 1 and 2).

Data synthesis

To assess clinically important change, we calculated effect size (ES, Cohen's d), based on the means and standard deviations (SD). We calculated ES both for the active and sham intervention to obtain information about the pre-to-post treatment change in both arms. Without first calculating ES of change in each trial arm, we would not be able to discern the relative contribution of placebo, which was one of the objectives of the study. Subtracting the average score after treatment from the average score before treatment and dividing the result by the average of the standard deviations before and after treatment calculated ES. An ES of 0.8 or more is assumed large, while an ES of 0.5 - 0.8 is considered moderate.¹³ In trials with multiple secondary endpoints we calculated the pooled mean ES, without weighting. Because of small sample sizes in most of the included trials, we calculated an adjusted ES in accordance with a recommended procedure.¹⁴ Unadjusted linear regression analyses were used to explore the association between outcome in the active and sham groups both for primary and pooled secondary endpoints. For this analysis, we used Medcalc Statistical Software version 12.7.4.0¹⁵

RESULTS

Selection of interventions

The searches provided sham-controlled trials of the following interventions: percutaneous laser revascularisation of myocardium for angina pectoris, closure of foramen ovale for migraine, arthroscopic meniscectomy for meniscal tears, debridement and injection of hyaluronic acid for symptomatic osteoarthritis of the knee and injection or transplantation of biologically active material for Parkinson's disease (human retinal pigmental cells, fetal nigral cells and Neurturin). Because of the large number of described interventions for neck- and back pain syndromes, we chose to restrict the analysis to sham-controlled trials of the following interventions: epidural injections of corticosteroids for sciatica

(caudal, interlaminar and transforaminal routes), percutaneous heating of the intervertebral disc for chronic low back pain (percutaneous intradiscal radiofrequency thermocoagulation and intradiscal electrothermal therapy) and vertebroplasty for vertebral body fractures. The searches provided no sham-controlled trials of arthroscopic procedures other than knee conditions.

Study selection

The study selection process is summarised in web appendix figure 1. Web appendix table 1 shows the excluded trials and the reasons for exclusion. The search provided five systematic reviews, all identified through searches in MEDLINE, none were commercially funded.¹⁶⁻²⁰ It identified a total of 71 clinical trials, twelve of them were not identified from the systematic reviews. Forty-four trials were excluded for methodological reasons, principally risk of bias. Six additional trials were excluded because ES could not be calculated.²¹⁻²⁶ Finally, 21 clinical trials with a total of 2519 participants were included in the present review (table 1). Trial interventions in active treatment and sham arms are also shown.

Author	Protocol approval / funding (commercial, non-commercial).	Invasive procedure / indication	Sham intervention	Adverse events related to procedure, active treatment	Adverse events related to procedure, sham
Leon 2005	Food and Drug Administration / NC	Percutaneous myocardial laser revascularization / intractable angina pectoris	Laser turned on but no procedure performed	MAE in hospital (high dose): 4.1%	MAE in hospital: 0
Salem 2004	Ethics committee / NC			No procedural AE	
Sihvonon 2013	Review board / NC	Arthroscopic partial meniscectomy / degenerate meniscal tear	Routine arthroscopy, simulation of meniscectomy by manipulation etc.	No MAE	mAE: 2.9%
Moseley 2002	Review Board / NC	Arthroscopic debridement / Knee osteoarthritis	Simulated arthroscopy preparation, intravenous anaesthesia, skin incisions, no instruments entered knee, knee manipulated	No procedural AE	
Pham 2004	Review Board /	Hyaluronic acid /	Intraarticular	No MAE	

	NC	Knee osteoarthritis	injection of saline solution	Any mAE: 81.7%	Any mAE: 1.2%
Altman 2004	Ethics committee / C			No MAE	
				mAE: 12.8%	mAE: 8%
Chevalier 2010	ClinicalTrials.org / C			No MAE	
				mAE: 35,8%	mAE: 33,8%
Kallmes 2009	Review Board / NC	Percutaneous vertebroplasty with PMMA cement	Conscious sedation + local anaesthesia, pressure put on spine, simulation of odor with mixing of PMMA to imitate the smell during the active procedure	No MAE	
				mAE: 14%	mAE: 16%
Buchbinder 2009	Ethics committee at each participating center / NC	injection / vertebral compression fracture	Conscious sedation + local anaesthesia, needle inserted to rest on the lamina, PMMA container opened to imitate the smell during the active procedure	No procedural AE	
Cohen 2012	Review Board / NC		2 ml sterile water at 1-2 injection sites, transforaminal approach	No MAE	
				mAE:36%	mAE: 20%
Arden 2005	Ethics committee / NC		2 mL saline into interspinous ligament	No MAE	
				mAE: 9%	mAE: 10%
Valat 2002	Ethics committee / NC	Epidural injection of corticosteroids / Sciatica	2 mL saline into epidural space, interlaminar approach	No MAE	
				mAE: 6%	mAE: 8%
Iversen 2011	Ethics committee / NC		Subcutaneous injection of 2 mL saline superficial to the sacral hiatus	Not reported	
Freeman 2005	Ethics committee / C	Intradiscal electrothermal therapy (IDET) / discogenic low back pain	17-gauge introducer needle inserted into disc under fluoroscopic guidance, catheter inserted but not connected to generator, both subject and surgeon blinded.	No MAE	
				mAE: 11%	mAE: 5%

Pauza 2003	Review Board / NC		17-gauge needle introduced onto the outer annulus, mock electrode passage shown on monitor, generator noises produced	Not reported	
Kvarstein 2009	Ethics committee / NC	Percutaneous intradiscal radiofrequency thermocoagulation (PIRFT) / discogenic low back pain	17-gauge canula and RF-probe inserted into annulus, no RF current applied	Not reported	
Olanow 2003	Review Board / NC	Fetal nigral transplantation, 4 donors / Parkinson's disease	Scalp incisions, partial thickness burr holes, no cell transplantation, 6 months low-dose cyclosporine	No MAE	
				mAE (rate/patient day): 0,66	mAE (rate/patient day): 0,39
Marks 2010	Review Board / C	Gene delivery of AAV2-Neurturin / Parkinson's disease	Scalp incisions, partial thickness burr holes, no intracranial injections	MAE: 4	MAE: 0
				Most frequent mAE: headache: 68%	Most frequent mAE: headache: 50%
Gross 2011	Review Board / C	Transplantation of human retinal pigmental cells / Parkinson's disease	Scalp incisions, partial thickness burr holes, no cell transplantation	1 death	0 deaths
				MAE: 23%	MAE: 0
LeWitt 2011	Review Board / C	Insertion of AAV-GAD gene into subthalamic nucleus / Parkinson's disease	Insertion of catheter caudal to nucleus, infusion of saline	No MAE	
				mAE (probably related to procedure): 56%	mAE (probably related to procedure): 14%
Dowson 2008	Ethics committee / C	Patent foramen ovale closure with STARFlex Septal Repair Implant / migraine	General anesthesia, skin incision in the groin	MAE (possibly or probably related to procedure): 11%	MAE (possibly or probably related to procedure): 4%
C=commercial; NC=non-commercial; MAE=major adverse events; mAE=minor adverse events; PMMA=polymethylmethacrylate; AAV2 =adeno-associated; GAD=glutamic acid decarboxylase					

Fourteen trials from the systematic reviews fulfilled at least four of the five methodological criteria.^{27 28 31-42} Seven trials provided through searches in MEDLINE fulfilled the same criteria.^{29 30 43-47} All trials reported approval of study protocol prior to patient enrolment (table 1). Eight trials were

commercially funded.^{32 33 41 44-47} Most of the trials had few participants, ranging from 20 to 346 (median 80).

Clinical outcomes after active treatment and sham

Twelve of the 21 trials showed a large ES on primary endpoints after active treatment, while 11 trials showed a similar ES after the sham procedure (figure 1, table 2).

Table 2. Effect size (ES) on primary and pooled secondary endpoints, showing differences between active treatment and sham arms.

Author / procedure	Limit disease duration / time to follow-up (months)	Trial arm / no of patients randomised	ES primary endpoint	ES pooled secondary endpoints (no of endpoints)
Leon 2005 / Percutaneous myocardial laser revascularization	None / 12		Exercise duration (s)	(10)
		Active / 98	0.23	0.60
		Sham / 102	0.22	0.54
ES active treatment vs sham			0.01	0.07
Salem 2004 / Percutaneous myocardial laser revascularization	None / 12		Exercise duration (s)	-
		Active / 40	0.04	
		Sham / 42	0.08	
ES active treatment vs sham			-0.04	
Sihvonen 2013 / Arthroscopic partial meniscectomy	>3 / 12		Lysholm knee score	(4)
		Active / 70	0.86	0.58
		Sham / 76	1.03	0.58
ES active treatment vs sham			-0.17	0.00
Moseley 2002 / Arthroscopic debridement	None / 12		Knee Specific Pain Scale	(5)
		Active / 59	0.54	0.11
		Sham / 60	0.85	0.20
ES active treatment vs sham			-0.31	-0.09
Pham 2004 / Hyaluronic acid			VAS Pain	(3)
	None / 12	Active / 131	1.48	1.35

		Sham / 85	1.54	1.30
ES active treatment vs sham			-0.06	0.05
Chevalier 2010 / Hyaluronic acid			Womac A	Womac C function
	None / 6	Active / 124	1.52	1.13
		Sham / 129	1.18	1.07
ES active treatment vs sham			0.34	0.06
Altman 2004 / Hyaluronic acid	None / 6		Womac pain	(2)
		Active / 172	0.76	0.38
		Sham / 174	0.85	0.53
ES active treatment vs sham			-0.09	-0.15
Kallmes 2009 / Percutaneous vertebroplasty	<12 / 1		Roland-Morris Disability Questionnaire	(7)
		Active / 68	0.86	0,72
		Sham / 63	0.81	0.63
ES active treatment vs sham			0.05	0.09
Buchbinder 2009 / Percutaneous vertebroplasty	<12 / 6		Pain Score	(4)
		Active / 38	0.83	0.46
		Sham / 40	0.71	0.51
ES active treatment vs sham			0.12	-0.05
Cohen 2012 / Epidural injection of corticosteroids	<6 / 1		NRS leg pain	(2)
		Active / 28	1.51	0.88
		Sham / 30	0.82	0.39
ES active treatment vs sham			0.69	0.49
Iversen 2011 / Epidural injection of corticosteroids	>3 / 12		Oswestry disability index	-
		Active / 36	1.68	
		Sham / 40	1.85	
ES active treatment vs sham			-0.17	
Arden 2005 / Epidural injection of corticosteroids	>1<18 / 12		Oswestry disability index	(2)

12

		Active /120	1.42	1.14
		Sham / 108	1.44	1.21
ES active treatment vs sham			-0.02	-0.07
Valat 2002 / Epidural injection of corticosteroids	<6 / 1		VAS Pain	(3)
		Active / 42	1.85	1.10
		Sham / 43	1.47	0.99
ES active treatment vs sham			0.38	0.10
Freeman 2005 / Intradiscal electrothermal therapy	≥3 / 6		Oswestry disability index	(6)
		Active / 38	0.10	-0.03
		Sham / 19	0.07	0.12
ES active treatment vs sham			0.17	-0.15
Pauza 2003 / Intradiscal electrothermal therapy	>6 / 6		Oswestry disability index	(3)
		Active / 32	0.94	0.90
		Sham / 24	0.35	0.46
ES active treatment vs sham			0.59	0.44
Kvarstein 2009 / Percutaneous intradiscal radiofrequency thermocoagulation	>6 / 12		Brief Pain Inventory	(5)
		Active / 10	0.34	0.54
		Sham / 10	0.23	0.24
ES active treatment vs sham			0.11	0.30
Olanow 2003 / Fetal nigral transplantation	None / 24		UPDRS 3 off	(5)
		Active / 12	0.04	-0.24
		Sham / 11	0.44	-0.19
ES active treatment vs sham			0.48	-0.06
Marks 2010 / Gene delivery of AAV2-Neurturin	≥60 / 12		UPDRS 3 off	(7)
		Active / 38	0.72	0.23
		Sham / 20	0.53	-0.05
ES active treatment vs sham			0.19	0.28

Gross 2011 / Transplantation of human retinal pigmental cells	≥60 / 12		UPDRS 3 off	(2)
		Active / 35	1.09	0.08
		Sham / 36	0.88	0.06
ES active treatment vs sham			0.21	0.02
LeWitt 2011 / AAV-GAD gene into subthalamic nucleus	≥60 / 6		UPDRS 3 off	(7)
		Active / 16	1.00	0.30
		Sham / 21	0.42	0.21
ES active treatment vs sham			0.58	0.08
Dowson 2008 / Patent foramen ovale closure	None / 6		Frequency migraine/month (per protocol)	Headache Impact Test
		Active / 74	0.74	1.02
		Sham / 73	0.45	1.06
ES active treatment vs sham			0.28	0.04
VAS=Visual Analogue Scale; NRS=Numerical Rating Scale; UPDRS=Unified Parkinson's Disease Rating Scale; Womac=Western Ontario and McMaster Universities Osteoarthritis Index				

ES on primary endpoints was moderate in three of the active treatment groups and in two of the sham groups.

On pooled secondary endpoints, a large ES was estimated in seven trials after active treatment and in five trials after sham, while a moderate ES was reported in four and three trials respectively (table 2).

In none of the trials did the actively treated group show a deterioration of primary endpoint during treatment, while this was the case for two of the sham groups (not reported to be related to the procedure). On secondary endpoints, deterioration occurred in two active treatment and two sham groups (table 2).

Differences in outcome between active treatment and sham

Better results on primary endpoints were reported with active treatment compared to sham in 14 of the 21 trials, but the differences were small. Three trials (one epidural study³⁷, one discogenic pain study⁴⁰ and one Parkinson study⁴⁶) reported a moderate effect but none showed a large effect (figure 2, table 2). Seven trials reported a better primary endpoint outcome after sham than after active treatment.

1
2
3
4
5
6
7
8 Nineteen trials reported secondary endpoints, 11 of these
9 reported better outcome after active treatment than after
10 sham, but in no case did the differences reach a moderate ES
11 (figure 2, table 2). In twelve trials, the outcome was better for
12 primary than for pooled secondary endpoints. This bore no
13 relation to funding source.

14 On regression analyses, effect sizes in the sham groups
15 predicted about 80 % of the variance of ES in the active
16 treatment groups, both on primary and pooled secondary
17 endpoints (figure 3 and 4).

18 **Adverse events**

19 Eighteen studies provided information about adverse events
20 (AE) (table 1). Three of these trials reported no procedural
21 adverse events in any of the groups.^{27 29 35} Major AEs were
22 reported after active treatment in four trials^{28 44 45 47} including
23 one death in one of the Parkinson studies.⁴⁵ In the sham
24 groups, one trial⁴⁷ listed three major AEs possibly or probably
25 related to the procedure, all thought to be caused by anti-
26 platelet medication, none of them life-threatening. Apart from
27 this trial, there were no major AEs in the sham groups. The
28 reported minor AEs were all of limited duration.

29 **DISCUSSION**

30 **Principal findings**

31 Analysis of 21 sham-controlled trials of minimally invasive
32 procedures showed that the effect sizes in the active arms
33 were predicted by the effect sizes in the sham arms. There was
34 a large ES on primary endpoints in about half of both the active
35 and sham interventions, but none of the trials showed a large
36 difference in ES between active treatment and sham groups
37 either on primary or secondary endpoints.

38
39
40 The magnitude of the effect in each trial arm varied
41 considerably, both between different procedures and between
42 trials using the same procedure. For instance, in the active
43 treatment groups, ES for primary endpoints varied from
44 around zero to almost 2 after active treatment, and from
45 about -0.4 to 1.5 after sham. Disparate outcomes were
46 reported even between trials where technical parameters
47 were similar. For instance, ES in the sham group in the three
48 hyaluronic acid-trials varied by a factor of three, and in the
49 epidural trials by a factor of two. This variability is probably
50 related to differences in study design, duration of disability
51 before inclusion, contextual factors, including the doctor-
52 patient relationship as well as other factors. The close
53 association between endpoints in the active treatment and
54 sham groups on regression analyses suggests that a large part
55 of the reported outcomes in the active treatment groups are
56
57
58
59
60

1
2
3
4
5
6
7 due to placebo effects, statistical regression to the mean or the
8 natural course of the condition.

9 **Strengths and limitations of study**

10 It is our opinion that the calculation of effect sizes in both
11 active treatment and placebo arms is a strength of the present
12 study. This made it possible to assess the magnitude of change
13 in both arms and the contribution of non-specific factors to
14 change in the active treatment arms. The calculation of effect
15 sizes provides an alternative assessment to probability
16 estimates. Another strength of the study is the supplementary
17 analyses of pooled secondary endpoints, enabling a more
18 comprehensive evaluation than using primary endpoints alone.
19 Reports of tactically motivated use of primary and secondary
20 endpoints before publication in order to improve study results
21 strengthen the argument for registering all relevant secondary
22 endpoints.⁴⁸ Our finding that a majority of trials reported
23 better results on primary than on secondary endpoints might
24 lend support to such a hypothesis, although all trials, according
25 to the authors, had sought and gained approval of the protocol
26 from ethics committee and/ or review board (table 1).

27 The present review is limited to selected minimally invasive
28 procedures in cardiology, neurology, and musculoskeletal
29 conditions. While some procedures are, or have been, in wide
30 clinical use, some are still in the clinical trial phase. Other
31 sources of heterogeneity are variable duration of disease
32 before inclusion, selection of outcome measures and time to
33 follow-up. Results cannot be generalised to minimally invasive
34 procedures in all medical disciplines, but a similar
35 methodology could be applied to more systematic analyses of
36 the role of non-specific effects in other minimally invasive
37 procedures.

38 We applied principles from guidelines for conducting
39 systematic reviews and meta-analyses and included an
40 independent assessment of methodological trial quality by two
41 of the authors. We cannot rule out that we have missed
42 relevant trials because we limited our search to the Cochrane
43 Library and MEDLINE, but most relevant trials are likely to have
44 been identified by our searches. By preferentially selecting
45 core journals and trials that had previously been
46 methodologically evaluated in systematic reviews, it was our
47 intention to reduce the risk of bias by excluding studies of low
48 quality. We realize that this selection process and the fact that
49 we relied on previous methodological evaluations may have
50 contributed to unrecognised selection bias.

51 The use of ES as a measure of clinical effect assumes a normal
52 distribution of the data. This does not necessarily apply in the
53 included trials because the majority of them are small.
54 Including trials reporting non-parametric data would however
55

necessitate other methods of statistical analysis. Small studies increase the likelihood of type-2 errors, though this is more relevant to probability estimates than analysis of ES.

Adequate blinding and lack of physiological effects?

We cannot rule out that treatment-specific effects in the actively treated groups may have jeopardised blinding, leading to overestimation of treatment effects through positive expectations. However, all the included trials gave a detailed description of the sham procedure, and both participant and assessor blinding seems to have been adequate.

On a more general level, it has been argued that sham procedures are not inert and may have specific physiological effects, thereby underestimating a treatment effect.⁴⁹ More recently, Bickett et al. hypothesised that epidural injection of small volumes of saline might have physiological effects.⁵⁰ However, it is to be noted that in the four selected epidural trials in the present study, improvements in the sham group were greater in the two trials using non-epidural saline than in those using epidural saline, making a physiological effect less likely. In our opinion, physiological effects of the sham interventions are also unlikely in the remaining procedures.

Surgery and other invasive procedures are commonly believed to be associated with enhanced placebo effects, a phenomenon coined mega-placebo.⁵¹ In spite of their heterogeneous nature, the 21 selected trials share a medico-technological context in which an a priori enhanced placebo response could be expected. If an ES >0.8 is considered as mega-placebo, half of the included sham interventions reached this level. Factors such as the level of enthusiasm and conviction conveyed by the therapist, the impression of advanced procedures and the extent to which these factors succeed in activating a placebo response are probably crucial in explaining the improvements after sham interventions and the correlation of endpoints in the active treatment and sham groups. Participants' perception of whether they received active treatment or sham has been shown to contribute more to clinical improvement than the biological effects per se.^{26,52}

Non-specific factors

The role of non-specific factors, primarily spontaneous remission or statistical regression-to-the-mean, in placebo-controlled studies is controversial.⁵³ A recent meta-analysis analysing 202 trials with an untreated group, spanning 60 different clinical conditions, found rather small differences between placebo and no treatment, with effect sizes in the range of 0.2 to 0.3.⁵⁴ Apart from acupuncture trials (mean ES 0.68), the authors did not include trials reporting the effectiveness of invasive procedures. Another meta-analysis studied the placebo effect of a range of treatments

(pharmacological, non-pharmacological and surgical) for osteoarthritis of the hand, hip and knee.⁵⁵ Of 198 included trials fourteen had a no-treatment arm. The mean ES in the placebo groups was about 0.5, while it was only slightly above zero in the no-treatment groups. The difference between the placebo and no-treatment groups was larger than the difference between the placebo and active treatment groups. Trials using injections, acupuncture and surgery had the largest placebo effects, and the effects were larger for subjective than objective endpoints. The authors concluded that there is a significant placebo effect on pain, stiffness and function in symptomatic osteoarthritis.

Because the trials in the present study did not include a no-treatment arm (i.e. waiting list), we cannot rule out that the changes appearing during the trial period also reflect non-specific factors, i.e. spontaneous improvement or regression to the mean. Such mechanisms would be expected to be most prominent in trials with brief illness duration before inclusion and with longer time to follow-up, while improvements in chronic, unremitting conditions such as Parkinson's disease would be more likely attributed to placebo. Interestingly, in three of the four included Parkinson trials, there were moderate to large improvements in the sham groups even at one-year follow-up.⁴³⁻⁴⁵ Other authors have also found improvements several years after sham surgery, indistinguishable from conventional surgery.^{26 56} This is in agreement with recent insights into the neurobiological effects of placebo and their relation to underlying psychological mechanisms, principally expectation and conditioning.⁵⁷

Are ethical objections to sham justified?

The use of sham in controlled surgical trials is a divisive issue, with scepticism, even frank opposition, being voiced by both ethics committees, involved surgeons and anaesthetists, and potential patients.⁵⁸ Ethical arguments include the inherent risks of sham procedures combined with the lack of obvious benefits to the participants. Barriers related primarily to feasibility include problems with patient and assessor blinding, differing technical expertise, the heterogeneity of the interventional techniques and variable outcome specifications, making standardization difficult to achieve. Existing ethical guidelines accept the role of placebo-controlled trials when certain conditions are met.⁵⁹ There must be genuine equipoise, i.e. conflicting or weak evidence of the effectiveness of a procedure. Blinding of both participants and assessors must be assured, and participants must freely consent to suspend knowledge of whether they are receiving sham or conventional treatment. The health risks and consequences of placebo or delayed treatment must be minimal, and outweighed by the societal importance of establishing the clinical utility of the intervention in question.^{60 61}

1
2
3
4
5
6
7
8 The selected trials gave a detailed description of adverse
9 events in both active and sham-treated groups (table 1). The
10 safety concerns frequently raised as an argument against the
11 use of sham were generally not supported. Major adverse
12 events related to the sham procedure were reported in only
13 one of the trials⁴⁷ and they were short-lived and not life
14 threatening. Minor adverse events were more frequent, but
15 also of limited duration. Positive placebo-induced effects
16 generally outweighed adverse events, thus weakening ethical
17 arguments against the use of sham interventions. In our
18 opinion, the consequences of the continued use of unproven
19 invasive procedures are of a different magnitude. In the light
20 of studies supporting the beneficial effects of sham
21 procedures, at least for pain and Parkinson symptoms,
22 research ethics committees should consider such factors in
23 their risk-benefit assessments of planned sham controlled
24 trials.^{62 63}

25 **Clinical implications.**

26 The present results are pertinent to the ongoing discussion
27 about wasteful and unproven medical practices, and
28 underscore the necessity for a continual assessment of existing
29 or novel unproven procedures. Minimally invasive techniques
30 have lowered the threshold for interventions, and led to their
31 application to a wider clinical spectrum (indication creep)
32 without an ongoing evaluation of effectiveness or safety.⁴ The
33 last two decades have seen dramatic increases in the use of
34 several of the described procedures, as well as interventions
35 we have not investigated, such as facet joint injections,
36 radiofrequency neurotomy, acromioplasty, percutaneous
37 coronary intervention and, more recently, robotic surgery.⁶⁴⁻⁶⁹
38 In light of the results in the present study, placebo effects
39 might well explain a large part of the purported effects of such
40 procedures. When clinicians and regulators are faced with
41 claims of large treatment effects for insufficiently tested
42 procedures, their default mode should be watchful scepticism.
43 The standards of the evaluation process before approval and
44 reimbursement of devices and procedures need to be
45 strengthened, and economic or regulatory incentives that
46 perpetuate the use of undocumented or harmful procedures
47 should be abrogated.

48 **CONCLUSION**

49 Sham-controlled trials are unique in their ability to
50 discriminate between true treatment effects and non-specific
51 effects. The results of the present study suggest that placebo
52 and other non-specific effects explain a large part of their
53 purported benefits. Further, results indicate that the risks of
54 adverse events in sham-controlled trials are overrated and
55 could be considered acceptable in view of the potential
56
57
58
59
60

personal harm and societal costs associated with unproven minimally invasive interventions.

Figure legends

Figure 1. Effect sizes of active treatment and sham, primary endpoints.

Figure 2. Differences in effect size between active treatment and sham.

Figure 3. Association between effect sizes of primary endpoints in active treatment and sham arms. Linear regression, 95% confidence intervals. N=21.

Figure 4. Association between effect sizes of pooled secondary endpoints in active treatment and sham arms. Linear regression, 95% confidence intervals. N=19.

References

1. Prasad V, Vandross A, Toomey C et al. A decade of reversal: an analysis of 146 contradicted medical practices. *Mayo Clin Proc* 2013;**88**:790-8.
2. Tiago V. Pereira TV, Horwitz RI et al. Empirical Evaluation of Very Large Treatment Effects of Medical Interventions. *JAMA* 2012;**308**:1676-84.
3. Roberts AL, Kewman DG, Mercier L et al. The power of nonspecific effects in healing: implications for psychosocial and biological treatments. *Clin Psychol Rev* 1993;**13**:375-91.
4. Garner S, Littlejohns P. Disinvestment from low value clinical interventions: NICEly done? *BMJ* 2011;**343**:d4519.

5. Scott IA, Elshaug AG. Foregoing low-value care: how much evidence is needed to change beliefs? *Intern Med J* 2013;**43**:107-9.
6. Obremsky WT, Pappas N, Attallah-Wasif E et al. Level of evidence in orthopaedic journals. *J Bone Joint Surg Am* 2005;**87**:2632-8.
7. Reeves B. Health-technology assessment in surgery. *Lancet* 1999;**353**:Suppl 1:S13-S15;
8. Wenner DM, Brody BA, Jarman AF et al. Do surgical trials meet the scientific standards for clinical trials? *J Am Coll Surg* 2012;**215**:722-30.
9. Ezekiel JE, Miller FG. The Ethics of Placebo-Controlled Trials — A Middle Ground. *N Engl J Med* 2001;**345**:915-9.
10. Campbell MK, Entwistle VA, Cuthbertson BH et al. Developing a placebo-controlled trial in surgery: issues of design, acceptability and feasibility. *Trials* 2011;**12**:50
11. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. <http://handbook.cochrane.org>; (11.11.2014)
12. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009;**339**:b2700.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
13. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.
14. Durlak JA. How to Select, Calculate, and Interpret Effect Sizes. *J Pediatr Psychol* 2009; **34**: 917-28.
15. MedCalc Software bvba, Ostend, Belgium; <http://www.medcalc.org>; (08.03.2014).
16. Rutjes AWS, Jünl P, da Costa BR et al. Viscosupplementation for Osteoarthritis of the Knee. A Systematic Review and Meta-analysis. *Ann Intern Med* 2012;**157**:180-91.
17. Pinto RZ, Maher CG, Ferreira ML et al. Epidural corticosteroid injections in the management of sciatica: a systematic review and meta-analysis. *Ann Intern Med* 2012;**157**:865-77.
18. McGillion M, Cook A, Victor JC et al. Effectiveness of percutaneous laser revascularization therapy for refractory angina. *Vasc Health Risk Manag* 2010;**6**:735-47.
19. Helm S II, Deer TR, Manchikanti L et al. Effectiveness of thermal annular procedures in treating discogenic low back pain. *Pain Physician* 2012; **15**:E279-E304.
20. Shi MM, Cai XZ, Lin T et al. Is there really no benefit of vertebroplasty for osteoporotic vertebral fractures? A meta-analysis. *Clin Orthop Relat Res* 2012;**470**:2785-99.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
21. Petrella RJ, Cogliano A, Decaria J. Combining two hyaluronic acids in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. *Clin Rheumatol* 2008;**27**:975-81.
22. Lundsgaard C, Dufour N, Fallentin E et al. Intra-articular sodium hyaluronate 2 mL versus physiological saline 20 mL versus physiological saline 2 mL for painful knee osteoarthritis: a randomized clinical trial. *Scand J Rheumatol* 2008 ;**37**:142-50.
23. Karppinen J, Malmivaara A, Kurunlahti M et al. Periradicular infiltration for sciatica: a randomized controlled trial. *Spine* 2001; **26**:1059-67.
24. Freed CR, Greene PE, Breeze RE et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. *N Engl J Med* 2001;**344**:710-9.
25. Gordon PH, Yu Q, Qualls C et al. Reaction time and movement time after embryonic cell implantation in Parkinson disease. *Arch Neurol* 2004;**61**:858-61.
26. McRae C, Cherin E, Yamazaki TG et al. Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial. *Arch Gen Psychiatry* 2004; **61**: 412-20.
27. Salem M, Rotevatn S, Stavnes S et al. Usefulness and safety of percutaneous myocardial laser revascularization for refractory angina pectoris. *Am J Cardiol* 2004;**93**:1086-91.

- 1
2
3
4
5
6
7 28. Leon MB, Kornowski R, Downey WE et al. A blinded,
8 randomized, placebo-controlled trial of percutaneous
9 laser myocardial revascularization to improve angina
10 symptoms in patients with severe coronary disease. *J*
11 *Am Coll Cardiol* 2005;**46**:1812-9.
12
13
14
15
16 29. Moseley JB, O'Malley K, Petersen NJ et al. A controlled
17 trial of arthroscopic surgery for osteoarthritis of the
18 knee. *N Engl J Med* 2002;**347**:81-8.
19
20
21
22 30. Sihvonen R, Paavola M, Malmivaara A et al.
23 Arthroscopic partial meniscectomy versus sham
24 surgery for a degenerative meniscal tear. *N Engl J Med*
25 2013;**369**:2515-24.
26
27
28
29 31. Pham T, Le Henanff A, Ravaud P et al. Evaluation of the
30 symptomatic and structural efficacy of a
31 new_hyaluronic_acid compound, NRD101, in
32 comparison with diacerein and placebo in a 1 year
33 randomised controlled study in symptomatic knee
34 osteoarthritis. *Ann Rheum Dis* 2004;**63**:1611-7.
35
36
37
38
39
40 32. Altman RD, Akermark C, Beaulieu AD et al. Efficacy and
41 safety of a single intra-articular injection of non-animal
42 stabilized_hyaluronic_acid (NASHA) in patients with
43 osteoarthritis of the knee. *Osteoarthritis*
44 *Cartilage* 2004;**12**:642-9.
45
46
47
48
49 33. Chevalier X, Jerosch J, Goupille P et al. Single, intra-
50 articular treatment with 6 ml hylan G-F 20 in patients
51 with symptomatic primary osteoarthritis of the knee: a
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7 randomised, multicentre, double-blind, placebo
8 controlled trial. *Ann Rheum Dis* 2010;**69**:113-9.
- 9
10
11 34. Kallmes DF, Comstock BA, Heagerty PJ et al. A
12 randomized trial of vertebroplasty for osteoporotic
13 spinal fractures. *N Engl J Med* 2009;**361**:569-79.
- 14
15
16 35. Buchbinder R, Osborne RH, Ebeling PR et al. A
17 randomized trial of vertebroplasty for painful
18 osteoporotic vertebral fractures. *N Engl J Med*
19
20 2009;**361**:557-68.
- 21
22
23 36. Iversen T, Solberg TK, Romner B et al. Effect of caudal
24 epidural steroid or saline injection in chronic lumbar
25 radiculopathy: multicentre, blinded, randomised
26 controlled trial. *BMJ* 2011;**343**:d5278.
- 27
28
29 37. Cohen SP, White RL, Kurihara C et al. Epidural steroids,
30 etanercept, or saline in subacute sciatica: a
31 multicenter, randomized trial. *Ann Intern Med*
32 2012;**156**:551-9.
- 33
34
35 38. Arden NK, Price C, Reading I et al. A multicentre
36 randomized controlled trial of epidural corticosteroid
37 injections for sciatica: the WEST study.
38
39
40
41
42
43
44
45
46
47 39. Valat JP, Giraudeau B, Rozenberg S et al. Epidural
48 corticosteroid injections for sciatica: a randomised,
49 double blind, controlled clinical trial. *Ann Rheum*
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7 40. Pauza KJ, Howell S, Dreyfuss P et al. A randomized,
8 placebo-controlled trial of intradiscal electrothermal
9 therapy for the treatment of discogenic low back pain.
10 *Spine J* 2004;**4**:27-35.
11
12
13
14 41. Freeman BJ, Fraser RD, Cain CM et al. A randomized,
15 double-blind, controlled trial: intradiscal
16 electrothermal therapy versus placebo for the
17 treatment of chronic discogenic low back pain. *Spine*
18 2005;**30**:2369-77.
19
20
21
22
23 42. Kvarstein G, Måwe L, Indahl A et al. A randomized
24 double-blind controlled trial of intra-annular
25 radiofrequency thermal disc therapy--a 12-month
26 follow-up. *Pain* 2009;**145**:279-86.
27
28
29
30
31 43. Olanow CW, Goetz CG, Kordower JH et al. A double-
32 blind controlled trial of bilateral fetal nigral
33 transplantation in Parkinson's disease. *Ann Neurol*
34 2003;**54**:403-14.
35
36
37
38 44. Marks WJ Jr, Bartus RT, Siffert J et al. Gene delivery of
39 AAV2-neurturin for Parkinson's disease: a double-
40 blind, randomised, controlled trial. *Lancet Neurol*
41 2010;**9**:1164-72.
42
43
44
45 45. Gross RE, Watts RL, Hauser RA et al. Intrastratial
46 transplantation of microcarrier-bound human retinal
47 pigment epithelial cells versus sham surgery in patients
48 with advanced Parkinson's disease: a double-blind,
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7 randomised, controlled trial. *Lancet Neurol*
8 2011;**10**:509-19.
9
- 10 46. LeWitt PA, Rezai AR, Leehey MA et al. AAV2-GAD gene
11 therapy for advanced Parkinson's disease: a double-
12 blind, sham-surgery controlled, randomised trial.
13 *Lancet Neurol* 2011;**10**:309-19.
14
- 15 47. Dowson A, Mullen MJ, Peatfield R et al. Migraine
16 Intervention With STARFlex Technology (MIST) trial: a
17 prospective, multicenter, double-blind, sham-
18 controlled trial to evaluate the effectiveness of patent
19 foramen ovale closure with STARFlex septal repair
20 implant to resolve refractory migraine headache.
21 *Circulation* 2008;**117**:1397-404.
22
- 23 48. Hannink G, Gooszen HG, Rovers MM. Comparison of
24 registered and published primary outcomes in
25 randomized clinical trials of surgical interventions. *Ann*
26 *Surg* 2013;**257**:818-23.
27
- 28 49. Birch S. A review and analysis of placebo treatments,
29 placebo effects, and placebo controls in trials of
30 medical procedures when sham is not inert. *J Altern*
31 *Complement Med* 2006;**12**:303-10.
32
- 33 50. Bicket MC, Gupta A, Brown CH 4th et al.
34 Epidural injections for spinal pain: a systematic review
35 and meta-analysis evaluating the "control" injections
36 in randomized controlled trials.
37 *Anesthesiology*. 2013;**119**:907-31.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7 51. Kaptchuk TJ, Goldman P, Stone DA et al. Do medical
8 devices have enhanced placebo effects? *J Clin*
9 *Epidemiol* 2000;**53**:786-92.
10
11
12 52. Einvik G, Tjomsland O, Kvernebo K et al. Preoperative
13 expectations and clinical outcome of transmyocardial
14 laser treatment in patients with angina pectoris.
15 *Tidsskr Nor Laegeforen* 2002;**122**:2102-4.
16
17
18 53. Turner JA, Deyo RA, Loeser JD et al. The importance of
19 placebo effects in pain treatment and research. *JAMA*
20 1994;**271**:1609-14.
21
22
23 54. Hróbjartsson A, Gøtzsche PC. Placebo interventions for
24 all clinical conditions. *Cochrane Database Syst Rev*
25 2010; CD003974.
26
27
28 55. Zhang W, Robertson J, Jones AC et al. The placebo
29 effect and its determinants in osteoarthritis: meta-
30 analysis of randomised controlled trials. *Ann Rheum*
31 *Dis* 2008;**67**:1716-23.
32
33
34 56. Marchand S, Kupers RC, Bushnell MC et al. Analgesic
35 and placebo effects of thalamic stimulation. *Pain*
36 2003;**105**:481-8.
37
38
39 57. Finniss DG, Kaptchuk TJ, Miller F et al. Biological,
40 clinical, and ethical advances of placebo effects. *Lancet*
41 2010;**375**:686-95.
42
43
44 58. Campbell MK, Entwistle VA, Cuthbertson BH et al.
45 Developing a placebo-controlled trial in surgery: issues
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- of design, acceptability and feasibility. *Trials* 2011;**12**:50. doi: 10.1186/1745-6215-12-50.
59. Snyder L. Review of the American College of Physicians Ethics Manual, Sixth Edition. *Ann Intern Med* 2012;**156**(1_Part_2):73-104.
60. Flum DR. Interpreting surgical trials with subjective outcomes: avoiding UnSPORTsmanlike conduct. *JAMA* 2006;**296**:2483-5.
61. Heckerling PS. Placebo surgery research: a blinding imperative. *J Clin Epidemiol* 2006;**59**:876-80.
62. Brim RL, Miller FG. The potential benefit of the placebo effect in sham-controlled trials: implications for risk-benefit assessments and informed consent. *J Med Ethics* 2013;**39**:703-7.
63. Redberg RF. Sham controls in medical device trials. *N Engl J Med* 2014;**371**:892-3.
64. Haahr JP, Østergaard S, Dalsgaard J et al. Exercises versus arthroscopic decompression in patients with subacromial impingement: a randomised, controlled study in 90 cases with a one year follow up. *Ann Rheum Dis* 2005;**64**:760-4.
65. Ketola S, Lehtinen J, Rousi T et al. No evidence of long-term benefits of arthroscopic acromioplasty in the treatment of shoulder impingement syndrome: Five-year results of a randomised controlled trial. *Bone Joint Res* 2013;**2**:132-9.

- 1
2
3
4
5
6
7 66. Herrlin S, Hållander M, Wange P et al. Arthroscopic or
8 conservative treatment of degenerative medial
9 meniscal tears: a prospective randomised trial. *Knee*
10 *Surg Sports Traumatol Arthrosc* 2007;**15**:393-401.
11
12
13
14 67. Yu E, Cil A, Harmsen WS et al. Arthroscopy and the
15 dramatic increase in frequency of anterior
16 acromioplasty from 1980 to 2005: an epidemiologic
17 study. *Arthroscopy* 2010;**26**,Supplement:S142-7.
18
19
20
21 68. Vitale MA, Arons RR, Hurwitz S et al. The rising
22 incidence of acromioplasty. *J Bone Joint Surg Am*
23 2010;**92**:1842-50.
24
25
26
27 69. Brox JI, Staff PH, Ljunggren AE et al. Arthroscopic
28 surgery compared with supervised exercises in
29 patients with rotator cuff disease (stage II
30 impingement syndrome). *BMJ* 1993;**307**:899-903.
31
32
33
34
35
36
37

38 Contributors: RH initiated and planned the project and
39 searched databases. JIB and OT assisted in developing
40 search strategies. Article screening and data extraction
41 was carried out by RH. Quality of data extraction and
42 checking was carried out by JIB and OT. Statistical analysis
43 was undertaken by RH, who also wrote the draft. OT and
44 JIB reviewed the draft and contributed to manuscript
45 revisions. RH is the guarantor for this study.

46 Funding sources: None.

47
48 All authors have completed the ICMJE uniform disclosure
49 form at www.icmje.org/coi_disclosure.pdf and declare: no
50 support from any organisation for the submitted work; no
51 financial relationships with any organisations that might
52 have an interest in the submitted work in the previous
53 three years; no other relationships or activities that could
54 appear to have influenced the submitted work.
55
56


Ethical approval: Ethical approval was not required for this work.

Data sharing: Dataset can be obtained from Robin Holtedahl (robi-hol@online.no).

The lead author affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.


This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Effect sizes of active treatment and sham, primary endpoints.
250x216mm (300 x 300 DPI)


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Differences in effect size between active treatment and sham.
221x173mm (300 x 300 DPI)


ew only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Association between effect sizes of primary endpoints in active treatment and sham arms. Linear regression, 95% confidence intervals. N=21. 67x50mm (300 x 300 DPI)

ew only



Association between effect sizes of pooled secondary endpoints in active treatment and sham arms. Linear regression, 95% confidence intervals. N=19. 67x50mm (300 x 300 DPI)

ew only



Appendix table 1. Search phrases, no of eligible studies and reasons for exclusion

Procedure	Search phrase MEDLINE	Source	Eligible studies	Excluded, ES not calculatable	Excluded, other methodo- logical reasons	Included studies
PMLR	Percutaneous myocardial laser revascularization	McGillion 2010 (17)	3	-	1	Salem 2004, Leon 2005
PIRFT /IDET	Intradiscal OR annular AND thermal AND "low back pain"	Helm 2012 (18)	3	-	-	Kvarstein, 2009
						Freeman 2005, Pauza 2003
Epidural injection corticosteroids	Epidural AND corticosteroid* AND sciatica	Pinto 2012 (16)	6	Karppinen 2001	1	Iversen 2011, Valat 2002, Arden 2005, Cohen 2012
Intraarticular hyaluronic acid for osteoarthritis knee	Hyaluron* OR viscosuppl* AND knee AND osteoarthritis	Rutjes 2012 (15)	47	Lundsgaard 2008, Petrella 2008	42	Chevalier 2010, Altman 2004, Pham 2004
Vertebroplasty	vertebroplast*	Shi 2012 (19)	2	-	-	Kallmes 2009, Buchbinder 2009
Invasive treatment of Parkinson's disease	transplantation OR gene OR "stem cell" AND Parkinson*	MEDLINE	7	Freed 2001, Gordon 2004, McRae 2004	-	Marks 2010, Olanow 2003, Gross 2011, LeWitt 2011
Arthroscopic debridement knee osteoarthritis	debridement AND lavage AND knee AND osteoarthr*	MEDLINE	1	-	-	Moseley 2002
Meniscectomy knee	meniscectomy AND knee	MEDLINE	1	-	-	Sihvonen 2013
Foramen ovale closure for migraine	"foramen ovale" AND migraine	MEDLINE	1	-	-	Dowson 2008
Number of trials			71	6	44	21

Appendix table 2. Indications, postulated mechanisms and history of selected interventions

Invasive procedure / indication	Postulated mechanism	History	References
Percutaneous myocardial laser revascularization / intractable angina pectoris	Increasing the delivery of oxygenated blood to poorly perfused myocardium by creating channels	Introduced in the 1980s, initially transmyocardial route, later percutaneous route, now mostly abandoned	Schofield PM, McNab D. NICE evaluation of transmyocardial laser revascularisation and percutaneous laser revascularisation for refractory angina. <i>Heart</i> 2010;96:312-3.
Patent foramen ovale closure with STARFlex Septal Repair Implant / migraine	Improvement of migraine headache, believed to block the formation of microembolies to the brain	Developed in the 1990s for the prevention of stroke, later thought to cure migraine, never in clinical use for this indication	Gornall J. A very public break-up. <i>BMJ</i> 2010;340:c110
Arthroscopic debridement / Knee osteoarthritis	Unclear, no documented effect on arthritic process, but about 50% report relief of pain (Mosely)	Annually about 650.000 procedures in the USA in the mid-nineteens, but 39% decrease between 2000 and 2008.	Holmes R, Moschetti W, Martin B, Tomek I, Finlayson S. Effect of evidence and changes in reimbursement on the rate of arthroscopy for osteoarthritis. <i>Am J Sports Med</i> 2013;41:1039-43.
Arthroscopic meniscectomy / degenerative meniscal lesions	Unclear, relief of symptoms attributed to trimming damaged meniscus down to viable meniscus and removing fragments.	The most common orthopedic procedure in the United States, 700.000 per year, up 50% last 15 years	Kim S, Bosque J, Meehan JP, Jamali A, Marder R. Increase in outpatient knee arthroscopy in the United States: a comparison of National Surveys of Ambulatory Surgery, 1996 and 2006. <i>J Bone Joint Surg Am</i> 2011;93:994-1000. Rutjes 2012 (15)
Viscosupplementation with hyaluronic acid / Knee osteoarthritis	Improve joint lubrication by increasing HA levels in joint, in spite of short half-lives (Marshall 2000)	Many positive reports since late 1980s, including sham-controlled trials. Still widely in use	
Percutaneous vertebroplasty with PMMA cement injection / vertebral compression fracture	Increase the strength of the damaged bone and alleviate pain by preventing microfractures	Numerous observational studies and single-blind trials reported substantial clinical benefits. Slight reduction of procedure since 2009	Manchikanti L, Pampati V, Hirsch JA. Analysis of utilization patterns of vertebroplasty and kyphoplasty in the Medicare population. <i>J Neurointerv Surg</i> 2013;5:467-72.
Epidural injection of corticosteroids / Sciatica	Dampen inflammatory reaction in nerve root sheaths caused by mechanical compression	Routinely used for sciatica since the 1950s (Pinto 2012). Since 2000 the number of injections increased by about 130% in the United States and 50% in the United Kingdom	Manchikanti L, Falco FJ, Singh V, Pampati V, Parr AT, Benyamin RM, Fellows B, Hirsch JA. Utilization of interventional techniques in managing chronic pain in the Medicare population: analysis of growth patterns from 2000 to 2011. <i>Pain Physician</i> 2012;15:E969-82

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

<p>Percutaneous intradiscal radiofrequency and thermocoagulation (PIRFT and IDET) / discogenic low back pain</p>	<p>Placement of a electrode or RF-probe into the annulus and applying heat or current to destruct nociceptors/annulus</p>	<p>Introduced in 1996 (IDET), later mostly abandoned</p>	<p>Helm 2012 (18)</p>
<p>Fetal nigral transplantation / Parkinson's disease</p>			<p>-</p>
<p>Gene delivery of AAV2-Neurturin / Parkinson's disease</p>	<p>Restoration of dopamin levels in basal ganglia through injection of growth factors, GAD gene or nigral dopamine neurons</p>	<p>Based on animal models and a few small observational trials from about 2000. None in routine clinical use due to insufficient evidence</p>	
<p>Transplantation of human retinal pigmental cells / Parkinson's disease</p>			
<p>Insertion of AAV-GAD gene into subthalamic nucleus / Parkinson's disease</p>			

For peer review only

Appendix table 3. Included and excluded secondary endpoints.		
Author	Included secondary endpoints	Excluded secondary endpoints (means not reported, or irrelevant)
Leon 2005		
	Time to onset angina	Improvement in angina class
	Time to onset ST depression	Radioisotope imaging
	Overall health	
	Frequency angina	
	Stability angina	
	Physical functioning	
	Disease perception	
	Treatment satisfaction	
	PCS	
	MCS	
Salem 2004		
		Proportion improved CCS angina class
		Medication usage
		Seattle Angina Questionnaire
		Left EF
		Angina stability
		Angina frequency
		Physical limitation
		Treatment satisfactioin
		Disease perception
Sihvonen 2013	WOMET score	-
	Knee pain at rest	
	Knee pain after exercise	
	15D score	
Moseley 2002		
	Arthritis Impact Scale	-
	Physical functioning Scale	
	Walking-bending	
	SF-36 Pain	
	SF-36 Physical functioning	
Pham 2004		
	Lequesne's algofunctional index	-
	Global assessment	
	% painful days	
Chevalier 2010		
	Womac C function	-
Altman 2004		
	Womac stiffness	-
	Womac physical	
Kallmes 2009		
	Pain Intensity	Opioid use

	SF-36 PCS	
	SF-36 MCS	
	Pain Frequency Index	
	Pain Bothersomeness Index	
	EQ-SD Index	
	SOF-ADL	
Buchbinder 2009		
	Roland-Morris Disability Questionnaire	-
	Life Questionnaire of the European Foundation	
	European Quality of Life-5 Dimensions	
Cohen 2012		
	Oswestry Disability Index	-
	Back pain	
Arden 2005		
	Leg pain	Analgesic use
	Back pain	
Valat 2002		
	Roland-Morris Disability Questionnaire	Dallas Pain Questionnaire
	Straight leg raising	
	Schober's test	
Iversen 2011		
		VAS back and leg pain, European Quality of Life scale
Freeman 2005		
	Modifiede Somatic Perception Questionnaire	SF-36 Mental, Role Physical/ Mental, Social Function
	Low Back Pain Outcome Score	
	SF-36 Physical Function	
	SF-36 Pain	
	SF-36 General Health	
	SF-36 Vitality	
Pauza 2003		
	VAS Pain	-
	SF-36 Physical Function	
	SF-36 Pain	
Kvarstein 2009		
	SF-36 Bodily pain	SF-36 Mental, Role Physical/ Mental, Social Function
	SF-36 Physical function	
	Oswestry Disability Index	
	SF-36 General health	
	SF-36 Vitality	
Olanow 2003		
	UPDRS motor on	Mean L-dopa dose equivalents
	UPDRS ADL off	
	UPDRS ADL on	

	% Off time day	
	% On time without dyskinesia	
Marks 2010		
	UPDRS OFF 1	Mean L-dopa dose equivalents
	UPDRS OFF 2	
	UPDRS ON 1	
	UPDRS ON 2	
	UPDRS ON 3	
	On without dyskinesia	
	On with dyskinesia	
Gross 2011		
	UPDRS ON	Mean L-dopa dose equivalents
	UPDRS ADL	
LeWitt 2011		
	UPDRS 1	Timed walking
	UPDRS2	BPRS other than taps
	UPDRS4	Dyskinesia rating scale
	Schwab and England ADL scale	Patient's diary
	BPRS taps 60 s	Clinical global impression
	Hoehan and Yahr stage	
	PDQ-39 total	
Dowson 2008		
	Headache Impact Test	-



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5, Appendix table 1
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5, Appendix 1
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5-6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	5-6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	5
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2 for each meta-analysis)	6



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	5
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	6, 7, Appendix Flow chart
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	7-13
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	7,9 Appendix table 1
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	10-13
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	10-13
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	7,9
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	14, Fig. 3,4
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14,15-17
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	13-17
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	18
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review	29



PRISMA 2009 Checklist

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2

For peer review only

1
2
3
4
5
6
7
8 **Placebo effects in trials evaluating 12 selected** minimally
9 **invasive interventions: an exploratory systematic review and**
10 **meta-analysis.**

11 Robin Holtedahl, Jens Ivar Brox, Ole Tjomsland

12
13
14 Fram Rehabilitation Centre, Rykkinveien 100, 1349 Rykkin,
15 Norway Robin Holtedahl Consultant Department of Physical
16 Medicine and Rehabilitation, Oslo University Hospital, Box
17 4956 Nydalen, 0424 Oslo, Norway Jens Ivar Brox Professor
18 South-Eastern Norway Regional Health Authority,
19 PB 404, 2303 Hamar, Norway Ole Tjomsland Director of Quality
20 and Specialist Areas

21 Correspondence to: Dr Robin Holtedahl; robi-hol@online,
22 telephone +4790248973

23
24 **Key words:**

25 Placebo effects
26 Invasive procedures
27 Biomedical ethics
28 Evidence based health care
29

30 **Word count:** 3783
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Objectives To analyse the impact of placebo effects on outcome in trials of selected minimally invasive procedures, and to assess reported adverse events in both trial arms.

Design [Exploratory](#) [A](#) [s](#) systematic review and meta-analysis.

Data Sources and Study Selection We searched MEDLINE and Cochrane library ~~for to identify~~ systematic reviews ~~of musculoskeletal, neurological and cardiocological conditions published between January 2009 and January 2014 including and randomised clinical trials musculoskeletal, neurological and cardiocological conditions~~ comparing selected minimally invasive ~~procedures~~ with placebo (sham) ~~procedures~~. ~~We selected the most recent systematic review with low risk of bias published in core medical journals. We searched For procedures that were not evaluated in systematic reviews we searched~~ MEDLINE for ~~additional randomised controlled trials published between January 2000 and January 2014. trials with low risk of bias.~~

Data synthesis Effect sizes (ES) in the active and placebo arms in the trials' primary and pooled secondary endpoints were calculated. Linear regression was used to analyse the association between endpoints in the active and sham groups. Reported adverse events in both trial arms were registered.

Results We included [221](#) trials involving [2519472](#) adult participants. For primary endpoints, there was a large clinical effect (ES ≥ 0.8) after active treatment in 12 trials and after sham procedures in 11 trials. For secondary endpoints, seven and five trials showed a large clinical effect, respectively. Three trials showed a moderate difference in ES between active treatment and sham on primary endpoints (ES ≥ 0.5) but no trials reported a large difference. No trials showed large or moderate differences in ES on pooled secondary endpoints. Regression analysis of endpoints in active treatment and sham arms estimated an R^2 of [0.798](#) for primary and 0.84 for secondary endpoints. Adverse events after sham were in most cases minor and of [short](#) duration.

Conclusion The generally small differences in effect size between active treatment and sham suggest that non-specific mechanisms, [principally-including](#) placebo, are major predictors of the observed effects. [Adverse events related to sham procedures were mainly minor and short-lived.](#) Ethical arguments frequently raised against ~~sham-controlled~~[sham-controlled](#) trials were generally not substantiated.

SUMMARY

Article focus

- Many minimally invasive procedures have gained increased popularity during the last two decades in spite of limited evidence of their clinical effectiveness.
- Systematic review and meta-analysis of published randomised double-blind placebo-controlled studies of minimally invasive procedures, with special emphasis on the magnitude of change in the placebo (sham) arms.
- Assessment of adverse events in the trials' active treatment and placebo arms.

Key messages

- The magnitude of change in the active treatment- and placebo arms varied greatly, but about 80% of the ~~varianction~~ variation in effect size of active treatment could be explained-predicted by placebo effects, regression to the mean or spontaneous improvement.
- Adverse events related to sham procedures were mainly minor and short-lived, and frequently outweighed by positive placebo effects.

Strengths and limitations

- + Strict selection criteria of trials, with low risk of bias mainly based on high-quality systematic reviews with low risk of bias.
- + Calculation of effect sizes on primary and pooled secondary endpoints both in active treatment and sham in both active treatment and sham arms.
- Heterogenous interventions, outcome measures and timing of assessment.
+ Searches limited to MEDLINE and Cochrane library

INTRODUCTION

It is normally assumed that medical practices are based on firm clinical evidence, and that new practices or techniques are ~~not~~ introduced ~~before when~~ superiority, or at least non-inferiority, ~~has, has,~~ been demonstrated compared to established treatments. However, medical history reveals numerous examples contradicting this assumption. Forty-two percent of 146 medical practices were found to be reversed in a recent review analysing 10 years of publication in a high-impact medical journal.¹ Large effects of an intervention in initial reports are often spurious findings, while the vast majority may represent substantial overestimations.²

Even though surgical and other invasive techniques generally have reached a high degree of sophistication through the last decades, not all invasive procedures have lived up to expectations. Promising results in initial observational studies have in some cases led to widespread clinical implementation, in spite of lack of documented effectiveness.³ The reluctance to abandon contradicted medical practice is commonly ascribed to both culturally embedded medical practices and different forms of vested interests.^{4,5} The continuation of unnecessary and potentially harmful interventions leads to major costs for both patients and society.

The randomised placebo-controlled trial is considered the gold standard for evaluating the effects of pharmacological treatments. However, there are relatively few controlled studies in peer-reviewed surgical journals, and even fewer placebo (sham)-controlled studies.⁶⁻⁸ Ethical concerns raised by the potential for harm to participants are usually cited as the main obstacle to sham-controlled studies.⁹ Problems of a practical nature relate to patient blinding, differing technical expertise, the heterogeneity of the interventional techniques and variable outcome specifications, making standardisation difficult to achieve.¹⁰

A meaningful effect in clinical trials may result from a large effect in the active treatment group, a small effect in the placebo group, or a combination. Even though a placebo effect has been documented in a range of clinical conditions, there are few studies assessing the magnitude of the placebo effect in surgical procedures. In the present ~~study~~ study, we analysed placebo-controlled trials of ~~selected~~ minimally invasive ~~procedures~~ interventions in musculoskeletal, neurological and ~~cardiacological~~ conditions. The aims were threefold: (a) to assess the magnitude of change in outcome from baseline to trial endpoint in both the active treatment and placebo (sham) arms, (b) to explore the contribution of non-specific factors, including placebo, to the outcome of active treatment, and (c) to assess the level of reported adverse effects in both trial arms.

METHODS

Search strategy and selection criteria

~~The main focus was evaluation of minimally invasive procedures that were claimed to have substantial clinical effects in cardiological, neurological and musculoskeletal conditions. We excluded ~~Open surgical interventions were excluded.~~~~

We first conducted electronic searches for [randomised placebo-controlled trials](#) of minimally invasive interventions [for cardiological, neurological and selected musculoskeletal conditions](#), using MEDLINE and Cochrane library to identify systematic reviews published ~~from between~~ January 2009 ~~to and~~ January 2014. ~~We defined minimally invasive procedures as interventions involving the introduction of a medical device, substance or other foreign material into the body through a cannula, catheter or arthroscope, thereby minimising damage to biological tissues at the point of entrance. We excluded open surgical and laparoscopic interventions. Where applicable, we used the “core clinical journals” filter in PubMed, which is an index of journals particularly relevant to practicing physicians. From the selected reviews, we selected randomised placebo-controlled randomised placebo-controlled trials published from January 2000 to January 2014 that according to the review fulfilled at least four of the following [methodological](#) criteria: random allocation, allocation concealment, blinding of participant, blinding of assessor and intention-to-treat analysis. We chose these criteria both because they were the most commonly used in the selected reviews, and because use of scales for assessing quality or risk of bias is explicitly discouraged in Cochrane reviews²⁹¹¹. Two of the authors (RH and JIB) independently ~~assessed~~ [analysed the five methodological criteria in the RCTs included selected from systematic reviews.](#) ~~to ascertain that they complied with the five criteria were fulfilled.~~~~

~~For interventions that were not evaluated in systematic reviews, we next searched MEDLINE and Cochrane library for additional randomised placebo-controlled trials published between January 2000 and January 2014. Two of the reviewers (OT and JIB) independently assessed the five criteria mentioned above risk of bias in the additional RCTs that were identified from this search. [not selected from systematic reviews, based on the same five criteria that were used for the selection of trials from systematic reviews.](#)~~

The searches provided trials of the following interventions: percutaneous laser revascularisation of myocardium for angina pectoris, closure of foramen ovale for migraine, arthroscopic meniscectomy for meniscal tears, debridement and injection of hyaluronic acid for symptomatic osteoarthritis of the knee, epidural injections of corticosteroids for sciatica, percutaneous heating of the intervertebral disc for chronic low back pain, vertebroplasty for vertebral body fractures, and injection or transplantation of biological tissue for Parkinson's disease.

The rationale for the introduction of most of these interventions is that a physiological derangement can be brought back to an original, healthy state by invasive techniques. Promising results in initial pragmatic uncontrolled trials in some cases led to widespread clinical implementation, even though some subsequent larger and methodologically more rigorous trials failed to replicate the initial findings. Another common feature of the included interventions is that their rationale is primarily based on improvements in subjective outcome, including pain and health related quality of life.

The searches provided no sham-controlled trials of percutaneous heating of the cervical intervertebral disc, lumbar facet joint injections, chemonucleolysis, transmyocardial laser revascularization for angina, deep brain stimulation for Parkinson's disease or arthroscopic procedures (other than knee conditions). No studies of radiofrequency denervation or intradiscal steroid injection for low back pain were found that provided SD, which is a requirement for calculation of effect size.

From the most recently published systematic review of each procedure, we selected randomised placebo-controlled trials that according to the review fulfilled at least four of the following criteria: random allocation, allocation concealment, blinding of participant, blinding of assessor and intention to treat analysis. For procedures that were not evaluated in systematic reviews, we searched MEDLINE and Cochrane library for randomised placebo-controlled trials. Two of the reviewers (OT and JIB) independently assessed the risk of bias in the RCTs that were not selected from systematic reviews, based on the same five criteria that were used for the selection of trials from systematic reviews.

Only English language journals were included. We excluded [crossover trials](#), trials that did not report results as means, standard deviation, standard error or confidence intervals in both active and sham-groups, as well as trials with only graphic representation of data. We excluded reviews with declared commercial conflicts of interest in order to avoid the risk of financially motivated selection of trials in these reviews.

Commercially funded RCTs were not excluded, because all the included trials had been screened for bias either by the high-quality systematic reviews or by two of the authors, using strict methodological criteria. Details of the search strategy are shown in web appendix table 1 and web appendix figure 1. [We give a](#) short description of each procedure's introduction, therapeutic rationale and history, [is given](#) in web appendix table 2. This review is reported in accordance with the PRISMA statement.¹²

Data extraction

We registered all continuous primary endpoints. In trials without continuous primary endpoints, with multiple endpoints or no defined primary endpoint, we selected an outcome related to pain or condition-specific endpoint. The heterogeneity of trials did not allow for use of pain as a primary outcome. We used the RCTs' defined primary outcome to avoid bias introduced by choosing our own endpoint. We also registered secondary endpoints in order to avoid potential bias from selective reporting in the included trials. The included and excluded secondary endpoints are shown in web appendix table 3. Endpoints describing medication, radiographic or physiological variables, social or psychological function, were not included. For the [Parkinson trials](#), only endpoints in the off-medication state were registered. Results [from](#) the last follow-up until 12 months were extracted. The trials' protocol [registration](#), funding source, [description of sham intervention](#), sample size, disease duration, length of follow-up and reported adverse events in both trial arms were registered ([tables 1 and 2](#)).

Data synthesis

To assess clinically important change, we calculated effect size (ES, Cohen's d), based on the means and standard deviations (SD). We calculated ES both for the active and sham intervention to obtain information about the pre-to-post treatment change in both arms. Without first calculating ES of change in each trial [arm](#), we would not be able to discern the relative contribution of placebo, which was one of the objectives of the study. [ES was calculated by subtracting the average score after treatment from the average score before treatment and dividing the result by the average of the standard deviations before and after treatment](#) Subtracting the average score after treatment from the average score before treatment and dividing the result by the average of the standard deviations before and after treatment calculated ES. An ES of 0.8 or more is assumed large, while an ES of 0.5 - 0.8 is considered moderate.¹³ In trials with multiple secondary endpoints we calculated the pooled mean ES, without weighting. Because of small sample sizes in most of the included trials, we calculated an adjusted ES in accordance

with a recommended procedure.¹⁴ Unadjusted linear regression analyses were used to explore the association between outcome in the active and sham groups both for primary and pooled secondary endpoints. For this analysis, we used Medcalc Statistical Software version 12.7.4.0¹⁵

RESULTS

Selection of interventions

The searches provided sham-controlled trials of the following interventions: percutaneous laser revascularisation of myocardium for angina pectoris, closure of foramen ovale for migraine, arthroscopic meniscectomy for meniscal tears, debridement and injection of hyaluronic acid for symptomatic osteoarthritis of the knee, epidural injections of corticosteroids for sciatica, percutaneous heating of the intervertebral disc for chronic low back pain (two techniques), vertebroplasty for vertebral body fractures, and injection or transplantation of biologically active material for Parkinson's disease (human retinal pigmental cells, fetal nigral cells and Neurturin-3 techniques). Because of the large number of described interventions for neck- and back pain syndromes, we chose to restrict the analysis to sham-controlled trials of the following interventions:

~~No studies of radiofrequency denervation or intradiscal steroid injection for low back pain were found that provided SD, which is a requirement for calculation of effect size. The epidural injections of corticosteroids for sciatica (sacralcaudal, interlaminar or and transforaminal routes), percutaneous heating of the intervertebral disc for chronic low back pain (percutaneous intradiscal radiofrequency thermocoagulation or and intradiscal electrothermal therapy) and vertebroplasty for vertebral body fractures. The searches provided no sham-controlled trials of arthroscopic procedures other than knee conditions.~~

Study selection

The study selection process is summarised in web appendix figure 1. Web appendix table 1 shows the excluded trials and the reasons for exclusion. The search provided five systematic reviews, all identified through searches in MEDLINE, none were commercially funded.¹⁶⁻²⁰ It identified a total of 7410 clinical trials, ten twelve of them were not identified from the systematic reviews. Forty three four trials were excluded for methodological reasons, principally due to risk of bias. Six additional trials were excluded because ES could not be calculated.²¹⁻²⁶ Finally, 221 clinical trials with a total of 257219 participants were included in the present review (table 1). Trial interventions in active treatment and sham arms are also shown.

Table 1. Included studies, protocol approval and funding, interventions in the active treatment and sham arms, and adverse events							
Author	Protocol approval / funding (commercial, non-commercial).	Invasive procedure / indication	Sham intervention	Adverse events related to procedure, active treatment	Adverse events related to procedure, sham		
Leon 2005	Food and Drug Administration / NC	Percutaneous myocardial laser revascularization / intractable angina pectoris	Laser turned on but no procedure performed	MAE in hospital (high dose): 4.1%	MAE in hospital: 0		
Salem 2004	Ethics committee / NC			No procedural AE			
Sihvonen 2013	Review board / NC	Arthroscopic partial meniscectomy / degenerate meniscal tear	Routine arthroscopy, simulation of meniscectomy by manipulation etc.	No MAE			
				mAE: 6.6%	mAE: 2.9%		
Moseley 2002	Review Board / NC	Arthroscopic debridement / Knee osteoarthritis	Simulated arthroscopy preparation, intravenous anaesthesia, skin incisions, no instruments entered knee, knee manipulated	No procedural AE			
Pham 2004	Review Board / NC	Hyaluronic acid / Knee osteoarthritis	Intraarticular injection of saline solution	No MAE			
Altman 2004	Ethics committee / C			Any mAE: 81.7%	Any mAE: 1.2%		
				No MAE			
Chevalier 2010	ClinicalTrials.org / C			No MAE			
		mAE: 35,8%	mAE: 33,8%				
Kallmes 2009	Review Board / NC	Percutaneous vertebroplasty with PMMA cement injection / vertebral compression fracture	Conscious sedation + local anaesthesia, pressure put on spine, simulation of odor with mixing of PMMA to imitate the smell during the active procedure	No MAE			
				mAE: 14%	mAE: 16%		
Buchbinder 2009	Ethics committee at each participating center Australian Clinical Trial Register / NC		Conscious sedation + local anaesthesia, needle inserted to rest on the lamina, PMMA container opened to imitate the smell during the active procedure	No procedural AE			

Cohen 2012	Review Board / NC	Epidural injection of corticosteroids / Sciatica	2 ml sterile water at 1-2 injection sites, transforaminal approach	No MAE	
				mAE:36%	mAE: 20%
Arden 2005	Ethics committee / NC		2 mL saline into interspinous ligament	No MAE	
				mAE: 9%	mAE: 10%
Valat 2002	Ethics committee / NC		2 mL saline into epidural space, interlaminar approach	No MAE	
				mAE: 6%	mAE: 8%
Iversen 2011	Ethics committee / NC		Subcutaneous injection of 2 mL saline superficial to the sacral hiatus	Not reported	
Freeman 2005	Ethics committee / C	Intradiscal electrothermal therapy (IDET) / discogenic low back pain	17-gauge introducer needle inserted into disc under fluoroscopic guidance, catheter inserted but not connected to generator, both subject and surgeon blinded.	No MAE	
				mAE: 11%	mAE: 5%
Pauza 2003	Review Board / NC		17-gauge needle introduced onto the outer annulus, mock electrode passage shown on monitor, generator noises produced	Not reported	
Kvarstein 2009	Ethics committee / NC	Percutaneous intradiscal radiofrequency thermocoagulation (PIRFT) / discogenic low back pain	17-gauge canula and RF-probe inserted into annulus, no RF current applied	Not reported	
Olanow 2003	Review Board / NC	Fetal nigral transplantation, 4 donors / Parkinson's disease	Scalp incisions, partial thickness burr holes, no cell transplantation, 6 months low-dose cyclosporine	No MAE	
				mAE (rate/patient day): 0,66	mAE (rate/patient day): 0,39
Marks 2010	Review Board / C	Gene delivery of AAV2-Neurturin / Parkinson's disease	Scalp incisions, partial thickness burr holes, no intracranial injections	MAE: 4	MAE: 0
				Most frequent mAE: headache: 68%	Most frequent mAE: headache: 50%
Gross 2011	Review Board /	Transplantation of	Scalp incisions,	1 death	0 deaths

	C	human retinal pigmental cells / Parkinson's disease	partial thickness burr holes, no cell transplantation	MAE: 23%	MAE: 0
LeWitt 2011	Review Board / C	Insertion of AAV-GAD gene into subthalamic nucleus / Parkinson's disease	Insertion of catheter caudal to nucleus, infusion of saline	No MAE	
				mAE (probably related to procedure): 56%	mAE (probably related to procedure): 14%
Dowson 2008	Ethics committee / C	Patent foramen ovale closure with STARFlex Septal Repair Implant / migraine	General anesthesia, skin incision in the groin	MAE (possibly or probably related to procedure): 11%	MAE (possibly or probably related to procedure): 4%
C=commercial; NC=non-commercial; MAE=major adverse events; mAE=minor adverse events; PMMA=polymethylmethacrylate; AAV2 =adeno-associated; GAD=glutamic acid decarboxylase					

Fourteen trials were selected from the systematic reviews fulfilled at least four of the five methodological criteria.^{27 28 31-42} One trial did not fulfil the methodological criteria and was excluded. Seven trials were selected provided through searches in MEDLINE fulfilled the same criteria.^{29 29-30,443-487} and all these trial fulfilled at least four of the five methodological criteria. The two authors who independently screened the individual trials, with special emphasis on concealment of treatment allocation and blinding, found the risk of bias to be generally low.

All trials reported approval of study protocol prior to patient enrolment (table 1). Eight trials were commercially funded.^{32 33 41 44-478} Most of the trials had few participants, ranging from 20 to 346 (median 80).

Clinical outcomes after active treatment and sham

Twelve of the 22 trials showed a large ES on primary endpoints after active treatment, while 11 trials showed a similar ES after the sham procedure (figure 1, table 2).

Table 2. Effect size (ES) on primary and pooled secondary endpoints, showing differences between active treatment and sham arms.

Author / procedure	Limit disease duration / time to follow-up (months)	Trial arm / no of patients randomised	ES primary endpoint	ES pooled secondary endpoints (no of endpoints)

12

Leon 2005 / Percutaneous myocardial laser revascularization	None / 12		Exercise duration (s)	(10)
		Active / 98	0.23	0.60
		Sham / 102	0.22	0.54
ES active treatment vs sham			0.01	0.07
Salem 2004 / Percutaneous myocardial laser revascularization	None / 12		Exercise duration (s)	-
		Active / 40	0.04	
		Sham / 42	0.08	
ES active treatment vs sham			-0.04	
Sihvonen 2013 / Arthroscopic partial meniscectomy	>3 / 12		Lysholm knee score	(4)
		Active / 70	0.86	0.58
		Sham / 76	1.03	0.58
ES active treatment vs sham			-0.17	0.00
Moseley 2002 / Arthroscopic debridement	None / 12		Knee Specific Pain Scale	(5)
		Active / 59	0.54	0.11
		Sham / 60	0.85	0.20
ES active treatment vs sham			-0.31	-0.09
Pham 2004 / Hyaluronic acid			VAS Pain	(3)
	None / 12	Active / 131	1.48	1.35
		Sham / 85	1.54	1.30
ES active treatment vs sham			-0.06	0.05
Chevalier 2010 / Hyaluronic acid			Womac A	Womac C function
	None / 6	Active / 124	1.52	1.13
		Sham / 129	1.18	1.07
ES active treatment vs sham			0.34	0.06
Petrella 2002 / Hyaluronic acid			Womac-pain	(8)
	None / 1	Active / 25	0.35	0.54
		Sham / 28	0.15	0.40

ES active treatment vs sham			0.22	0.14
Altman 2004 / Hyaluronic acid	None / 6		Womac pain	(2)
		Active / 172	0.76	0.38
		Sham / 174	0.85	0.53
ES active treatment vs sham			-0.09	-0.15
Kallmes 2009 / Percutaneous vertebroplasty	<12 / 1		Roland-Morris Disability Questionnaire	(7)
		Active / 68	0.86	0.72
		Sham / 63	0.81	0.63
ES active treatment vs sham			0.05	0.09
Buchbinder 2009 / Percutaneous vertebroplasty	<12 / 6		Pain Score	(4)
		Active / 38	0.83	0.46
		Sham / 40	0.71	0.51
ES active treatment vs sham			0.12	-0.05
Cohen 2012 / Epidural injection of corticosteroids	<6 / 1		NRS leg pain	(2)
		Active / 28	1.51	0.88
		Sham / 30	0.82	0.39
ES active treatment vs sham			0.69	0.49
Iversen 2011 / Epidural injection of corticosteroids	>3 / 12		Oswestry disability index	-
		Active / 36	1.68	
		Sham / 40	1.85	
ES active treatment vs sham			-0.17	
Arden 2005 / Epidural injection of corticosteroids	>1<18 / 12		Oswestry disability index	(2)
		Active / 120	1.42	1.14
		Sham / 108	1.44	1.21
ES active treatment vs sham			-0.02	-0.07
Valat 2002 / Epidural injection of corticosteroids	<6 / 1		VAS Pain	(3)
		Active / 42	1.85	1.10
		Sham / 43		0.99

14

			1.47	
ES active treatment vs sham			0.38	0.10
Freeman 2005 / Intradiscal electrothermal therapy	≥3 / 6		Oswestry disability index (6)	
		Active / 38	0.10	-0.03
		Sham / 19	0.07	0.12
ES active treatment vs sham			0.17	-0.15
Pauza 2003 / Intradiscal electrothermal therapy	>6 / 6		Oswestry disability index (3)	
		Active / 32	0.94	0.90
		Sham / 24	0.35	0.46
ES active treatment vs sham			0.59	0.44
Kvarstein 2009 / Percutaneous intradiscal radiofrequency thermocoagulation	>6 / 12		Brief Pain Inventory (5)	
		Active / 10	0.34	0.54
		Sham / 10	0.23	0.24
ES active treatment vs sham			0.11	0.30
Olanow 2003 / Fetal nigral transplantation	None / 24		UPDRS 3 off (5)	
		Active / 12	0.04	-0.24
		Sham / 11	0.44	-0.19
ES active treatment vs sham			0.48	-0.06
Marks 2010 / Gene delivery of AAV2-Neurturin	≥60 / 12		UPDRS 3 off (7)	
		Active / 38	0.72	0.23
		Sham / 20	0.53	-0.05
ES active treatment vs sham			0.19	0.28
Gross 2011 / Transplantation of human retinal pigmental cells	≥60 / 12		UPDRS 3 off (2)	
		Active / 35	1.09	0.08
		Sham / 36	0.88	0.06
ES active treatment vs sham			0.21	0.02
LeWitt 2011 / AAV-GAD gene into subthalamic nucleus	≥60 / 6		UPDRS 3 off (7)	
		Active / 16		0.30

			1.00	
		Sham / 21	0.42	0.21
ES active treatment vs sham			0.58	0.08
Dowson 2008 / Patent foramen ovale closure	None / 6		Frequency migraine/month (per protocol)	Headache Impact Test
		Active / 74	0.74	1.02
		Sham / 73	0.45	1.06
ES active treatment vs sham			0.28	0.04
VAS=Visual Analogue Scale; NRS=Numerical Rating Scale; UPDRS=Unified Parkinson's Disease Rating Scale; Womac=Western Ontario and McMaster Universities Osteoarthritis Index				

ES on primary endpoints was moderate in ~~four~~three of the active treatment groups and in two of the sham groups.

On pooled secondary endpoints, a large ES was estimated in seven trials after active treatment and in five trials after sham, while a moderate ES was reported in ~~five~~four and ~~four~~three trials respectively (table 2).

In none of the trials did the actively treated group show a deterioration of primary endpoint during treatment, while this was the case for two of the sham groups (not reported to be related to the procedure). On secondary endpoints, deterioration occurred in two active treatment and two sham groups (table 2).

Differences in outcome between active treatment and sham

Better results on primary endpoints were reported with active treatment compared to sham in ~~15~~4 of the ~~22~~1 trials, but the differences were small. Three trials (one epidural study³⁸⁷, one discogenic pain study⁴⁰³ and one Parkinson study⁴⁵⁶) reported a moderate effect but none showed a large effect (figure 2, table 2). Seven trials reported a better primary endpoint outcome after sham than after active treatment.

~~Nineteen trials reported On~~ secondary endpoints, ~~12~~1 of ~~these~~19~~20~~ trials reported better outcome after active treatment than after sham, but in no case did the differences reach a moderate ES (figure 2, table 2). In ~~twelve~~13~~19~~20 trials, with both primary and secondary endpoints, the outcome was better for primary than for pooled secondary endpoints. This bore no relation to funding source.

On regression ~~analyses~~analyses, effect sizes in the sham groups ~~explained~~predicted about 80 % of the variance ~~tion~~ of

ES in the active treatment groups, both on primary and pooled secondary endpoints (figure 3 and 4).

Adverse events

~~Eigh~~Nineteen of the 221 studies provided information about adverse events (AE) (table 1). Three of these trials reported no procedural adverse events in any of the groups.^{27 29 356} Major AEs were reported after active treatment in four trials^{28 445 456 478} including one death in one of the Parkinson studies.⁴⁶⁵ In the sham groups, one trial⁴⁷⁸ listed three major AEs possibly or probably related to the procedure, all thought to be caused by anti-platelet medication, none of them life-threatening. Apart from this trial, there were no major AEs in the sham groups. The reported minor AEs were all of limited duration.

DISCUSSION

Principal findings

~~Our analysis of these 21 selected sham-controlled trials of minimally invasive procedures showed that the general lack of clinical effect sizes effect in the active in the selected trials arms werewas predicted by the effect sizes mainly due to large effects in the sham arms and not to small effects in the active treatment arms. There was in these 221 selected sham-controlled trials of invasive procedures, there was a large clinical ES effect on primary endpoints in about half of both similar number of the active and sham interventions, but none of the trials showed a large ES effect between active treatment and sham groups either on primary or secondary endpoints.~~

~~I was moderate in three trials, while none demonstrated a large effect. On pooled secondary endpoints, none of the trials showed even a moderate clinical effect.~~

~~Our analysis of effect sizes showed that the general lack of clinical effect in the selected trials was mainly due to large effects in the sham arms and not to small effects in the active treatment arms. However,~~ the magnitude of the effect in each trial arm varied considerably, both between different procedures and between trials using the same procedure. For instance, in the active treatment groups, ES for primary endpoints varied from around zero to almost 2 after active treatment, and from about -0.4 to 1.5 after sham. Disparate outcomes were reported even between trials where technical parameters were similar. For instance, ES in the sham group in the three hyaluronic acid-trials varied by a factor of three, and in the epidural trials by a factor of two. This variability is probably related to differences in study design, duration of disability before inclusion, contextual factors, including the doctor-patient relationship as well as other factors. The close

association between endpoints in the active treatment and sham groups on regression analyses suggests that a large part of the reported outcomes in the active treatment groups are due to placebo effects, statistical regression to the mean or the natural course of the condition.

Strengths and limitations of study

It is our opinion that the calculation of effect sizes in both active treatment and placebo arms is a strength of the present study. This made it possible to assess the magnitude of change in both arms as well as and the contribution of non-specific factors to change in the active treatment arms. The calculation of effect sizes provides an alternative assessment to probability estimates. Another strength of the study is the supplementary analyses of pooled secondary endpoints, enabling a more comprehensive evaluation than using primary endpoints alone. Reports of tactically motivated use of primary and secondary endpoints before publication in order to improve study results strengthen the argument for registering all relevant secondary endpoints.⁴⁸ Our finding that a majority of trials reported better results on primary than on secondary endpoints might lend support to such a hypothesis, although all trials, according to the authors, had sought and gained approval of the protocol from ethics committee and/ or review board (table 1).

The use of ES as a measure of clinical effect assumes a normal distribution of the data. This does not necessarily apply in the included trials because the majority of them are small. Including trials reporting non-parametric data would however necessitate other methods of statistical analysis. Small studies increase the likelihood of type-2 errors, though this is more relevant to probability estimates than analysis of ES.

We applied principles from guidelines for conducting systematic reviews and meta-analyses and included an independent assessment of methodological trial quality by two of the authors. However, we cannot rule out that we have missed relevant trials because we limited our search to the Cochrane Library and MEDLINE, but most relevant trials are likely to have been identified by our searches. By preferentially selecting core journals and trials that had previously been methodologically evaluated in systematic reviews, it was our intention to reduce the risk of bias by excluding studies of low quality. We realize that this selection process and the fact that we relied on previous methodological evaluations may have contributed to unrecognised selection bias.

The present It must be emphasised that this review is exploratory, being limited to some selected minimally invasive procedures in cardiology, neurology, and musculoskeletal

~~conditions. to certain conditions and interventions, and also excluding interventions for life threatening conditions. We applied principles from guidelines for conducting systematic reviews and meta-analyses. By selecting core journals and trials that had previously been methodologically evaluated in systematic reviews, it was our intention to reduce the risk of bias by excluding studies of low quality. We realize that this selection process and the fact that we relied on previous methodological evaluations may contribute to unrecognised selection bias.~~ The strengths of the present systematic review include the use of strictly defined selection criteria to minimise bias.

~~For five six of the eighttwelvenine procedures we identified selected trials that, according to from the most recent systematic reviews published in core clinical journals, fulfilled at least four of the following criteria: random allocation, allocation concealment, blinding of participant, blinding of assessor and intention to treat analysis.~~

~~For the remaining, all of them by authors without declared commercial interests. From these reviews, we selected trials that complied with a set of predefined methodological criteria. †Threefour procedures six four procedures, additional trials that were identified by directly through MEDLINE searches and the same criteria were used to assess bias. We cannot rule out that we have missed relevant trials because we limited our search to the Cochrane Library and MEDLINE, but most relevant trials are likely to have been identified by our searches. It must be emphasised that our limitation to certain conditions, as well as the heterogeneous nature of selected interventions, imply that our findings cannot be generalised to minimally invasive procedures in all medical disciplines. We believe, however, that the same methodology could be applied to more systematic analyses of the role of placebo effects in other conditions and procedures.~~

~~We applied principles from guidelines for conducting systematic reviews and meta-analyses. By selecting core journals and trials that had previously been methodologically evaluated in systematic reviewsreviews, it was our intention to reduce the risk of bias by excluding studies of low quality. We realize that this selection process and the fact that we relied on previous methodological evaluations may contribute to unrecognised selection bias. We also emphasise that our limitation to certain conditions and highly heterogeneous interventions implies that our findings cannot be generalised to minimally invasive procedures in all medical disciplines.~~

~~The calculation of effect sizes in both active treatment and placebo arms enabled us to assess the magnitude of change in both groups. This in turn made it possible, through regression analysis, to show that non-specific effects, including placebo, can largely explain the variation in outcomes after the active~~

1
2
3
4
5
6
7 interventions. The calculation of effect sizes provides a better
8 assessment of clinically important effects than using
9 probability estimates, and supplementary analyses of pooled
10 secondary endpoints contribute to a more comprehensive
11 evaluation than using primary endpoints alone. Reports of
12 tactically motivated manipulation of primary and secondary
13 endpoints before publication in order to improve study results
14 are also arguments in favour of registering all relevant
15 secondary endpoints.⁴⁹ Our finding that a majority of trials
16 reported better results on primary than on secondary
17 endpoints might lend support to such a hypothesis. However,
18 according to the authors, all trials had sought and gained
19 approval of the protocol from ethics committee and/ or review
20 board (table 1).

21 The described indications and procedures are heterogeneous,
22 encompassing both neurological, orthopaedic and cardiological
23 specialties. While some procedures are, or have been, in wide
24 clinical use, some are still in the clinical trial phase. are still
25 considered experimental. Other sources of heterogeneity are
26 variable duration of disease before inclusion, the selection of
27 outcome measures and time to follow-up. R~~though~~ esults our
28 findings cannot be generalised to minimally invasive
29 procedures in all medical disciplines, but we hypothesise that a
30 similar methodology could be applied to more systematic
31 analyses of the role of non-specific effects in other minimally
32 invasive procedures.

33 We emphasise that our limitation to certain conditions and
34 interventions implies that our findings cannot be generalised
35 to minimally invasive procedures in all medical disciplines.
36 Other sources of heterogeneity were are variable duration of
37 disease before inclusion, time to follow-up and variable and
38 outcome measures. The contribution of spontaneous
39 improvement relative to placebo effect might be expected to
40 be greater with longer time to follow-up.

41 screened for bias using the same methodology.

42 Moreover, we ~~Our~~ calculation of ed the effect sizes in both
43 active treatment and placebo arms, enabled ing us to assess
44 the magnitude of change in both groups. This in turn made it
45 possible, through regression analysis, to show that non-specific
46 effects, including placebo, can largely explain the variation in
47 outcomes after the active interventions. The calculation of
48 effect sizes provides a better assessment of clinically important
49 effects than using probability estimates, and supplementary
50 analyses of pooled secondary endpoints contribute to a more
51 comprehensive evaluation than using primary endpoints alone.
52 Reports of tactically motivated manipulation of primary and
53 secondary endpoints before publication in order to improve
54 study results are also arguments in favour of registering all
55 relevant secondary endpoints.⁴⁹ Our finding that a majority of

1
2
3
4
5
6
7 trials reported better results on primary than on secondary
8 endpoints might lend support to such a hypothesis. However,
9 according to the authors, all trials had sought and gained
10 approval of the protocol from ethics committee and/or review
11 board (table 1).

12
13 The present study has several potential limitations. The
14 described indications and procedures are heterogeneous,
15 encompassing both neurological, orthopaedic and cardiological
16 specialties. While some procedures are, or have been, in wide
17 clinical use, some are still considered experimental. Duration
18 of disease before inclusion, time to follow up and outcome
19 measures varied considerably, adding to the heterogeneity.
20 The contribution of spontaneous improvement relative to
21 placebo effect might be expected to be greater with longer
22 time to follow up. We cannot exclude that we have missed
23 may have missed relevant trials because we limited our search
24 to the Cochrane Library and MEDLINE, but most relevant trials
25 are likely to be identified by our searches, or because of
26 publication bias in the MEDLINE searches, though this is less
27 likely for trials selected from the included systematic reviews.
28 The use of ES as a measure of clinical effect assumes a normal
29 distribution of the data. This does not necessarily apply in the
30 included trials because the majority of them are small.
31 Including trials reporting non-parametric data would however
32 necessitate other methods of statistical analysis. Small studies
33 increase the likelihood of type-2 errors, though this is more
34 relevant to probability estimates than analysis of ES.

35 We applied principles from guidelines for conducting
36 systematic reviews and meta-analyses and included an ~~The~~
37 independent assessment of methodological trial quality by
38 two of the authors. authors gives added confidence in the trial
39 selection. However, we cannot rule out that we have missed
40 relevant trials because we limited our search to the Cochrane
41 Library and MEDLINE, but most relevant trials are likely to have
42 been identified by our searches. By preferentially selecting
43 core journals and trials that had previously been
44 methodologically evaluated in systematic reviews, it was our
45 intention to reduce the risk of bias by excluding studies of low
46 quality. We realize that this selection process and the fact that
47 we relied on previous methodological evaluations may have
48 contributed to unrecognised selection bias.

49 The use of ES as a measure of clinical effect assumes a normal
50 distribution of the data. This does not necessarily apply in the
51 included trials because the majority of them are small.
52 Including trials reporting non-parametric data would however
53 necessitate other methods of statistical analysis. Small studies
54 increase the likelihood of type-2 errors, though this is more
55 relevant to probability estimates than analysis of ES.

Adequate blinding and lack of physiological effects?

We cannot rule out that treatment-specific effects in the actively treated groups may have jeopardised blinding, leading to overestimation of treatment effects through positive expectations. However, all the included trials gave a detailed description of the sham procedure, and both participant and assessor blinding seems to have been adequate.

On a more general level, it has been argued that sham procedures are not inert and may have specific physiological effects, thereby underestimating a treatment effect.^{50,49} More recently, Bickett et al. hypothesised that epidural injection of small volumes of saline might have physiological effects.^{50,4} However, it is to be noted that in the four selected epidural trials in the present study, improvements in the sham group were greater in the two trials using non-epidural saline than in those using epidural saline, making a physiological effect less likely. In our opinion, physiological effects of the sham interventions are also unlikely in the remaining procedures.

Surgery and other invasive procedures are commonly believed to be associated with enhanced placebo effects, a phenomenon coined mega-placebo.^{51,2} In spite of their heterogeneous nature, the 22¹ selected trials share a medico-technological context in which an a priori enhanced placebo response could be expected. If an ES >0.8 is considered as mega-placebo, nearly half of the included sham interventions reached this level. Factors such as the level of enthusiasm and conviction conveyed by the therapist, the impression of advanced procedures and the extent to which these factors succeed in activating a placebo response are probably crucial in explaining the improvements after sham interventions and the correlation of endpoints in the active treatment and sham groups. Participants' perception of whether they received active treatment or sham has been shown to contribute more to clinical improvement than the biological effects per se.^{26 52,3}

Non-specific factors

The role of non-specific factors, primarily spontaneous remission or statistical regression-to-the-mean, in placebo-controlled studies is controversial.^{53,4} A recent meta-analysis analysing 202 trials with an untreated group, spanning 60 different clinical conditions, found rather small differences between placebo and no treatment, with effect sizes in the range of 0.2 to 0.3.^{54,5} Apart from acupuncture trials (mean ES 0.68), the authors did not include trials reporting the effectiveness of invasive procedures. Another meta-analysis studied the placebo effect of a range of treatments (pharmacological, non-pharmacological and surgical) for osteoarthritis of the hand, hip and knee.^{56,2} Of 198 included trials fourteen had a no-treatment arm. The mean ES in the

1
2
3
4
5
6
7 placebo groups was about 0.5, while it was only slightly above
8 zero in the no-treatment groups. The difference between the
9 placebo and no-treatment groups was larger than the
10 difference between the placebo and active treatment groups.
11 Trials using injections, acupuncture and surgery had the largest
12 placebo effects, and the effects were larger for subjective than
13 objective endpoints. The authors concluded that there is a
14 significant placebo effect on pain, stiffness and function in
15 symptomatic osteoarthritis.

16 Because the trials in the present study did not include a no-
17 treatment arm (i.e. waiting list), we cannot rule out that the
18 changes appearing during the trial period also reflect non-
19 specific factors, i.e. spontaneous improvement or regression to
20 the mean. Such mechanisms would be expected to be most
21 prominent in trials with brief illness duration before inclusion
22 [and with longer time to follow-up](#), while improvements in
23 chronic, unremitting conditions such as Parkinson's disease
24 would be more likely attributed to placebo. Interestingly, in
25 three of the four included Parkinson trials, there were
26 moderate to large improvements in the sham groups even at
27 one-year follow-up.⁴⁴³⁻⁴⁶⁵ Other authors have also found
28 improvements several years after sham surgery,
29 indistinguishable from conventional surgery.^{26 562} This is in
30 agreement with recent insights into the neurobiological effects
31 of placebo and their relation to underlying psychological
32 mechanisms, principally expectation and conditioning.⁵⁷⁹

33 **Are ethical objections to sham justified?**

34 The use of sham in controlled surgical trials is a divisive issue,
35 with scepticism, even frank opposition, being voiced by both
36 ethics committees, involved surgeons and anaesthetists, and
37 potential patients.⁵⁸⁹ Ethical arguments include the inherent
38 risks of sham procedures combined with the lack of obvious
39 benefits to the participants. Barriers related primarily to
40 feasibility include problems with patient and assessor blinding,
41 differing technical expertise, the heterogeneity of the
42 interventional techniques and variable outcome specifications,
43 making standardization difficult to achieve. Existing ethical
44 guidelines accept the role of placebo-controlled trials when
45 certain conditions are met.⁶⁰⁻⁵⁹ There must be genuine
46 equipoise, i.e. conflicting or weak evidence of the effectiveness
47 of a procedure. Blinding of both participants and assessors
48 must be assured, and participants must freely consent to
49 suspend knowledge of whether they are receiving sham or
50 conventional treatment. The health risks and consequences of
51 placebo or delayed treatment must be minimal, and
52 outweighed by the societal importance of establishing the
53 clinical utility of the intervention in question.^{60 61 62}

54 The selected trials gave a detailed description of adverse
55 events in both active and sham-treated groups (table 1). The
56
57
58
59
60

safety concerns frequently raised as an argument against the use of sham were generally not supported. Major adverse events related to the sham procedure were reported in only one of the trials^{42,6} and they were short-lived and not life threatening. Minor adverse events were more frequent, but also of limited duration. Positive placebo-induced effects generally outweighed adverse events, thus weakening ethical arguments against the use of sham interventions. In our opinion, the ~~ethical~~ consequences of the continued use of unproven invasive procedures are of a different magnitude. In the light of studies supporting the beneficial effects of sham procedures, at least for pain and Parkinson symptoms, research ethics committees should consider such factors in their risk-benefit assessments of planned sham controlled trials.^{62,63,64}

~~Behov for mer homogene pas mat~~

Clinical implications.

The present results are pertinent to the ongoing discussion about wasteful and unproven medical practices, and underscore the necessity for a continual assessment of existing or novel unproven procedures. Minimally invasive techniques have lowered the threshold for interventions, and led to their application to a wider clinical spectrum (indication creep) without an ongoing evaluation of effectiveness or safety.⁴ The last two decades have seen dramatic increases in the use of several of the described procedures, as well as interventions we have not investigated, such as -facet joint injections, radiofrequency neurotomy, acromioplasty, percutaneous coronary intervention and, more recently, robotic surgery.^{65-70,69} In light of the results in the present study, placebo effects might well explain a large part of the purported effects of such procedures. When clinicians and regulators are faced with claims of large treatment effects for insufficiently tested procedures, their default mode should be watchful scepticism. The standards of the evaluation process before approval and reimbursement of devices and procedures need to be strengthened, and economic or regulatory incentives that perpetuate the use of undocumented or harmful procedures should be abrogated.

CONCLUSION

Sham-controlled trials are unique in their ability to discriminate between true treatment effects and non-specific effects. The results of the present study suggest that placebo ~~and other non-specific~~ effects ~~associated with minimally invasive~~ ~~the selected interventions~~ ~~explain~~ ~~explain~~ a large part of their ~~purported benefits~~ ~~of the selected procedures~~. Further, results indicate that the risks of adverse events in sham-controlled trials are overrated, ~~and~~ ~~The risks are could~~ ~~be considered,~~ ~~and in many cases could~~ ~~might be viewed as~~ acceptable, ~~not least~~ in view of the ~~potential for large~~ personal

~~harm and societal costs-harm costs and associated dubious ethics of with the continued use of~~ unproven minimally invasive interventions.

Figure legends

Figure 1. Effect sizes of active treatment and sham, primary endpoints.

Figure 2. Differences in effect size between active treatment and sham.

Figure 3. Association between effect sizes of primary endpoints in active treatment and sham arms. Linear regression, 95% confidence intervals. N=~~221~~.

Figure 4. Association between effect sizes of pooled secondary endpoints in active treatment and sham arms. Linear regression, 95% confidence intervals. N=~~2019~~.

References

1. Prasad V, Vandross A, Toomey C et al. A decade of reversal: an analysis of 146 contradicted medical practices. *Mayo Clin Proc* 2013;**88**:790-8.
2. Tiago V, Pereira TV, Horwitz RI et al. Empirical Evaluation of Very Large Treatment Effects of Medical Interventions. *JAMA* 2012;**308**:1676-84.
3. Roberts AL, Kewman DG, Mercier L et al. The power of nonspecific effects in healing: implications for psychosocial and biological treatments. *Clin Psychol Rev* 1993;**13**:375-91.
4. Garner S, Littlejohns P. Disinvestment from low value clinical interventions: NICEly done? *BMJ* 2011;**343**:d4519.

- 1
2
3
4
5
6
7 5. Scott IA, Elshaug AG. Foregoing low-value care: how
8 much evidence is needed to change beliefs? *Intern*
9 *Med J* 2013;**43**:107-9.
- 10
11
12 6. Obremsky WT, Pappas N, Attallah-Wasif E et al. Level
13 of evidence in orthopaedic journals. *J Bone Joint Surg*
14 *Am* 2005;**87**:2632-8.
- 15
16
17 7. Reeves B. Health-technology assessment in surgery.
18 *Lancet* 1999;**353**:Suppl 1:S13-S15;
- 19
20
21 8. Wenner DM, Brody BA, Jarman AF et al. Do surgical
22 trials meet the scientific standards for clinical trials? *J*
23 *Am Coll Surg* 2012;**215**:722-30.
- 24
25
26 9. Ezekiel JE, Miller FG. The Ethics of Placebo-Controlled
27 Trials — A Middle Ground. *N Engl J Med* 2001;**345**:915-
28 9.
- 29
30
31 10. Campbell MK, Entwistle VA, Cuthbertson BH et al.
32 Developing a placebo-controlled trial in surgery: issues
33 of design, acceptability and feasibility. *Trials*
34 2011;**12**:50
- 35
36
37 11. Cochrane Handbook for Systematic Reviews of
38 Interventions. Version 5.1.0.
39 <http://handbook.cochrane.org>; (11.11.2014)
- 40
41
42 12. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA
43 statement for reporting systematic reviews and meta-
44 analyses of studies that evaluate healthcare
45 interventions: explanation and elaboration. *BMJ*
46 2009;**339**:b2700.
- 47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
13. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.
14. Durlak JA. How to Select, Calculate, and Interpret Effect Sizes. *J Pediatr Psychol* 2009; **34**: 917-28.
15. MedCalc Software bvba, Ostend, Belgium; <http://www.medcalc.org>; (08.03.2014).
16. Rutjes AWS, Jünl P, da Costa BR et al. Viscosupplementation for Osteoarthritis of the Knee. A Systematic Review and Meta-analysis. *Ann Intern Med* 2012;**157**:180-91.
17. Pinto RZ, Maher CG, Ferreira ML et al. Epidural corticosteroid injections in the management of sciatica: a systematic review and meta-analysis. *Ann Intern Med* 2012;**157**:865-77.
18. McGillion M, Cook A, Victor JC et al. Effectiveness of percutaneous laser revascularization therapy for refractory angina. *Vasc Health Risk Manag* 2010;**6**:735-47.
19. Helm S II, Deer TR, Manchikanti L et al. Effectiveness of thermal annular procedures in treating discogenic low back pain. *Pain Physician* 2012; **15**:E279-E304.
20. Shi MM, Cai XZ, Lin T et al. Is there really no benefit of vertebroplasty for osteoporotic vertebral fractures? A meta-analysis. *Clin Orthop Relat Res* 2012;**470**:2785-99.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
21. Petrella RJ, Cogliano A, Decaria J. Combining two hyaluronic acids in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. *Clin Rheumatol* 2008;**27**:975-81.
22. Lundsgaard C, Dufour N, Fallentin E et al. Intra-articular sodium hyaluronate 2 mL versus physiological saline 20 mL versus physiological saline 2 mL for painful knee osteoarthritis: a randomized clinical trial. *Scand J Rheumatol* 2008 ;**37**:142-50.
23. Karppinen J, Malmivaara A, Kurunlahti M et al. Periradicular infiltration for sciatica: a randomized controlled trial. *Spine* 2001; **26**:1059-67.
24. Freed CR, Greene PE, Breeze RE et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. *N Engl J Med* 2001;**344**:710-9.
25. Gordon PH, Yu Q, Qualls C et al. Reaction time and movement time after embryonic cell implantation in Parkinson disease. *Arch Neurol* 2004;**61**:858-61.
26. McRae C, Cherin E, Yamazaki TG et al. Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial. *Arch Gen Psychiatry* 2004; **61**: 412-20.
27. Salem M, Rotevatn S, Stavnes S et al. Usefulness and safety of percutaneous myocardial laser revascularization for refractory angina pectoris. *Am J Cardiol* 2004;**93**:1086-91.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
28. Leon MB, Kornowski R, Downey WE et al. A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. *J Am Coll Cardiol* 2005;**46**:1812-9.
29. Moseley JB, O'Malley K, Petersen NJ et al. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. *N Engl J Med* 2002;**347**:81-8.
30. Sihvonen R, Paavola M, Malmivaara A et al. Arthroscopic partial meniscectomy versus sham surgery for a degenerative meniscal tear. *N Engl J Med* 2013;**369**:2515-24.
31. Pham T, Le Henanff A, Ravaud P et al. Evaluation of the symptomatic and structural efficacy of a new_hyaluronic_acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis. *Ann Rheum Dis* 2004;**63**:1611-7.
32. Altman RD, Akermark C, Beaulieu AD et al. Efficacy and safety of a single intra-articular injection of non-animal stabilized_hyaluronic_acid (NASHA) in patients with osteoarthritis of the knee. *Osteoarthritis Cartilage* 2004;**12**:642-9.
33. Chevalier X, Jerosch J, Goupille P et al. Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a

randomised, multicentre, double-blind, placebo controlled trial. *Ann Rheum Dis* 2010;**69**:113-9.

[34.Petrella RJ, DiSilvestro MD, Hildebrand C. Effects of hyaluronate sodium on pain and physical functioning in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled clinical trial. *Arch Intern Med* 2002;**162**:292-8.](#)

[35.34.](#) Kallmes DF, Comstock BA, Heagerty PJ et al. A randomized trial of vertebroplasty for osteoporotic spinal fractures. *N Engl J Med* 2009;**361**:569-79.

[36.35.](#) Buchbinder R, Osborne RH, Ebeling PR et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. *N Engl J Med* 2009;**361**:557-68.

[37.36.](#) Iversen T, Solberg TK, Romner B et al. Effect of caudal epidural steroid or saline injection in chronic lumbar radiculopathy: multicentre, blinded, randomised controlled trial. *BMJ* 2011;**343**:d5278.

[38.37.](#) Cohen SP, White RL, Kurihara C et al. Epidural steroids, etanercept, or saline in subacute sciatica: a multicenter, randomized trial. *Ann Intern Med* 2012;**156**:551-9.

[39.38.](#) Arden NK, Price C, Reading I et al. A multicentre randomized controlled trial

of epidural corticosteroid injections for sciatica: the WEST study. *Rheumatology* 2005;**44**:1399-406.

[40-39.](#) Valat JP, Giraudeau B, Rozenberg S et al. Epidural corticosteroid injections for sciatica: a randomised, double blind, controlled clinical trial. *Ann Rheum Dis* 2003;**62**:639-43.

[41-40.](#) Pauza KJ, Howell S, Dreyfuss P et al. A randomized, placebo-controlled trial of intradiscal electrothermal therapy for the treatment of discogenic low back pain. *Spine J* 2004;**4**:27-35.

[42-41.](#) Freeman BJ, Fraser RD, Cain CM et al. A randomized, double-blind, controlled trial: intradiscal electrothermal therapy versus placebo for the treatment of chronic discogenic low back pain. *Spine* 2005;**30**:2369-77.

[43-42.](#) Kvarstein G, Måwe L, Indahl A et al. A randomized double-blind controlled trial of intradiscal annular radiofrequency thermal disc therapy--a 12-month follow-up. *Pain* 2009;**145**:279-86.

[44-43.](#) Olanow CW, Goetz CG, Kordower JH et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. *Ann Neurol* 2003;**54**:403-14.

[45-44.](#) Marks WJ Jr, Bartus RT, Siffert J et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a

double-blind, randomised, controlled trial. *Lancet Neurol* 2010;**9**:1164-72.

[46-45.](#) Gross RE, Watts RL, Hauser RA et al.

Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial. *Lancet Neurol* 2011;**10**:509-19.

[47-46.](#) LeWitt PA, Rezai AR, Leehey MA et al.

AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. *Lancet Neurol* 2011;**10**:309-19.

[48-47.](#) Dowson A, Mullen MJ, Peatfield R et al.

Migraine Intervention With STARFlex Technology (MIST) trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. *Circulation* 2008;**117**:1397-404.

[49-48.](#) Hannink G, Gooszen HG, Rovers MM.

Comparison of registered and published primary outcomes in randomized clinical trials of surgical interventions. *Ann Surg* 2013;**257**:818-23.

[50-49.](#) Birch S. A review and analysis of placebo

treatments, placebo effects, and placebo controls in

1
2
3
4
5
6
7 trials of medical procedures when sham is not inert. *J*

8
9 *Altern Complement Med* 2006;**12**:303-10.

10 ~~51-50.~~ Bicket MC, Gupta A, Brown CH 4th et al.

11
12 Epidural injections for spinal pain: a systematic review
13
14 and meta-analysis evaluating the "control" injections
15
16 in randomized controlled trials.

17
18 *Anesthesiology*. 2013;**119**:907-31.

19
20 ~~52-51.~~ Kaptchuk TJ, Goldman P, Stone DA et al. Do

21
22 medical devices have enhanced placebo effects? *J Clin*
23
24 *Epidemiol* 2000;**53**:786-92.

25
26 ~~53-52.~~ Einvik G, Tjomsland O, Kvernebo K et al.

27
28 Preoperative expectations and clinical outcome of
29
30 transmyocardial laser treatment in patients with
31
32 angina pectoris. *Tidsskr Nor*

33
34 *Laegeforen* 2002;**122**:2102-4.

35
36 ~~54-53.~~ Turner JA, Deyo RA, Loeser JD et al. The

37
38 importance of placebo effects in pain treatment and
39
40 research. *JAMA* 1994;**271**:1609-14.

41
42 ~~55-54.~~ Hróbjartsson A, Gøtzsche PC. Placebo

43
44 interventions for all clinical conditions. *Cochrane*
45
46 *Database Syst Rev* 2010; CD003974.

47
48 ~~56-55.~~ Zhang W, Robertson J, Jones AC et al. The

49
50 placebo effect and its determinants in osteoarthritis:
51
52 meta-analysis of randomised controlled trials. *Ann*

53
54
55
56
57
58
59
60 *Rheum Dis* 2008;**67**:1716-23.

~~57-56.~~ Marchand S, Kupers RC, Bushnell MC et al.

Analgesic and placebo effects of thalamic stimulation.

Pain 2003;**105**:481-8.

~~58-57.~~ Finniss DG, Kaptchuk TJ, Miller F et al.

Biological, clinical, and ethical advances of placebo effects. *Lancet* 2010;**375**:686-95.

~~59-58.~~ Campbell MK, Entwistle VA, Cuthbertson

BH et al. Developing a placebo-controlled trial in surgery: issues of design, acceptability and feasibility.

Trials 2011;**12**:50. doi: 10.1186/1745-6215-12-50.

~~60-59.~~ Snyder L. Review of the American College

of Physicians Ethics Manual, Sixth Edition. *Ann Intern Med* 2012;**156**(1_Part_2):73-104.

~~61-60.~~ Flum DR. Interpreting surgical trials with

subjective outcomes: avoiding UnSPORTsmanlike

conduct. *JAMA* 2006;**296**:2483-5.

~~62-61.~~ Heckerling PS. Placebo surgery research: a

blinding imperative. *J Clin Epidemiol* 2006;**59**:876-80.

~~63-62.~~ Brim RL, Miller FG. The potential benefit of

the placebo effect in sham-controlled trials:

implications for risk-benefit assessments and informed consent. *J Med Ethics* 2013;**39**:703-7.

~~64-63.~~ Redberg RF. Sham controls in medical

device trials. *N Engl J Med* 2014;**371**:892-3.

~~65-64.~~ Haahr JP, Østergaard S, Dalsgaard J et al.

Exercises versus arthroscopic decompression in

patients with subacromial impingement: a randomised, controlled study in 90 cases with a one year follow up. *Ann Rheum Dis* 2005;**64**:760-4.

66-65. Ketola S, Lehtinen J, Rousi T et al. No evidence of long-term benefits of arthroscopicacromioplasty in the treatment of shoulder impingement syndrome: Five-year results of a randomised controlled trial. *Bone Joint Res* 2013;**2**:132-9.

67-66. Herrlin S, Hällander M, Wange P et al. Arthroscopic or conservative treatment of degenerative medial meniscal tears: a prospective randomised trial. *Knee Surg Sports Traumatol Arthrosc* 2007;**15**:393-401.

68-67. Yu E, Cil A, Harmsen WS et al. Arthroscopy and the dramatic increase in frequency of anterior acromioplasty from 1980 to 2005: an epidemiologic study. *Arthroscopy* 2010;**26**,Supplement:S142-7.

69-68. Vitale MA, Arons RR, Hurwitz S et al. The rising incidence of acromioplasty. *J Bone Joint Surg Am* 2010;**92**:1842-50.

70-69. Brox JI, Staff PH, Ljunggren AE et al. Arthroscopic surgery compared with supervised exercises in patients with rotator cuff disease (stage II impingement syndrome). *BMJ* 1993;**307**:899-903.

Contributors: RH initiated and planned the project and searched databases. JIB and OT assisted in developing search strategies. Article screening and data extraction was carried out by RH. Quality of data extraction and checking was carried out by JIB and OT. Statistical analysis was undertaken by RH, who also wrote the draft. OT and JIB reviewed the draft and contributed to manuscript revisions. RH is the guarantor for this study.

Funding sources: None.

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: Ethical approval was not required for this work.

Data sharing: Dataset can be obtained from Robin Holtedah (robi-hol@online.no).

The lead author affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.

BMJ Open

Placebo effects in trials evaluating 12 selected minimally invasive interventions: a systematic review and meta-analysis.

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-007331.R1
Article Type:	Research
Date Submitted by the Author:	18-Dec-2014
Complete List of Authors:	HOLTEDAHL, ROBIN; Fram Rehabilitation Centre, Tjomsland, Ole; South-Eastern Norway Regional Health Authority, Division of Quality and Specialist Areas Brox, Jens; Oslo University Hospital, Orthopaedic
Primary Subject Heading:	Evidence based practice
Secondary Subject Heading:	Evidence based practice, Ethics, Research methods, Health services research
Keywords:	Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Health economics < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Clinical trials < THERAPEUTICS, MEDICAL ETHICS, PAIN MANAGEMENT

SCHOLARONE™
Manuscripts

only

1
2
3
4 **Placebo effects in trials evaluating 12 selected minimally**
5 **invasive interventions: a systematic review and meta-**
6 **analysis.**
7

8 Robin Holtedahl, Jens Ivar Brox, Ole Tjomsland
9

10
11 Fram Rehabilitation Centre, Rykkinveien 100, 1349 Rykkin,
12 Norway Robin Holtedahl Consultant Department of Physical
13 Medicine and Rehabilitation, Oslo University Hospital, Box
14 4956 Nydalen, 0424 Oslo, Norway Jens Ivar Brox Professor
15 South-Eastern Norway Regional Health Authority,
16 PB 404, 2303 Hamar, Norway Ole Tjomsland Director of Quality
17 and Specialist Areas
18

19
20 Correspondence to: Dr Robin Holtedahl; robi-hol@online,
21 telephone +4790248973
22

23 **Key words:**

24 Placebo effects
25 Invasive procedures
26 Biomedical ethics
27 Evidence based health care
28

29
30 **Word count:** 5801
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 **Objectives** To analyse the impact of placebo effects on outcome in trials of selected minimally
7 invasive procedures, and to assess reported adverse events in both trial arms.
8

9 **Design** A systematic review and meta-analysis.
10

11 **Data Sources and Study Selection** We searched MEDLINE and Cochrane library to identify
12 systematic reviews of musculoskeletal, neurological and cardiac conditions published between
13 January 2009 and January 2014 comparing selected minimally invasive with placebo (sham)
14 procedures. We searched MEDLINE for additional randomised controlled trials published
15 between January 2000 and January 2014.
16

17 **Data synthesis** Effect sizes (ES) in the active and placebo arms in the
18 trials' primary and pooled secondary endpoints were calculated. Linear
19 regression was used to analyse the association between endpoints in
20 the active and sham groups. Reported adverse events in both trial
21 arms were registered.
22
23

24 **Results** We included 21 trials involving 2519 adult participants. For primary endpoints, there
25 was a large clinical effect ($ES \geq 0.8$) after active treatment in 12 trials and after sham
26 procedures in 11 trials. For secondary endpoints, seven and five trials showed a large clinical
27 effect, respectively. Three trials showed a moderate difference in ES between active treatment
28 and sham on primary endpoints ($ES \geq 0.5$) but no trials reported a large difference. No trials
29 showed large or moderate differences in ES on pooled secondary endpoints. Regression
30 analysis of endpoints in active treatment and sham arms estimated an R^2 of 0.78 for primary
31 and 0.84 for secondary endpoints. Adverse events after sham were in most cases minor and of
32 short duration.
33
34

35 **Conclusion** The generally small differences in effect size between active treatment and sham
36 suggest that non-specific mechanisms, including placebo, are major predictors of the observed
37 effects. Adverse events related to sham procedures were mainly minor and short-lived. Ethical
38 arguments frequently raised against sham-controlled trials were generally not substantiated.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

SUMMARY

Key messages

- The magnitude of change in the active treatment and placebo arms varied greatly, but about 80% of the variance in effect size of active treatment could be predicted by placebo effects, regression to the mean or spontaneous improvement.
- Adverse events related to sham procedures were mainly minor and short-lived, and frequently outweighed by positive placebo effects.

Strengths and limitations

- Selection of trials with low risk of bias
- Calculation of effect sizes on primary and pooled secondary endpoints in both active treatment and sham arms.
- Heterogeneous interventions, outcome measures and timing of assessment.

INTRODUCTION

It is normally assumed that medical practices are based on firm clinical evidence, and that new practices or techniques are introduced when superiority, or at least non-inferiority, has been demonstrated compared to established treatments. However, medical history reveals numerous examples contradicting this assumption. Forty-two percent of 146 medical practices were found to be reversed in a recent review analysing 10 years of publication in a high-impact medical journal.¹ Large effects of an intervention in initial reports are often spurious findings, while the vast majority may represent substantial overestimations.²

Even though surgical and other invasive techniques generally have reached a high degree of sophistication through the last decades, not all invasive procedures have lived up to expectations. Promising results in initial observational studies have in some cases led to widespread clinical implementation, in spite of lack of documented effectiveness.³ The reluctance to abandon contradicted medical practice is commonly ascribed to both culturally embedded medical practices and different forms of vested interests.^{4,5} The continuation of unnecessary and potentially harmful interventions leads to major costs for both patients and society.

The randomised placebo-controlled trial is considered the gold standard for evaluating the effects of pharmacological treatments. However, there are relatively few controlled studies in peer-reviewed surgical journals, and even fewer placebo (sham)-controlled studies.⁶⁻⁸ Ethical concerns raised by the potential for harm to participants are usually cited as the main obstacle to sham-controlled studies.⁹ Problems of a practical nature relate to patient blinding, differing technical expertise, the heterogeneity of the interventional techniques and variable outcome specifications, making standardisation difficult to achieve.¹⁰

A meaningful effect in clinical trials may result from a large effect in the active treatment group, a small effect in the placebo group, or a combination. Even though a placebo effect has been documented in a range of clinical conditions, there are few studies assessing the magnitude of the placebo effect in surgical procedures. In the present study, we analysed placebo-controlled trials of minimally invasive interventions in musculoskeletal, neurological and cardiac conditions. The aims were threefold: (a) to assess the magnitude of change in outcome from baseline to trial endpoint in both the active treatment and placebo (sham) arms, (b) to explore the contribution of non-specific factors, including placebo, to the outcome of active treatment, and (c) to assess the level of reported adverse effects in both trial arms.

METHODS

Search strategy and selection criteria

We conducted electronic searches for randomised placebo-controlled trials of minimally invasive interventions for cardiac, neurological and musculoskeletal conditions. We defined minimally invasive procedures as interventions involving the introduction of a medical device, substance or other foreign material into the body through a cannula, catheter or arthroscope, thereby minimising damage to biological tissues at the point of entrance. We first used MEDLINE and Cochrane library to identify systematic reviews published between January 2009 and January 2014. The following key words were used in our search strategies: "randomi* controlled trial", "placebo OR sham" in combination with "low back pain", "neck OR cervical pain", "radiofrequency denervation", "facet joint AND "nerve block" OR injection", "intradiscal OR annular AND thermal", "epidural AND corticosteroid* AND sciatica OR radic*", "hyaluron* OR viscosuppl* AND knee AND osteoarthritis", "vertebroplast*", "arthroscop*", "debridement AND lavage AND knee AND osteoarthr*", "meniscectomy AND knee", "myocardial laser revascularization", "transplantation OR gene OR stem cell OR deep brain stimulation AND Parkinson* OR dystonia", "spinal cord stimulation", and "foramen ovale AND migraine". We used the "core clinical journals" filter in PubMed, which is an index of journals particularly relevant to practicing physicians.

From the most recently published systematic review of each procedure, we selected randomised placebo-controlled trials published later than January 2000. We excluded trials published before January 2000 because our primary aim was to assess interventions that are currently, or until recently have been, in common use. We selected trials that according to the review fulfilled at least four of the following methodological criteria: random allocation, allocation concealment, blinding of participant, blinding of assessor and intention-to-treat analysis. We chose these criteria both because they were the most commonly used in the selected reviews, and because use of scales for assessing quality or risk of bias is explicitly discouraged in Cochrane reviews¹¹. Two of the authors (RH and JIB) independently assessed the five methodological criteria in the RCTs included from systematic reviews.

We next searched MEDLINE for additional randomised placebo-controlled trials published between January 2000 and January 2014. Two of the reviewers (OT and JIB) independently assessed the five criteria mentioned above in the additional RCTs that were identified from this search.

1
2
3 Only English language journals were included. We excluded
4 crossover trials, trials that did not report results as means,
5 standard deviation, standard error or confidence intervals in
6 both active and sham-groups, as well as trials with only graphic
7 representation of data. This review is reported in accordance
8 with the PRISMA statement.¹²
9

10 **Data extraction**

11 We registered all continuous primary endpoints. In trials without
12 continuous primary endpoints, with multiple endpoints or no
13 defined primary endpoint, we selected an outcome related to
14 pain or condition-specific endpoint. The heterogeneity of trials
15 did not allow for use of pain as a primary outcome. We used the
16 RCTs' defined primary outcome to avoid bias introduced by
17 choosing our own endpoint. We also registered secondary
18 endpoints in order to avoid potential bias from selective
19 reporting in the included trials. Endpoints describing medication,
20 radiographic or physiological variables, social or psychological
21 function, were not included. For the Parkinson-trials, only
22 endpoints in the off-medication state were registered. Results
23 from the last follow-up until 12 months were extracted. The
24 trials' protocol registration, funding source, description of sham
25 intervention, sample size, disease duration, length of follow-up
26 and reported adverse events in both trial arms were registered.
27
28
29

30 **Data synthesis**

31 To assess clinically important change, we calculated effect size
32 (ES, Cohen's d), based on the means and standard deviations
33 (SD). We calculated ES both for the active and sham
34 intervention to obtain information about the pre-to-post
35 treatment change in both arms. Without first calculating ES of
36 change in each trial arm, we would not be able to discern the
37 relative contribution of placebo, which was one of the
38 objectives of the study. Subtracting the average score after
39 treatment from the average score before treatment and
40 dividing the result by the average of the standard deviations
41 before and after treatment calculated ES. An ES of 0.8 or more
42 is assumed large, while an ES of 0.5 - 0.8 is considered
43 moderate.¹³ In trials with multiple secondary endpoints we
44 calculated the pooled mean ES, without weighting. Because of
45 small sample sizes in most of the included trials, we calculated
46 an adjusted ES in accordance with a recommended
47 procedure.¹⁴ Unadjusted linear regression analyses were used
48 to explore the association between outcome in the active and
49 sham groups both for primary and pooled secondary
50 endpoints. For this analysis, we used Medcalc Statistical
51 Software version 12.7.4.0¹⁵
52
53
54

55 **RESULTS**

56 **Selection of interventions and trials**

57
58
59
60

The searches provided sham-controlled trials of the following interventions: percutaneous laser revascularisation of myocardium for angina pectoris (n=2), closure of foramen ovale for migraine (n=1), arthroscopic meniscectomy for meniscal tears (n=1), debridement (n=1) and injection of hyaluronic acid (n=3) for symptomatic osteoarthritis of the knee, injection or transplantation of biologically active material for Parkinson's disease (human retinal pigmental cells (n=1), fetal nigral cells (n=1) and Neurturin (n=2)), epidural injections of corticosteroids for sciatica (caudal (n=1), interlaminar (n=2) and transforaminal (n=1)) routes, percutaneous heating of the intervertebral disc for chronic low back pain (intradiscal radiofrequency thermocoagulation (n=1), intradiscal electrothermal therapy (n=2)) and vertebroplasty for vertebral body fractures (n=2). We give a short description of each procedure's introduction, therapeutic rationale and history in web appendix table 1.

The searches provided no sham-controlled trials of cervical, thoracic or lumbar facet joint nerve blocks or joint injections, spinal cord stimulation for low back pain, cervical epidural injections, transmyocardial laser revascularisation for angina pectoris, deep brain stimulation for Parkinson's disease or dystonia or arthroscopic procedures other than knee conditions. We found six placebo-controlled trials of radiofrequency denervation for low back pain, but all were excluded: SD not provided (n=1),¹⁶ compound primary endpoint (n=1),¹⁷ risk of false positive response because of only one diagnostic block (n=4).¹⁸⁻²¹

The study selection process is summarised in figure 1. The search provided five systematic reviews, all identified through searches in MEDLINE, none were commercially funded.²²⁻²⁶ It identified a total of 71 clinical trials, twelve of them were not identified from the systematic reviews. Forty-four trials were excluded for methodological reasons, principally risk of bias. Six additional trials were excluded because ES could not be calculated.²⁷⁻³² Web appendix table 2 shows the excluded trials and the reasons for exclusion. Finally, 21 clinical trials with a total of 2519 participants were included in the present review (table 1). Trial interventions in active treatment and sham arms are also shown.

Table 1. Included studies, protocol approval and funding, interventions in the active treatment and sham arms, and adverse events					
Author	Protocol approval / funding (commercial, non-commercial).	Invasive procedure / indication	Sham intervention	Adverse events related to procedure, active treatment	Adverse events related to procedure, sham

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	Leon 2005	Food and Drug Administration / NC	Percutaneous myocardial laser revascularization / intractable angina pectoris	Laser turned on but no procedure performed	MAE in hospital (high dose): 4.1%	MAE in hospital: 0
Salem 2004	Ethics committee / NC	No procedural AE				
Sihvonen 2013	Review board / NC	Arthroscopic partial meniscectomy / degenerate meniscal tear	Routine arthroscopy, simulation of meniscectomy by manipulation etc.	No MAE		
				mAE: 6.6%	mAE: 2.9%	
Moseley 2002	Review Board / NC	Arthroscopic debridement / Knee osteoarthritis	Simulated arthroscopy preparation, intravenous anaesthesia, skin incisions, no instruments entered knee, knee manipulated	No procedural AE		
Pham 2004	Review Board / NC	Hyaluronic acid / Knee osteoarthritis	Intraarticular injection of saline solution	No MAE		
				Any mAE: 81.7%	Any mAE: 1.2%	
Altman 2004	Ethics committee / C			No MAE		
				mAE: 12.8%	mAE: 8%	
Chevalier 2010	ClinicalTrials.org / C			No MAE		
				mAE: 35,8%	mAE: 33,8%	
Kallmes 2009	Review Board / NC	Percutaneous vertebroplasty with PMMA cement injection / vertebral fracture	Conscious sedation + local anaesthesia, pressure put on spine, simulation of odor with mixing of PMMA to imitate the smell during the active procedure	No MAE		
				mAE: 14%	mAE: 16%	
Buchbinder 2009	Ethics committee at each participating center / NC		Conscious sedation + local anaesthesia, needle inserted to rest on the lamina, PMMA container opened to imitate the smell during the active procedure	No procedural AE		
Cohen 2012	Review Board / NC	Epidural injection of corticosteroids / Sciatica	2 ml sterile water at 1-2 injection sites, transforaminal approach	No MAE		
				mAE:36%	mAE: 20%	
Arden 2005	Ethics committee / NC		2 mL saline into interspinous ligament	No MAE		
				mAE: 9%	mAE: 10%	

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	Valat 2002	Ethics committee / NC		2 mL saline into epidural space, interlaminar approach	No MAE	
					mAE: 6%	mAE: 8%
	Iversen 2011	Ethics committee / NC		Subcutaneous injection of 2 mL saline superficial to the sacral hiatus	Not reported	
	Freeman 2005	Ethics committee / C	Intradiscal electrothermal therapy (IDET) / discogenic low back pain	17-gauge introducer needle inserted into disc under fluoroscopic guidance, catheter inserted but not connected to generator, both subject and surgeon blinded.	No MAE	
					mAE: 11%	mAE: 5%
	Pauza 2003	Review Board / NC		17-gauge needle introduced onto the outer annulus, mock electrode passage shown on monitor, generator noises produced	Not reported	
	Kvarstein 2009	Ethics committee / NC	Percutaneous intradiscal radiofrequency thermocoagulation (PIRFT) / discogenic low back pain	17-gauge canula and RF-probe inserted into annulus, no RF current applied	Not reported	
	Olanow 2003	Review Board / NC	Fetal nigral transplantation, 4 donors / Parkinson's disease	Scalp incisions, partial thickness burr holes, no cell transplantation, 6 months low-dose cyclosporine	No MAE	
					mAE (rate/patient day): 0,66	mAE (rate/patient day): 0,39
	Marks 2010	Review Board / C	Gene delivery of AAV2-Neurturin / Parkinson's disease	Scalp incisions, partial thickness burr holes, no intracranial injections	MAE: 4	MAE: 0
					Most frequent mAE: headache: 68%	Most frequent mAE: headache: 50%
	Gross 2011	Review Board / C	Transplantation of human retinal pigmental cells / Parkinson's disease	Scalp incisions, partial thickness burr holes, no cell transplantation	1 death	0 deaths
					MAE: 23%	MAE: 0
	LeWitt 2011	Review Board /	Insertion of AAV-	Insertion of catheter	No MAE	

	C	GAD gene into subthalamic nucleus / Parkinson's disease	caudal to nucleus, infusion of saline	mAE (probably related to procedure): 56%	mAE (probably related to procedure): 14%
Dowson 2008	Ethics committee / C	Patent foramen ovale closure with STARFlex Septal Repair Implant / migraine	General anesthesia, skin incision in the groin	MAE (possibly or probably related to procedure): 11%	MAE (possibly or probably related to procedure): 4%
C=commercial; NC=non-commercial; MAE=major adverse events; mAE=minor adverse events; PMMA=polymethylmethacrylate; AAV2 =adeno-associated; GAD=glutamic acid decarboxylase					

Fourteen trials from the systematic reviews fulfilled at least four of the five methodological criteria.^{33 34 37-48} Seven trials provided through searches in MEDLINE fulfilled the same criteria.^{35 36 49-53} The included and excluded secondary endpoints are shown in web appendix table 3. All trials reported approval of study protocol prior to patient enrolment (table 1). Seven trials were commercially funded.^{38 39 47 50-53} Most of the trials had few participants, ranging from 20 to 346 (median 80).

Clinical outcomes after active treatment and sham

Twelve of the 21 trials showed a large ES on primary endpoints after active treatment, while 11 trials showed a similar ES after the sham procedure (figure 2, table 2).

Table 2. Effect size (ES) on primary and pooled secondary endpoints, showing differences between active treatment and sham arms.

Author / procedure	Limit disease duration / time to follow-up (months)	Trial arm / no of patients randomised	ES primary endpoint	ES pooled secondary endpoints (no of endpoints)
Leon 2005 / Percutaneous myocardial laser revascularization	None / 12		Exercise duration (s)	(10)
		Active / 98	0.23	0.60
		Sham / 102	0.22	0.54
ES active treatment vs sham			0.01	0.07
Salem 2004 / Percutaneous myocardial laser revascularization	None / 12		Exercise duration (s)	-
		Active / 40	0.04	

		Sham / 42	0.08	
ES active treatment vs sham				-0.04
Sihvonen 2013 / Arthroscopic partial meniscectomy	>3 / 12		Lysholm knee score	(4)
		Active / 70	0.86	0.58
		Sham / 76	1.03	0.58
ES active treatment vs sham				-0.17 0.00
Moseley 2002 / Arthroscopic debridement	None / 12		Knee Specific Pain Scale	(5)
		Active / 59	0.54	0.11
		Sham / 60	0.85	0.20
ES active treatment vs sham				-0.31 -0.09
Pham 2004 / Hyaluronic acid			VAS Pain	(3)
	None / 12	Active / 131	1.48	1.35
		Sham / 85	1.54	1.30
ES active treatment vs sham				-0.06 0.05
Chevalier 2010 / Hyaluronic acid			Womac A	Womac C function
	None / 6	Active / 124	1.52	1.13
		Sham / 129	1.18	1.07
ES active treatment vs sham				0.34 0.06
Altman 2004 / Hyaluronic acid	None / 6		Womac pain	(2)
		Active / 172	0.76	0.38
		Sham / 174	0.85	0.53
ES active treatment vs sham				-0.09 -0.15
Kallmes 2009 / Percutaneous vertebroplasty	<12 / 1		Roland-Morris Disability Questionnaire	(7)
		Active / 68	0.86	0,72
		Sham / 63	0.81	0.63
ES active treatment vs sham				0.05 0.09
Buchbinder 2009 / Percutaneous vertebroplasty	<12 / 6		Pain Score	(4)
		Active / 38		0.46

			0.83	
		Sham / 40	0.71	0.51
ES active treatment vs sham			0.12	-0.05
Cohen 2012 / Epidural injection of corticosteroids	<6 / 1		NRS leg pain	(2)
		Active / 28	1.51	0.88
		Sham / 30	0.82	0.39
ES active treatment vs sham			0.69	0.49
Iversen 2011 / Epidural injection of corticosteroids	>3 / 12		Oswestry disability index	-
		Active / 36	1.68	
		Sham / 40	1.85	
ES active treatment vs sham			-0.17	
Arden 2005 / Epidural injection of corticosteroids	>1<18 / 12		Oswestry disability index	(2)
		Active / 120	1.42	1.14
		Sham / 108	1.44	1.21
ES active treatment vs sham			-0.02	-0.07
Valat 2002 / Epidural injection of corticosteroids	<6 / 1		VAS Pain	(3)
		Active / 42	1.85	1.10
		Sham / 43	1.47	0.99
ES active treatment vs sham			0.38	0.10
Freeman 2005 / Intradiscal electrothermal therapy	≥3 / 6		Oswestry disability index	(6)
		Active / 38	0.10	-0.03
		Sham / 19	0.07	0.12
ES active treatment vs sham			0.17	-0.15
Pauza 2003 / Intradiscal electrothermal therapy	>6 / 6		Oswestry disability index	(3)
		Active / 32	0.94	0.90
		Sham / 24	0.35	0.46
ES active treatment vs sham			0.59	0.44
Kvarstein 2009 / Percutaneous intradiscal radiofrequency	>6 / 12		Brief Pain Inventory	(5)

thermocoagulation				
		Active / 10	0.34	0.54
		Sham / 10	0.23	0.24
ES active treatment vs sham			0.11	0.30
Olanow 2003 / Fetal nigral transplantation	None / 24		UPDRS 3 off	(5)
		Active / 12	0.04	-0.24
		Sham / 11	0.44	-0.19
ES active treatment vs sham			0.48	-0.06
Marks 2010 / Gene delivery of AAV2-Neurturin	≥60 / 12		UPDRS 3 off	(7)
		Active / 38	0.72	0.23
		Sham / 20	0.53	-0.05
ES active treatment vs sham			0.19	0.28
Gross 2011 / Transplantation of human retinal pigmental cells	≥60 / 12		UPDRS 3 off	(2)
		Active / 35	1.09	0.08
		Sham / 36	0.88	0.06
ES active treatment vs sham			0.21	0.02
LeWitt 2011 / AAV-GAD gene into subthalamic nucleus	≥60 / 6		UPDRS 3 off	(7)
		Active / 16	1.00	0.30
		Sham / 21	0.42	0.21
ES active treatment vs sham			0.58	0.08
Dowson 2008 / Patent foramen ovale closure	None / 6		Frequency migraine/month (per protocol)	Headache Impact Test
		Active / 74	0.74	1.02
		Sham / 73	0.45	1.06
ES active treatment vs sham			0.28	0.04
VAS=Visual Analogue Scale; NRS=Numerical Rating Scale; UPDRS=Unified Parkinson's Disease Rating Scale; Womac=Western Ontario and McMaster Universities Osteoarthritis Index				

ES on primary endpoints was moderate in three of the active treatment groups and in two of the sham groups.

1
2
3
4 On pooled secondary endpoints, a large ES was estimated in
5 seven trials after active treatment and in five trials after sham,
6 while a moderate ES was reported in four and three trials
7 respectively (table 2).
8

9
10 In none of the trials did the actively treated group show a
11 deterioration of primary endpoint during treatment, while this
12 was the case for two of the sham groups (not reported to be
13 related to the procedure). On secondary endpoints,
14 deterioration occurred in two active treatment and two sham
15 groups (table 2).
16

17 **Differences in outcome between active treatment and sham**

18 Better results on primary endpoints were reported with active
19 treatment compared to sham in 14 of the 21 trials, but the
20 differences were small. Three trials (one epidural study⁴³, one
21 discogenic pain study⁴⁶ and one Parkinson study⁵²) reported a
22 moderate effect but none showed a large effect (figure 3, table
23 2). Seven trials reported a better primary endpoint outcome
24 after sham than after active treatment.
25

26
27 Nineteen trials reported secondary endpoints, 11 of these
28 reported better outcome after active treatment than after
29 sham, but in no case did the differences reach a moderate ES
30 (figure 3, table 2). In twelve trials, the outcome was better for
31 primary than for pooled secondary endpoints. This bore no
32 relation to funding source.
33

34 On regression analyses, effect sizes in the sham groups
35 predicted about 80 % of the variance of ES in the active
36 treatment groups, both on primary and pooled secondary
37 endpoints (figure 4 and 5).
38

39 **Adverse events**

40 Eighteen studies provided information about adverse events
41 (AE) (table 1). Three of these trials reported no procedural
42 adverse events in any of the groups.^{33 35 41} Major AEs were
43 reported after active treatment in four trials^{34 50 51 53}, including
44 one death in one of the Parkinson studies.⁵¹ In the sham
45 groups, one trial⁵³ listed three major AEs possibly or probably
46 related to the procedure, all thought to be caused by anti-
47 platelet medication, none of them life-threatening. Apart from
48 this trial, there were no major AEs in the sham groups. The
49 reported minor AEs were all of limited duration.
50
51

52 **DISCUSSION**

53 **Principal findings**

54
55 Analysis of 21 sham-controlled trials of minimally invasive
56 procedures showed that the effect sizes in the active
57 treatment arms were predicted by the effect sizes in the sham
58
59
60

1
2
3 arms. There was a large ES on primary endpoints in about half
4 of both the active and sham interventions, but none of the
5 trials showed a large difference in ES between active treatment
6 and sham groups either on primary or secondary endpoints.
7

8
9 The magnitude of the effect in each trial arm varied
10 considerably, both between different procedures and between
11 trials using the same procedure. For instance, in the active
12 treatment groups, ES for primary endpoints varied from
13 around zero to almost 2 after active treatment, and from
14 about -0.4 to 1.5 after sham. Disparate outcomes were
15 reported even between trials where technical parameters
16 were similar. For instance, ES in the sham group in the three
17 hyaluronic acid-trials varied by a factor of three, and in the
18 epidural trials by a factor of two. This variability is probably
19 related to differences in study design, duration of disability
20 before inclusion, contextual factors, including the doctor-
21 patient relationship as well as other factors. The close
22 association between endpoints in the active treatment and
23 sham groups on regression analyses suggests that a large part
24 of the reported outcomes in the active treatment groups are
25 due to placebo effects, statistical regression to the mean or the
26 natural course of the condition.
27

28 29 **Strengths and limitations of study**

30 It is our opinion that the calculation of effect sizes in both
31 active treatment and placebo arms is a strength of the present
32 study. This made it possible to assess the magnitude of change
33 in both arms and the contribution of non-specific factors to
34 change in the active treatment arms. The calculation of effect
35 sizes provides an alternative assessment to probability
36 estimates. Another strength of the study is the supplementary
37 analyses of pooled secondary endpoints, enabling a more
38 comprehensive evaluation than using primary endpoints alone.
39 Reports of tactically motivated use of primary and secondary
40 endpoints before publication in order to improve study results
41 strengthen the argument for registering all relevant secondary
42 endpoints.⁵⁴ Our finding that a majority of trials reported
43 better results on primary than on secondary endpoints might
44 lend support to such a hypothesis, although all trials, according
45 to the authors, had sought and gained approval of the protocol
46 from ethics committee and/ or review board (table 1).
47
48

49 The present review is limited to selected minimally invasive
50 procedures in cardiology, neurology, and musculoskeletal
51 conditions. While some procedures are, or have been, in wide
52 clinical use, some are still in the clinical trial phase. Other
53 sources of heterogeneity are variable duration of disease
54 before inclusion, selection of outcome measures and time to
55 follow-up. Results cannot be generalised to minimally invasive
56 procedures in all medical disciplines, but a similar
57 methodology could be applied to more systematic analyses of
58
59
60

1
2
3 the role of non-specific effects in other minimally invasive
4 procedures.

5
6 We applied principles from guidelines for conducting
7 systematic reviews and meta-analyses and included an
8 independent assessment of methodological trial quality by two
9 of the authors. We cannot rule out that we have missed
10 relevant trials because we limited our search to the Cochrane
11 Library and MEDLINE, but most relevant trials are likely to have
12 been identified by our searches. By preferentially selecting
13 core journals and trials that had previously been
14 methodologically evaluated in systematic reviews, it was our
15 intention to reduce the risk of bias by excluding studies of low
16 quality. We realize that this selection process and the fact that
17 we relied on previous methodological evaluations may have
18 contributed to unrecognised selection bias.
19

20
21 The use of ES as a measure of clinical effect assumes a normal
22 distribution of the data. This does not necessarily apply in the
23 included trials because the majority of them are small.
24 Including trials reporting non-parametric data would however
25 necessitate other methods of statistical analysis. Small studies
26 increase the likelihood of type-2 errors, though this is more
27 relevant to probability estimates than analysis of ES.
28

29 30 **Adequate blinding and lack of physiological effects?**

31 We cannot rule out that treatment-specific effects in the
32 actively treated groups may have jeopardised blinding, leading
33 to overestimation of treatment effects through positive
34 expectations. However, all the included trials gave a detailed
35 description of the sham procedure, and both participant and
36 assessor blinding seems to have been adequate.
37

38
39 On a more general level, it has been argued that sham
40 procedures are not inert and may have specific physiological
41 effects, thereby underestimating a treatment effect.⁵⁵ More
42 recently, Bickett et al. hypothesised that epidural injection of
43 small volumes of saline might have physiological effects.⁵⁶
44 However, it is to be noted that in the four selected epidural
45 trials in the present study, improvements in the sham group
46 were greater in the two trials using non-epidural saline than in
47 those using epidural saline, making a physiological effect less
48 likely. In our opinion, physiological effects of the sham
49 interventions are also unlikely in the remaining procedures.
50

51
52 Surgery and other invasive procedures are commonly believed
53 to be associated with enhanced placebo effects, a
54 phenomenon coined mega-placebo.⁵⁷ In spite of their
55 heterogeneous nature, the 21 selected trials share a medico-
56 technological context in which an a priori enhanced placebo
57 response could be expected. If an ES >0.8 is considered as
58 mega-placebo, half of the included sham interventions reached
59
60

1
2
3 this level. Factors such as the level of enthusiasm and
4 conviction conveyed by the therapist, the impression of
5 advanced procedures and the extent to which these factors
6 succeed in activating a placebo response are probably crucial
7 in explaining the improvements after sham interventions and
8 the correlation of endpoints in the active treatment and sham
9 groups. Participants' perception of whether they received
10 active treatment or sham has been shown to contribute more
11 to clinical improvement than the biological effects per se.^{32 58}

13 **Non-specific factors**

14 The role of non-specific factors, primarily spontaneous
15 remission or statistical regression-to-the-mean, in placebo-
16 controlled studies is controversial.⁵⁹ A recent meta-analysis
17 analysing 202 trials with an untreated group, spanning 60
18 different clinical conditions, found rather small differences
19 between placebo and no treatment, with effect sizes in the
20 range of 0.2 to 0.3.⁶⁰ Apart from acupuncture trials (mean ES
21 0.68), the authors did not include trials reporting the
22 effectiveness of invasive procedures. Another meta-analysis
23 studied the placebo effect of a range of treatments
24 (pharmacological, non-pharmacological and surgical) for
25 osteoarthritis of the hand, hip and knee.⁶¹ Of 198 included
26 trials fourteen had a no-treatment arm. The mean ES in the
27 placebo groups was about 0.5, while it was only slightly above
28 zero in the no-treatment groups. The difference between the
29 placebo and no-treatment groups was larger than the
30 difference between the placebo and active treatment groups.
31 Trials using injections, acupuncture and surgery had the largest
32 placebo effects, and the effects were larger for subjective than
33 objective endpoints. The authors concluded that there is a
34 significant placebo effect on pain, stiffness and function in
35 symptomatic osteoarthritis.
36
37
38

39 Because the trials in the present study did not include a no-
40 treatment arm (i.e. waiting list), we cannot rule out that the
41 changes appearing during the trial period also reflect non-
42 specific factors, i.e. spontaneous improvement or regression to
43 the mean. Such mechanisms would be expected to be most
44 prominent in trials with brief illness duration before inclusion
45 and with longer time to follow-up, while improvements in
46 chronic, unremitting conditions such as Parkinson's disease
47 would be more likely attributed to placebo. Interestingly, in
48 three of the four included Parkinson trials, there were
49 moderate to large improvements in the sham groups even at
50 one-year follow-up.⁴⁹⁻⁵¹ Other authors have also found
51 improvements several years after sham surgery,
52 indistinguishable from conventional surgery.^{32 62} This is in
53 agreement with recent insights into the neurobiological effects
54 of placebo and their relation to underlying psychological
55 mechanisms, principally expectation and conditioning.⁶³
56
57
58
59
60

Are ethical objections to sham justified?

The use of sham in controlled surgical trials is a divisive issue, with scepticism, even frank opposition, being voiced by both ethics committees, involved surgeons and anaesthetists, and potential patients.⁶⁴ Ethical arguments include the inherent risks of sham procedures combined with the lack of obvious benefits to the participants. Barriers related primarily to feasibility include problems with patient and assessor blinding, differing technical expertise, the heterogeneity of the interventional techniques and variable outcome specifications, making standardization difficult to achieve. Existing ethical guidelines accept the role of placebo-controlled trials when certain conditions are met.⁶⁵ There must be genuine equipoise, i.e. conflicting or weak evidence of the effectiveness of a procedure. Blinding of both participants and assessors must be assured, and participants must freely consent to suspend knowledge of whether they are receiving sham or conventional treatment. The health risks and consequences of placebo or delayed treatment must be minimal, and outweighed by the societal importance of establishing the clinical utility of the intervention in question.^{66 67}

The selected trials gave a detailed description of adverse events in both active and sham-treated groups (table 1). The safety concerns frequently raised as an argument against the use of sham were generally not supported. Major adverse events related to the sham procedure were reported in only one of the trials⁵³ and they were short-lived and not life threatening. Minor adverse events were more frequent, but also of limited duration. Positive placebo-induced effects generally outweighed adverse events, thus weakening ethical arguments against the use of sham interventions. In our opinion, the consequences of the continued use of unproven invasive procedures are of a different magnitude. In the light of studies supporting the beneficial effects of sham procedures, at least for pain and Parkinson symptoms, research ethics committees should consider such factors in their risk-benefit assessments of planned sham controlled trials.^{68 69}

Clinical implications.

The present results are pertinent to the ongoing discussion about wasteful and unproven medical practices, and underscore the necessity for a continual assessment of existing or novel unproven procedures. Minimally invasive techniques have lowered the threshold for interventions, and led to their application to a wider clinical spectrum (indication creep) without an ongoing evaluation of effectiveness or safety.⁴ The last two decades have seen dramatic increases in the use of several of the described procedures, as well as interventions we have not investigated, such as acromioplasty, percutaneous coronary intervention and, more recently, robotic surgery.⁷⁰⁻⁷⁵

1
2
3 In light of the results in the present study, placebo effects
4 might well explain a large part of the purported effects of such
5 procedures. When clinicians and regulators are faced with
6 claims of large treatment effects for insufficiently tested
7 procedures, their default mode should be watchful scepticism.
8 The standards of the evaluation process before approval and
9 reimbursement of devices and procedures need to be
10 strengthened, and economic or regulatory incentives that
11 perpetuate the use of undocumented or harmful procedures
12 should be abrogated.
13

14 15 **CONCLUSION**

16 Sham-controlled trials are unique in their ability to
17 discriminate between true treatment effects and non-specific
18 effects. The results of the present study suggest that placebo
19 and other non-specific effects explain a large part of their
20 purported benefits. Further, results indicate that the risks of
21 adverse events in sham-controlled trials are overrated and
22 could be considered acceptable in view of the potential
23 personal harm and societal costs associated with unproven
24 minimally invasive interventions.
25

26 27 **Figure legends**

28 Figure 1. Flow chart of study selection in the present meta-
29 analysis.
30

31 Figure 2. Effect sizes of active treatment and sham, primary
32 endpoints.
33

34 Figure 3. Differences in effect size between active treatment
35 and sham.
36

37 Figure 4. Association between effect sizes of primary endpoints in active treatment and sham
38 arms. Linear regression, 95% confidence intervals. N=21.
39

40 Figure 5. Association between effect sizes of pooled secondary endpoints in active treatment
41 and sham arms. Linear regression, 95% confidence intervals. N=19.
42
43
44
45
46

47 48 **References**

- 49 1. Prasad V, Vandross A, Toomey C et al. A decade of
50 reversal: an analysis of 146 contradicted medical
51 practices. *Mayo Clin Proc* 2013;**88**:790-8.
52
53
54
55
56
57
58
59
60

- 1
2
3 2. Tiago V. Pereira TV, Horwitz RI et al. Empirical
4
5 Evaluation of Very Large Treatment Effects of Medical
6
7 Interventions. *JAMA* 2012;**308**:1676-84.
8
- 9
10 3. Roberts AL, Kewman DG, Mercier L et al. The power of
11
12 nonspecific effects in healing: implications for
13
14 psychosocial and biological treatments. *Clin Psychol*
15
16 *Rev* 1993;**13**:375-91.
17
- 18
19 4. Garner S, Littlejohns P. Disinvestment from low value
20
21 clinical interventions: NICEly done? *BMJ*
22
23 2011;**343**:d4519.
24
- 25
26 5. Scott IA, Elshaug AG. Foregoing low-value care: how
27
28 much evidence is needed to change beliefs? *Intern*
29
30 *Med J* 2013;**43**:107-9.
31
- 32
33 6. Obremskey WT, Pappas N, Attallah-Wasif E et al. Level
34
35 of evidence in orthopaedic journals. *J Bone Joint Surg*
36
37 *Am* 2005;**87**:2632-8.
38
- 39
40 7. Reeves B. Health-technology assessment in surgery.
41
42 *Lancet* 1999;**353**:Suppl 1:S13-S15;
43
- 44
45 8. Wenner DM, Brody BA, Jarman AF et al. Do surgical
46
47 trials meet the scientific standards for clinical trials? *J*
48
49 *Am Coll Surg* 2012;**215**:722-30.
50
- 51
52 9. Ezekiel JE, Miller FG. The Ethics of Placebo-Controlled
53
54 Trials — A Middle Ground. *N Engl J Med* 2001;**345**:915-
55
56 9.
57
- 58
59 10. Campbell MK, Entwistle VA, Cuthbertson BH et al.
60
61 Developing a placebo-controlled trial in surgery: issues

of design, acceptability and feasibility. *Trials*
2011;**12**:50

11. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0.
<http://handbook.cochrane.org>; (11.11.2014)
12. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009;**339**:b2700.
13. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.
14. Durlak JA. How to Select, Calculate, and Interpret Effect Sizes. *J Pediatr Psychol* 2009; **34**: 917-28.
15. MedCalc Software bvba, Ostend, Belgium;
<http://www.medcalc.org>; (08.03.2014).
16. Nath S, Nath CA, Pettersson K et al. Percutaneous lumbar zygapophysial (Facet) joint neurotomy using radiofrequency current, in the management of chronic low back pain: a randomized double-blind trial. *Spine* **2008**;33:1291-7.
17. Patel N, Gross A, Brown L et al. A randomized, placebo-controlled study to assess the efficacy of lateral branch neurotomy for chronic sacroiliac joint pain. *Pain Med* 2012;13:383-398.

- 1
2
3 18. Cohen SP, Hurley RW, Buckenmaier CC et al.
4
5 Randomized placebo-controlled study evaluating
6
7 lateral branch radiofrequency denervation for
8
9 sacroiliac joint pain. *Anesthesiology* 2008;**109**:279-88.
10
11
12 19. Tekin I, Mirzai H, Ok G et al. A comparison of
13
14 conventional and pulsed radiofrequency denervation
15
16 in the treatment of chronic facet joint pain. *Clin J*
17
18 *Pain* 2007;**23**:524-9.
19
20
21 20. Leclaire R, Fortin L, Lambert R et al. Radiofrequency
22
23 facet joint denervation in the treatment of low back
24
25 pain: a placebo-controlled clinical trial to assess
26
27 efficacy. *Spine* 2001;**26**:1411-6.
28
29
30 21. van Wijk RM, Geurts JW, Wynne HJ et al.
31
32 Radiofrequency denervation of lumbar facet joints in
33
34 the treatment of chronic low back pain: a randomized,
35
36 double-blind, sham lesion-controlled trial. *Clin J*
37
38 *Pain* 2005 ;**21**:335-44.
39
40
41 22. Rutjes AWS, Jünl P, da Costa BR et al.
42
43 Viscosupplementation for Osteoarthritis of the Knee. A
44
45 Systematic Review and Meta-analysis. *Ann Intern Med*
46
47 2012;**157**:180-91.
48
49
50 23. Pinto RZ, Maher CG, Ferreira ML et al. Epidural
51
52 corticosteroid injections in the management of
53
54 sciatica: a systematic review and meta-analysis. *Ann*
55
56 *Intern Med* 2012;**157**:865-77.
57
58
59
60

- 1
2
3 24. McGillion M, Cook A, Victor JC et al. Effectiveness of
4 percutaneous laser revascularization therapy for
5 refractory angina. *Vasc Health Risk Manag* 2010;**6**:735-
6 47.
7
8
9
10
11 25. Helm S II, Deer TR, Manchikanti L et al. Effectiveness of
12 thermal annular procedures in treating discogenic low
13 back pain. *Pain Physician* 2012; **15**:E279-E304.
14
15
16
17 26. Shi MM, Cai XZ, Lin T et al. Is there really no benefit
18 of vertebroplasty for osteoporotic vertebral fractures?
19 A meta-analysis. *Clin Orthop Relat Res* 2012;**470**:2785-
20 99.
21
22
23
24
25
26
27 27. Petrella RJ, Cogliano A, Decaria J. Combining
28 two hyaluronic acids in osteoarthritis of the knee: a
29 randomized, double-blind, placebo-controlled trial.
30
31
32
33
34
35
36 28. Lundsgaard C, Dufour N, Fallentin E et al. Intra-articular
37 sodium hyaluronate 2 mL versus physiological saline 20
38 mL versus physiological saline 2 mL for painful knee
39 osteoarthritis: a randomized clinical trial. *Scand J*
40
41
42
43
44
45
46 29. Karppinen J, Malmivaara A, Kurunlahti M et al.
47 Periradicular infiltration for sciatica: a randomized
48 controlled trial. *Spine* 2001; **26**:1059-67.
49
50
51
52
53 30. Freed CR, Greene PE, Breeze RE et al. Transplantation
54 of embryonic dopamine neurons for severe Parkinson's
55 disease. *N Engl J Med* 2001;**344**:710-9.
56
57
58
59
60

- 1
2
3 31. Gordon PH, Yu Q, Qualls C et al. Reaction time and
4
5 movement time after embryonic cell implantation in
6
7 Parkinson disease. *Arch Neurol* 2004;**61**:858-61.
8
9
10 32. McRae C, Cherin E, Yamazaki TG et al. Effects of
11
12 perceived treatment on quality of life and medical
13
14 outcomes in a double-blind placebo surgery trial. *Arch*
15
16 *Gen Psychiatry* 2004; **61**: 412-20.
17
18 33. Salem M, Rotevatn S, Stavnes S et al. Usefulness and
19
20 safety of percutaneous myocardial laser
21
22 revascularization for refractory angina pectoris. *Am J*
23
24 *Cardiol* 2004;**93**:1086-91.
25
26 34. Leon MB, Kornowski R, Downey WE et al. A blinded,
27
28 randomized, placebo-controlled trial of percutaneous
29
30 laser myocardial revascularization to improve angina
31
32 symptoms in patients with severe coronary disease. *J*
33
34 *Am Coll Cardiol* 2005;**46**:1812-9.
35
36 35. Moseley JB, O'Malley K, Petersen NJ et al. A controlled
37
38 trial of arthroscopic surgery for osteoarthritis of the
39
40 knee. *N Engl J Med* 2002;**347**:81-8.
41
42
43 36. Sihvonen R, Paavola M, Malmivaara A et al.
44
45 Arthroscopic partial meniscectomy versus sham
46
47 surgery for a degenerative meniscal tear. *N Engl J Med*
48
49 2013;**369**:2515-24.
50
51
52 37. Pham T, Le Henanff A, Ravaud P et al. Evaluation of the
53
54 symptomatic and structural efficacy of a
55
56 new_hyaluronic_acid compound, NRD101, in
57
58
59
60

- 1
2
3 comparison with diacerein and placebo in a 1 year
4
5 randomised controlled study in symptomatic knee
6
7 osteoarthritis. *Ann Rheum Dis* 2004;**63**:1611-7.
8
9
10 38. Altman RD, Akermark C, Beaulieu AD et al. Efficacy and
11
12 safety of a single intra-articular injection of non-animal
13
14 stabilized_hyaluronic_acid (NASHA) in patients with
15
16 osteoarthritis of the knee. *Osteoarthritis*
17
18 *Cartilage* 2004;**12**:642-9.
19
20
21 39. Chevalier X, Jerosch J, Goupille P et al. Single, intra-
22
23 articular treatment with 6 ml hylan G-F 20 in patients
24
25 with symptomatic primary osteoarthritis of the knee: a
26
27 randomised, multicentre, double-blind, placebo
28
29 controlled trial. *Ann Rheum Dis* 2010;**69**:113-9.
30
31
32 40. Kallmes DF, Comstock BA, Heagerty PJ et al. A
33
34 randomized trial of vertebroplasty for osteoporotic
35
36 spinal fractures. *N Engl J Med* 2009;**361**:569-79.
37
38
39 41. Buchbinder R, Osborne RH, Ebeling PR et al. A
40
41 randomized trial of vertebroplasty for painful
42
43 osteoporotic vertebral fractures. *N Engl J Med*
44
45 2009;**361**:557-68.
46
47
48 42. Iversen T, Solberg TK, Romner B et al. Effect of caudal
49
50 epidural steroid or saline injection in chronic lumbar
51
52 radiculopathy: multicentre, blinded, randomised
53
54 controlled trial. *BMJ* 2011;**343**:d5278.
55
56
57 43. Cohen SP, White RL, Kurihara C et al. Epidural steroids,
58
59 etanercept, or saline in subacute sciatica: a
60

- 1
2
3 multicenter, randomized trial. *Ann Intern Med*
4
5 2012;**156**:551-9.
6
7 44. Arden NK, Price C, Reading I et al. A multicentre
8
9 randomized controlled trial of epidural corticosteroid
10
11 injections for sciatica: the WEST study.
12
13 *Rheumatology* 2005;**44**:1399-406.
14
15 45. Valat JP, Giraudeau B, Rozenberg S et al. Epidural
16
17 corticosteroid injections for sciatica: a randomised,
18
19 double blind, controlled clinical trial. *Ann Rheum*
20
21 *Dis* 2003;**62**:639-43.
22
23
24 46. Pauza KJ, Howell S, Dreyfuss P et al. A randomized,
25
26 placebo-controlled trial of intradiscal electrothermal
27
28 therapy for the treatment of discogenic low back pain.
29
30 *Spine J* 2004;**4**:27-35.
31
32
33 47. Freeman BJ, Fraser RD, Cain CM et al. A randomized,
34
35 double-blind, controlled trial: intradiscal
36
37 electrothermal therapy versus placebo for the
38
39 treatment of chronic discogenic low back pain. *Spine*
40
41 2005;**30**:2369-77.
42
43
44 48. Kvarstein G, Måwe L, Indahl A et al. A randomized
45
46 double-blind controlled trial of intra-annular
47
48 radiofrequency thermal disc therapy--a 12-month
49
50 follow-up. *Pain* 2009;**145**:279-86.
51
52
53 49. Olanow CW, Goetz CG, Kordower JH et al. A double-
54
55 blind controlled trial of bilateral fetal nigral
56
57
58
59
60

1
2
3 transplantation in Parkinson's disease. *Ann Neurol*
4
5 2003;**54**:403-14.
6

7 50. Marks WJ Jr, Bartus RT, Siffert J et al. Gene delivery of
8
9 AAV2-neurturin for Parkinson's disease: a double-
10
11 blind, randomised, controlled trial. *Lancet Neurol*
12
13 2010;**9**:1164-72.
14

15
16 51. Gross RE, Watts RL, Hauser RA et al. Intrastriatal
17
18 transplantation of microcarrier-bound human retinal
19
20 pigment epithelial cells versus sham surgery in patients
21
22 with advanced Parkinson's disease: a double-blind,
23
24 randomised, controlled trial. *Lancet Neurol*
25
26 2011;**10**:509-19.
27

28
29 52. LeWitt PA, Rezai AR, Leehey MA et al. AAV2-GAD gene
30
31 therapy for advanced Parkinson's disease: a double-
32
33 blind, sham-surgery controlled, randomised trial.
34
35 *Lancet Neurol* 2011;**10**:309-19.
36

37
38 53. Dowson A, Mullen MJ, Peatfield R et al. Migraine
39
40 Intervention With STARFlex Technology (MIST) trial: a
41
42 prospective, multicenter, double-blind, sham-
43
44 controlled trial to evaluate the effectiveness of patent
45
46 foramen ovale closure with STARFlex septal repair
47
48 implant to resolve refractory migraine headache.
49
50 *Circulation* 2008;**117**:1397-404.
51

52
53 54. Hannink G, Gooszen HG, Rovers MM. Comparison of
54
55 registered and published primary outcomes in
56
57
58
59
60

- 1
2
3 randomized clinical trials of surgical interventions. *Ann*
4
5 *Surg* 2013;**257**:818-23.
6
7 55. Birch S. A review and analysis of placebo treatments,
8
9 placebo effects, and placebo controls in trials of
10
11 medical procedures when sham is not inert. *J Altern*
12
13 *Complement Med* 2006;**12**:303-10.
14
15 56. Bicket MC, Gupta A, Brown CH 4th et al.
16
17 Epidural injections for spinal pain: a systematic review
18
19 and meta-analysis evaluating the "control" injections
20
21 in randomized controlled trials.
22
23 *Anesthesiology*. 2013;**119**:907-31.
24
25 57. Kaptchuk TJ, Goldman P, Stone DA et al. Do medical
26
27 devices have enhanced placebo effects? *J Clin*
28
29 *Epidemiol* 2000;**53**:786-92.
30
31 58. Einvik G, Tjomsland O, Kvernebo K et al. Preoperative
32
33 expectations and clinical outcome of transmyocardial
34
35 laser treatment in patients with angina pectoris.
36
37 *Tidsskr Nor Laegeforen* 2002;**122**:2102-4.
38
39 59. Turner JA, Deyo RA, Loeser JD et al. The importance of
40
41 placebo effects in pain treatment and research. *JAMA*
42
43 1994;**271**:1609-14.
44
45 60. Hróbjartsson A, Gøtzsche PC. Placebo interventions for
46
47 all clinical conditions. *Cochrane Database Syst Rev*
48
49 2010; CD003974.
50
51 61. Zhang W, Robertson J, Jones AC et al. The placebo
52
53 effect and its determinants in osteoarthritis: meta-
54
55
56
57
58
59
60

- 1
2
3 analysis of randomised controlled trials. *Ann Rheum*
4
5 *Dis* 2008;**67**:1716-23.
6
7 62. Marchand S, Kupers RC, Bushnell MC et al. Analgesic
8
9 and placebo effects of thalamic stimulation. *Pain*
10
11 2003;**105**:481-8.
12
13 63. Finniss DG, Kaptchuk TJ, Miller F et al. Biological,
14
15 clinical, and ethical advances of placebo effects. *Lancet*
16
17 2010;**375**:686-95.
18
19 64. Campbell MK, Entwistle VA, Cuthbertson BH et al.
20
21 Developing a placebo-controlled trial in surgery: issues
22
23 of design, acceptability and feasibility. *Trials*
24
25 2011;**12**:50. doi: 10.1186/1745-6215-12-50.
26
27 65. Snyder L. Review of the American College of Physicians
28
29 Ethics Manual, Sixth Edition. *Ann Intern Med*
30
31 2012;**156**(1_Part_2):73-104.
32
33 66. Flum DR. Interpreting surgical trials with subjective
34
35 outcomes: avoiding UnSPORTsmanlike conduct.
36
37 *JAMA* 2006;**296**:2483-5.
38
39 67. Heckerling PS. Placebo surgery research: a blinding
40
41 imperative. *J Clin Epidemiol* 2006;**59**:876-80.
42
43 68. **Brim** RL, Miller FG. The potential benefit of
44
45 the placebo effect in sham-controlled trials:
46
47 implications for risk-benefit assessments and informed
48
49 consent. *J Med Ethics* 2013;**39**:703-7.
50
51 69. Redberg RF. Sham controls in medical device trials. *N*
52
53 *Engl J Med* 2014;**371**:892-3.
54
55
56
57
58
59
60

- 1
2
3 70. Haahr JP, Østergaard S, Dalsgaard J et al. Exercises
4 versus arthroscopic decompression in patients with
5 subacromial impingement: a randomised, controlled
6 study in 90 cases with a one year follow up. *Ann*
7 *Rheum Dis* 2005;**64**:760-4.
8
9
10
11
12
13 71. Ketola S, Lehtinen J, Rousi T et al. No evidence of long-
14 term benefits of arthroscopic acromioplasty in the
15 treatment of shoulder impingement syndrome: Five-
16 year results of a randomised controlled trial. *Bone*
17 *Joint Res* 2013;**2**:132-9.
18
19
20
21
22
23 72. Herrlin S, Hållander M, Wange P et al. Arthroscopic or
24 conservative treatment of degenerative medial
25 meniscal tears: a prospective randomised trial. *Knee*
26 *Surg Sports Traumatol Arthrosc* 2007;**15**:393-401.
27
28
29
30
31
32
33 73. Yu E, Cil A, Harmsen WS et al. Arthroscopy and the
34 dramatic increase in frequency of anterior
35 acromioplasty from 1980 to 2005: an epidemiologic
36 study. *Arthroscopy* 2010;**26**,Supplement:S142-7.
37
38
39
40
41
42 74. Vitale MA, Arons RR, Hurwitz S et al. The rising
43 incidence of acromioplasty. *J Bone Joint Surg Am*
44 2010;**92**:1842-50.
45
46
47
48 75. Brox JI, Staff PH, Ljunggren AE et al. Arthroscopic
49 surgery compared with supervised exercises in
50 patients with rotator cuff disease (stage II
51 impingement syndrome). *BMJ* 1993;**307**:899-903.
52
53
54
55
56
57
58
59
60

Contributors: RH initiated and planned the project and searched databases. JIB and OT assisted in developing search strategies. Article screening and data extraction was carried out by RH. Quality of data extraction and checking was carried out by JIB and OT. Statistical analysis was undertaken by RH, who also wrote the draft. OT and JIB reviewed the draft and contributed to manuscript revisions. RH is the guarantor for this study.

Funding sources: None.

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: Ethical approval was not required for this work.

Data sharing: Dataset can be obtained from Robin Høltedahl (robi-hol@online.no).

The lead author affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.

1
2
3
4
5
6
7
8 **Placebo effects in trials evaluating 12 selected minimally**
9 **invasive interventions: a systematic review and meta-**
10 **analysis.**

11 Robin Holtedahl, Jens Ivar Brox, Ole Tjomsland

12
13
14 Fram Rehabilitation Centre, Rykkinveien 100, 1349 Rykkin,
15 Norway Robin Holtedahl Consultant Department of Physical
16 Medicine and Rehabilitation, Oslo University Hospital, Box
17 4956 Nydalen, 0424 Oslo, Norway Jens Ivar Brox Professor
18 South-Eastern Norway Regional Health Authority,
19 PB 404, 2303 Hamar, Norway Ole Tjomsland Director of Quality
20 and Specialist Areas

21
22 Correspondence to: Dr Robin Holtedahl; robi-hol@online,
23 telephone +4790248973

24 **Key words:**

25 Placebo effects
26 Invasive procedures
27 Biomedical ethics
28 Evidence based health care
29

30 **Word count:** 5801
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Objectives To analyse the impact of placebo effects on outcome in trials of selected minimally invasive procedures, and to assess reported adverse events in both trial arms.

Design A systematic review and meta-analysis.

Data Sources and Study Selection We searched MEDLINE and Cochrane library to identify systematic reviews of musculoskeletal, neurological and cardiac conditions published between January 2009 and January 2014 comparing selected minimally invasive with placebo (sham) procedures. We searched MEDLINE for additional randomised controlled trials published between January 2000 and January 2014.

Data synthesis Effect sizes (ES) in the active and placebo arms in the trials' primary and pooled secondary endpoints were calculated. Linear regression was used to analyse the association between endpoints in the active and sham groups. Reported adverse events in both trial arms were registered.

Results We included 21 trials involving 2519 adult participants. For primary endpoints, there was a large clinical effect ($ES \geq 0.8$) after active treatment in 12 trials and after sham procedures in 11 trials. For secondary endpoints, seven and five trials showed a large clinical effect, respectively. Three trials showed a moderate difference in ES between active treatment and sham on primary endpoints ($ES \geq 0.5$) but no trials reported a large difference. No trials showed large or moderate differences in ES on pooled secondary endpoints. Regression analysis of endpoints in active treatment and sham arms estimated an R^2 of 0.78 for primary and 0.84 for secondary endpoints. Adverse events after sham were in most cases minor and of short duration.

Conclusion The generally small differences in effect size between active treatment and sham suggest that non-specific mechanisms, including placebo, are major predictors of the observed effects. Adverse events related to sham procedures were mainly minor and short-lived. Ethical arguments frequently raised against sham-controlled trials were generally not substantiated.

3

SUMMARY**Key messages**

- The magnitude of change in the active treatment and placebo arms varied greatly, but about 80% of the variance in effect size of active treatment could be predicted by placebo effects, regression to the mean or spontaneous improvement.
- Adverse events related to sham procedures were mainly minor and short-lived, and frequently outweighed by positive placebo effects.

Strengths and limitations

- Selection of trials with low risk of bias
- Calculation of effect sizes on primary and pooled secondary endpoints in both active treatment and sham arms.
- Heterogeneous interventions, outcome measures and timing of assessment.

1

INTRODUCTION

It is normally assumed that medical practices are based on firm clinical evidence, and that new practices or techniques are introduced when superiority, or at least non-inferiority, has been demonstrated compared to established treatments. However, medical history reveals numerous examples contradicting this assumption. Forty-two percent of 146 medical practices were found to be reversed in a recent review analysing 10 years of publication in a high-impact medical journal.¹ Large effects of an intervention in initial reports are often spurious findings, while the vast majority may represent substantial overestimations.²

Even though surgical and other invasive techniques generally have reached a high degree of sophistication through the last decades, not all invasive procedures have lived up to expectations. Promising results in initial observational studies have in some cases led to widespread clinical implementation, in spite of lack of documented effectiveness.³ The reluctance to abandon contradicted medical practice is commonly ascribed to both culturally embedded medical practices and different forms of vested interests.^{4,5} The continuation of unnecessary and potentially harmful interventions leads to major costs for both patients and society.

The randomised placebo-controlled trial is considered the gold standard for evaluating the effects of pharmacological treatments. However, there are relatively few controlled studies in peer-reviewed surgical journals, and even fewer placebo (sham)-controlled studies.⁶⁻⁸ Ethical concerns raised by the potential for harm to participants are usually cited as the main obstacle to sham-controlled studies.⁹ Problems of a practical nature relate to patient blinding, differing technical expertise, the heterogeneity of the interventional techniques and variable outcome specifications, making standardisation difficult to achieve.¹⁰

A meaningful effect in clinical trials may result from a large effect in the active treatment group, a small effect in the placebo group, or a combination. Even though a placebo effect has been documented in a range of clinical conditions, there are few studies assessing the magnitude of the placebo effect in surgical procedures. In the present study, we analysed placebo-controlled trials of minimally invasive interventions in musculoskeletal, neurological and cardiac conditions. The aims were threefold: (a) to assess the magnitude of change in outcome from baseline to trial endpoint in both the active treatment and placebo (sham) arms, (b) to explore the contribution of non-specific factors, including placebo, to the outcome of active treatment, and (c) to assess the level of reported adverse effects in both trial arms.

5

METHODS

Search strategy and selection criteria

We ~~first~~ conducted electronic searches for randomised placebo-controlled trials of minimally invasive interventions for cardiac, neurological and ~~selected~~ musculoskeletal conditions. ~~We primarily searched for interventions addressing subjective endpoints, including pain states, but included trials for Parkinson's disease. Open surgical and laparoscopic interventions and interventions targeting hard endpoints (i.e. hypertension) were excluded. We defined minimally invasive procedures as interventions involving the introduction of a medical device, substance or other foreign material into the body through a cannula, catheter or arthroscope, thereby minimising damage to biological tissues at the point of entrance. We first, using~~ MEDLINE and Cochrane library to identify systematic reviews published between January 2009 and January 2014. ~~The following key words were used in our search strategies: "randomi* controlled trial", "placebo OR sham" in combination with "low back pain", "neck OR cervical pain", "radiofrequency denervation", "facet joint AND "nerve block" OR injection", "intradiscal OR annular AND thermal", "epidural AND corticosteroid* AND sciatica OR radic*", "hyaluron* OR viscosuppl* AND knee AND osteoarthritis", "vertebroplast*", "arthroscop*", "debridement AND lavage AND knee AND osteoarthr*", "meniscectomy AND knee", "myocardial laser revascularization", "transplantation OR gene OR stem cell OR deep brain stimulation AND Parkinson* OR dystonia", "spinal cord stimulation", and "foramen ovale AND migraine".~~ ~~Sett inn søkestrategi, søkeord osv.~~ We defined minimally invasive procedures as interventions involving the introduction of a medical device, substance or other foreign material into the body through a cannula, catheter or arthroscope, thereby minimising damage to biological tissues at the point of entrance. ~~We excluded open surgical and laparoscopic interventions. Where applicable, W~~we used the "core clinical journals" filter in PubMed, which is an index of journals particularly relevant to practicing physicians.

~~From the most recently published systematic review of each procedure~~From the reviews, we selected randomised placebo-controlled trials published ~~from later than~~ January 2000 ~~to~~ January 2014. ~~Dette er ikke helt persist, fordi du har gjort søk på sham RCT på studier publisert etter siste inklusionsdato I SR.~~ We excluded ~~earlier~~ trials published before January 2000 because our primary aim was to assess interventions that are currently, or until recently have been, in common use. We selected trials that according to the review fulfilled at least four of the following methodological criteria: random allocation, allocation concealment, blinding of participant, blinding of assessor and intention-to-treat analysis. We chose

1

1
2
3
4
5
6
7 these criteria both because they were the most commonly
8 used in the selected reviews, and because use of scales for
9 assessing quality or risk of bias is explicitly discouraged in
10 Cochrane reviews¹¹. Two of the authors (RH and JIB)
11 independently assessed the five methodological criteria in the
12 RCTs included from systematic reviews.

13 We next searched MEDLINE for additional randomised
14 placebo-controlled trials published between January 2000 and
15 January 2014. Two of the reviewers (OT and JIB) independently
16 assessed the five criteria mentioned above in the additional
17 RCTs that were identified from this search.

18 Only English language journals were included. We excluded
19 crossover trials, trials that did not report results as means,
20 standard deviation, standard error or confidence intervals in
21 both active and sham-groups, as well as trials with only graphic
22 representation of data. This review is reported in accordance
23 with the PRISMA statement.¹²

24 25 **Data extraction**

26 We registered all continuous primary endpoints. In trials without
27 continuous primary endpoints, with multiple endpoints or no
28 defined primary endpoint, we selected an outcome related to
29 pain or condition-specific endpoint. The heterogeneity of trials
30 did not allow for use of pain as a primary outcome. We used the
31 RCTs' defined primary outcome to avoid bias introduced by
32 choosing our own endpoint. We also registered secondary
33 endpoints in order to avoid potential bias from selective
34 reporting in the included trials. Endpoints describing medication,
35 radiographic or physiological variables, social or psychological
36 function, were not included. For the Parkinson-trials, only
37 endpoints in the off-medication state were registered. Results
38 from the last follow-up until 12 months were extracted. The
39 trials' protocol registration, funding source, description of sham
40 intervention, sample size, disease duration, length of follow-up
41 and reported adverse events in both trial arms were registered.

42 **Data synthesis**

43 To assess clinically important change, we calculated effect size
44 (ES, Cohen's d), based on the means and standard deviations
45 (SD). We calculated ES both for the active and sham
46 intervention to obtain information about the pre-to-post
47 treatment change in both arms. Without first calculating ES of
48 change in each trial arm, we would not be able to discern the
49 relative contribution of placebo, which was one of the
50 objectives of the study. Subtracting the average score after
51 treatment from the average score before treatment and
52 dividing the result by the average of the standard deviations
53 before and after treatment calculated ES. An ES of 0.8 or more
54 is assumed large, while an ES of 0.5 - 0.8 is considered
55 moderate.¹³ In trials with multiple secondary endpoints we
56
57
58
59
60

calculated the pooled mean ES, without weighting. Because of small sample sizes in most of the included trials, we calculated an adjusted ES in accordance with a recommended procedure.¹⁴ Unadjusted linear regression analyses were used to explore the association between outcome in the active and sham groups both for primary and pooled secondary endpoints. For this analysis, we used Medcalc Statistical Software version 12.7.4.0¹⁵

RESULTS

Selection of interventions and trials

The searches provided sham-controlled trials of the following interventions: percutaneous laser revascularisation of myocardium for angina pectoris (n=2), closure of foramen ovale for migraine (n=1), arthroscopic meniscectomy for meniscal tears (n=1), debridement (n=1) and injection of hyaluronic acid (n=3) for symptomatic osteoarthritis of the knee, injection or transplantation of biologically active material for Parkinson's disease (human retinal pigmental cells (n=1), fetal nigral cells (n=1) and Neurturin (n=2)). ~~Because of the large number of described interventions for neck and back pain syndromes, we chose to restrict the analysis to sham-controlled trials of the following interventions:~~ epidural injections of corticosteroids for sciatica (caudal (n=1), interlaminar (n=2) and transforaminal (n=1)) routes, percutaneous heating of the intervertebral disc for chronic low back pain (intradiscal radiofrequency thermocoagulation (n=1), intradiscal electrothermal therapy (n=2)) and vertebroplasty for vertebral body fractures (n=2). We give a short description of each procedure's introduction, therapeutic rationale and history in web appendix table 1.

The searches provided no sham-controlled trials of cervical, thoracic or lumbar facet joint nerve blocks or joint injections, spinal cord stimulation for low back pain, cervical-cervical epidural injections, transmyocardial laser revascularisation for angina pectoris, deep brain stimulation for Parkinson's disease or dystonia or arthroscopic procedures other than knee conditions. ~~We found six placebo-controlled trials of radiofrequency denervation for low back pain, but all were excluded: SD not provided (n=1),¹⁶ (ref) compound primary endpoint (n=1),¹⁷ (ref) risk of false positive response because of only one diagnostic block (n=4),¹⁸⁻²¹~~

Study selection

The study selection process is summarised in web appendix figure 1. Web appendix table 2 shows the excluded trials and the reasons for exclusion. The search provided five systematic reviews, all identified through searches in MEDLINE, none were commercially funded.²²⁻²⁶ It identified a total of 71 clinical trials, twelve of them were not identified from the systematic

7

1

reviews. Forty-four trials were excluded for methodological reasons, principally risk of bias. Six additional trials were excluded because ES could not be calculated.²⁷⁻³² [Web appendix table 2 shows the excluded trials and the reasons for exclusion.](#) Finally, 21 clinical trials with a total of 2519 participants were included in the present review (table 1). Trial interventions in active treatment and sham arms are also shown.

Author	Protocol approval / funding (commercial, non-commercial).	Invasive procedure / indication	Sham intervention	Adverse events related to procedure, active treatment	Adverse events related to procedure, sham
Leon 2005	Food and Drug Administration / NC	Percutaneous myocardial laser revascularization / intractable angina pectoris	Laser turned on but no procedure performed	MAE in hospital (high dose): 4.1%	MAE in hospital: 0
Salem 2004	Ethics committee / NC			No procedural AE	
Sihvonon 2013	Review board / NC	Arthroscopic partial meniscectomy / degenerate meniscal tear	Routine arthroscopy, simulation of meniscectomy by manipulation etc.	No MAE	
				mAE: 6.6%	mAE: 2.9%
Moseley 2002	Review Board / NC	Arthroscopic debridement / Knee osteoarthritis	Simulated arthroscopy preparation, intravenous anaesthesia, skin incisions, no instruments entered knee, knee manipulated	No procedural AE	
Pham 2004	Review Board / NC	Hyaluronic acid / Knee osteoarthritis	Intraarticular injection of saline solution	No MAE	
				Any mAE: 81.7%	Any mAE: 1.2%
Altman 2004	Ethics committee / C			No MAE	
Chevalier 2010	ClinicalTrials.org / C			mAE: 12.8%	mAE: 8%
Kallmes 2009	Review Board / NC	Percutaneous vertebroplasty with	Conscious sedation + local anaesthesia,	No MAE	
				mAE: 35,8%	mAE: 33,8%

		PMMA cement injection / vertebral compression fracture	pressure put on spine, simulation of odor with mixing of PMMA to imitate the smell during the active procedure	mAE: 14%	mAE: 16%
Buchbinder 2009	Ethics committee at each participating center / NC		Conscious sedation + local anaesthesia, needle inserted to rest on the lamina, PMMA container opened to imitate the smell during the active procedure	No procedural AE	
Cohen 2012	Review Board / NC	Epidural injection of corticosteroids / Sciatica	2 ml sterile water at 1-2 injection sites, transforaminal approach	No MAE	
Arden 2005	Ethics committee / NC		2 mL saline into interspinous ligament	mAE: 36%	mAE: 20%
Valat 2002	Ethics committee / NC		2 mL saline into epidural space, interlaminar approach	No MAE	
Iversen 2011	Ethics committee / NC		Subcutaneous injection of 2 mL saline superficial to the sacral hiatus	mAE: 9%	mAE: 10%
Freeman 2005	Ethics committee / C	Intradiscal electrothermal therapy (IDET) / discogenic low back pain	17-gauge introducer needle inserted into disc under fluoroscopic guidance, catheter inserted but not connected to generator, both subject and surgeon blinded.	No MAE	
Pauza 2003	Review Board / NC		17-gauge needle introduced onto the outer annulus, mock electrode passage shown on monitor, generator noises produced	mAE: 11%	mAE: 5%
Kvarstein 2009	Ethics committee / NC	Percutaneous intradiscal radiofrequency thermocoagulation (PIRFT) / discogenic	17-gauge canula and RF-probe inserted into annulus, no RF current applied	Not reported	

		low back pain			
Olanow 2003	Review Board / NC	Fetal nigral transplantation, 4 donors / Parkinson's disease	Scalp incisions, partial thickness burr holes, no cell transplantation, 6 months low-dose cyclosporine	No MAE	
				mAE (rate/patient day: 0,66)	mAE (rate/patient day: 0,39)
Marks 2010	Review Board / C	Gene delivery of AAV2-Neurturin / Parkinson's disease	Scalp incisions, partial thickness burr holes, no intracranial injections	MAE: 4	MAE: 0
				Most frequent mAE: headache: 68%	Most frequent mAE: headache: 50%
Gross 2011	Review Board / C	Transplantation of human retinal pigmental cells / Parkinson's disease	Scalp incisions, partial thickness burr holes, no cell transplantation	1 death	0 deaths
				MAE: 23%	MAE: 0
LeWitt 2011	Review Board / C	Insertion of AAV-GAD gene into subthalamic nucleus / Parkinson's disease	Insertion of catheter caudal to nucleus, infusion of saline	No MAE	
				mAE (probably related to procedure): 56%	mAE (probably related to procedure): 14%
Dowson 2008	Ethics committee / C	Patent foramen ovale closure with STARFlex Septal Repair Implant / migraine	General anesthesia, skin incision in the groin	MAE (possibly or probably related to procedure): 11%	MAE (possibly or probably related to procedure): 4%
C=commercial; NC=non-commercial; MAE=major adverse events; mAE=minor adverse events; PMMA=polymethylmethacrylate; AAV2 =adeno-associated; GAD=glutamic acid decarboxylase					

Fourteen trials from the systematic reviews fulfilled at least four of the five methodological criteria.^{33 34 37-48} Seven trials provided through searches in MEDLINE fulfilled the same criteria.^{35 36 49-53} The included and excluded secondary endpoints are shown in web appendix table 3. -All trials reported approval of study protocol prior to patient enrolment (table 1). Seven trials were commercially funded.^{38 39 47 50-53} Most of the trials had few participants, ranging from 20 to 346 (median 80).

Clinical outcomes after active treatment and sham

Twelve of the 21 trials showed a large ES on primary endpoints after active treatment, while 11 trials showed a similar ES after the sham procedure (figure 42, table 2).

Table 2. Effect size (ES) on primary and pooled secondary endpoints, showing differences between active treatment and sham arms.

Author / procedure	Limit disease duration / time to follow-up (months)	Trial arm / no of patients randomised	ES primary endpoint	ES pooled secondary endpoints (no of endpoints)
Leon 2005 / Percutaneous myocardial laser revascularization	None / 12		Exercise duration (s)	(10)
		Active / 98	0.23	0.60
		Sham / 102	0.22	0.54
ES active treatment vs sham			0.01	0.07
Salem 2004 / Percutaneous myocardial laser revascularization	None / 12		Exercise duration (s)	-
		Active / 40	0.04	
		Sham / 42	0.08	
ES active treatment vs sham			-0.04	
Sihvonon 2013 / Arthroscopic partial meniscectomy	>3 / 12		Lysholm knee score	(4)
		Active / 70	0.86	0.58
		Sham / 76	1.03	0.58
ES active treatment vs sham			-0.17	0.00
Moseley 2002 / Arthroscopic debridement	None / 12		Knee Specific Pain Scale	(5)
		Active / 59	0.54	0.11
		Sham / 60	0.85	0.20
ES active treatment vs sham			-0.31	-0.09
Pham 2004 / Hyaluronic acid			VAS Pain	(3)
	None / 12	Active / 131	1.48	1.35
		Sham / 85	1.54	1.30
ES active treatment vs sham			-0.06	0.05
Chevalier 2010 / Hyaluronic acid			Womac A	Womac C function
	None / 6	Active / 124	1.52	1.13

		Sham / 129	1.18	1.07
			0.34	0.06
ES active treatment vs sham				
Altman 2004 / Hyaluronic acid	None / 6		Womac pain	(2)
		Active / 172	0.76	0.38
		Sham / 174	0.85	0.53
ES active treatment vs sham			-0.09	-0.15
Kallmes 2009 / Percutaneous vertebroplasty	<12 / 1		Roland-Morris Disability Questionnaire	(7)
		Active / 68	0.86	0,72
		Sham / 63	0.81	0.63
ES active treatment vs sham			0.05	0.09
Buchbinder 2009 / Percutaneous vertebroplasty	<12 / 6		Pain Score	(4)
		Active / 38	0.83	0.46
		Sham / 40	0.71	0.51
ES active treatment vs sham			0.12	-0.05
Cohen 2012 / Epidural injection of corticosteroids	<6 / 1		NRS leg pain	(2)
		Active / 28	1.51	0.88
		Sham / 30	0.82	0.39
ES active treatment vs sham			0.69	0.49
Iversen 2011 / Epidural injection of corticosteroids	>3 / 12		Oswestry disability index	-
		Active / 36	1.68	
		Sham / 40	1.85	
ES active treatment vs sham			-0.17	
Arden 2005 / Epidural injection of corticosteroids	>1<18 / 12		Oswestry disability index	(2)
		Active / 120	1.42	1.14
		Sham / 108	1.44	1.21
ES active treatment vs sham			-0.02	-0.07
Valat 2002 / Epidural injection of corticosteroids	<6 / 1		VAS Pain	(3)
		Active / 42		1.10

13

			1.85	
		Sham / 43	1.47	0.99
ES active treatment vs sham			0.38	0.10
Freeman 2005 / Intradiscal electrothermal therapy	≥3 / 6		Oswestry disability index	(6)
		Active / 38	0.10	-0.03
		Sham / 19	0.07	0.12
ES active treatment vs sham			0.17	-0.15
Pauza 2003 / Intradiscal electrothermal therapy	>6 / 6		Oswestry disability index	(3)
		Active / 32	0.94	0.90
		Sham / 24	0.35	0.46
ES active treatment vs sham			0.59	0.44
Kvarstein 2009 / Percutaneous intradiscal radiofrequency thermocoagulation	>6 / 12		Brief Pain Inventory	(5)
		Active / 10	0.34	0.54
		Sham / 10	0.23	0.24
ES active treatment vs sham			0.11	0.30
Olanow 2003 / Fetal nigral transplantation	None / 24		UPDRS 3 off	(5)
		Active / 12	0.04	-0.24
		Sham / 11	0.44	-0.19
ES active treatment vs sham			0.48	-0.06
Marks 2010 / Gene delivery of AAV2-Neurturin	≥60 / 12		UPDRS 3 off	(7)
		Active / 38	0.72	0.23
		Sham / 20	0.53	-0.05
ES active treatment vs sham			0.19	0.28
Gross 2011 / Transplantation of human retinal pigmental cells	≥60 / 12		UPDRS 3 off	(2)
		Active / 35	1.09	0.08
		Sham / 36	0.88	0.06
ES active treatment vs sham			0.21	0.02
LeWitt 2011 / AAV-GAD gene into	≥60 / 6		UPDRS 3 off	(7)

1

subthalamic nucleus				
		Active / 16	1.00	0.30
		Sham / 21	0.42	0.21
ES active treatment vs sham			0.58	0.08
Dowson 2008 / Patent foramen ovale closure	None / 6		Frequency migraine/month (per protocol)	Headache Impact Test
		Active / 74	0.74	1.02
		Sham / 73	0.45	1.06
ES active treatment vs sham			0.28	0.04
VAS=Visual Analogue Scale; NRS=Numerical Rating Scale; UPDRS=Unified Parkinson's Disease Rating Scale; Womac=Western Ontario and McMaster Universities Osteoarthritis Index				

ES on primary endpoints was moderate in three of the active treatment groups and in two of the sham groups.

On pooled secondary endpoints, a large ES was estimated in seven trials after active treatment and in five trials after sham, while a moderate ES was reported in four and three trials respectively (table 2).

In none of the trials did the actively treated group show a deterioration of primary endpoint during treatment, while this was the case for two of the sham groups (not reported to be related to the procedure). On secondary endpoints, deterioration occurred in two active treatment and two sham groups (table 2).

Differences in outcome between active treatment and sham

Better results on primary endpoints were reported with active treatment compared to sham in 14 of the 21 trials, but the differences were small. Three trials (one epidural study⁴³, one discogenic pain study⁴⁶ and one Parkinson study⁵²) reported a moderate effect but none showed a large effect (figure 23, table 2). Seven trials reported a better primary endpoint outcome after sham than after active treatment.

Nineteen trials reported secondary endpoints, 11 of these reported better outcome after active treatment than after sham, but in no case did the differences reach a moderate ES (figure 23, table 2). In twelve trials, the outcome was better for primary than for pooled secondary endpoints. This bore no relation to funding source.

On regression analyses, effect sizes in the sham groups predicted about 80 % of the variance of ES in the active treatment groups, both on primary and pooled secondary endpoints (figure 34 and 45).

Adverse events

Eighteen studies provided information about adverse events (AE) (table 1). Three of these trials reported no procedural adverse events in any of the groups.^{33 35 41} Major AEs were reported after active treatment in four trials^{34 50 51 53} including one death in one of the Parkinson studies.⁵¹ In the sham groups, one trial⁵³ listed three major AEs possibly or probably related to the procedure, all thought to be caused by anti-platelet medication, none of them life-threatening. Apart from this trial, there were no major AEs in the sham groups. The reported minor AEs were all of limited duration.

DISCUSSION

Principal findings

Analysis of 21 sham-controlled trials of minimally invasive procedures showed that the effect sizes in the active treatment arms were predicted by the effect sizes in the sham arms. There was a large ES on primary endpoints in about half of both the active and sham interventions, but none of the trials showed a large difference in ES between active treatment and sham groups either on primary or secondary endpoints.

The magnitude of the effect in each trial arm varied considerably, both between different procedures and between trials using the same procedure. For instance, in the active treatment groups, ES for primary endpoints varied from around zero to almost 2 after active treatment, and from about -0.4 to 1.5 after sham. Disparate outcomes were reported even between trials where technical parameters were similar. For instance, ES in the sham group in the three hyaluronic acid-trials varied by a factor of three, and in the epidural trials by a factor of two. This variability is probably related to differences in study design, duration of disability before inclusion, contextual factors, including the doctor-patient relationship as well as other factors. The close association between endpoints in the active treatment and sham groups on regression analyses suggests that a large part of the reported outcomes in the active treatment groups are due to placebo effects, statistical regression to the mean or the natural course of the condition.

Strengths and limitations of study

It is our opinion that the calculation of effect sizes in both active treatment and placebo arms is a strength of the present study. This made it possible to assess the magnitude of change in both arms and the contribution of non-specific factors to

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

change in the active treatment arms. The calculation of effect sizes provides an alternative assessment to probability estimates. Another strength of the study is the supplementary analyses of pooled secondary endpoints, enabling a more comprehensive evaluation than using primary endpoints alone. Reports of tactically motivated use of primary and secondary endpoints before publication in order to improve study results strengthen the argument for registering all relevant secondary endpoints.⁵⁴ Our finding that a majority of trials reported better results on primary than on secondary endpoints might lend support to such a hypothesis, although all trials, according to the authors, had sought and gained approval of the protocol from ethics committee and/ or review board (table 1).

The present review is limited to selected minimally invasive procedures in cardiology, neurology, and musculoskeletal conditions. While some procedures are, or have been, in wide clinical use, some are still in the clinical trial phase. Other sources of heterogeneity are variable duration of disease before inclusion, selection of outcome measures and time to follow-up. Results cannot be generalised to minimally invasive procedures in all medical disciplines, but a similar methodology could be applied to more systematic analyses of the role of non-specific effects in other minimally invasive procedures.

We applied principles from guidelines for conducting systematic reviews and meta-analyses and included an independent assessment of methodological trial quality by two of the authors. We cannot rule out that we have missed relevant trials because we limited our search to the Cochrane Library and MEDLINE, but most relevant trials are likely to have been identified by our searches. By preferentially selecting core journals and trials that had previously been methodologically evaluated in systematic reviews, it was our intention to reduce the risk of bias by excluding studies of low quality. We realize that this selection process and the fact that we relied on previous methodological evaluations may have contributed to unrecognised selection bias.

The use of ES as a measure of clinical effect assumes a normal distribution of the data. This does not necessarily apply in the included trials because the majority of them are small. Including trials reporting non-parametric data would however necessitate other methods of statistical analysis. Small studies increase the likelihood of type-2 errors, though this is more relevant to probability estimates than analysis of ES.

Adequate blinding and lack of physiological effects?

We cannot rule out that treatment-specific effects in the actively treated groups may have jeopardised blinding, leading to overestimation of treatment effects through positive

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

expectations. However, all the included trials gave a detailed description of the sham procedure, and both participant and assessor blinding seems to have been adequate.

On a more general level, it has been argued that sham procedures are not inert and may have specific physiological effects, thereby underestimating a treatment effect.⁵⁵ More recently, Bickett et al. hypothesised that epidural injection of small volumes of saline might have physiological effects.⁵⁶ However, it is to be noted that in the four selected epidural trials in the present study, improvements in the sham group were greater in the two trials using non-epidural saline than in those using epidural saline, making a physiological effect less likely. In our opinion, physiological effects of the sham interventions are also unlikely in the remaining procedures.

Surgery and other invasive procedures are commonly believed to be associated with enhanced placebo effects, a phenomenon coined mega-placebo.⁵⁷ In spite of their heterogeneous nature, the 21 selected trials share a medico-technological context in which an a priori enhanced placebo response could be expected. If an ES >0.8 is considered as mega-placebo, half of the included sham interventions reached this level. Factors such as the level of enthusiasm and conviction conveyed by the therapist, the impression of advanced procedures and the extent to which these factors succeed in activating a placebo response are probably crucial in explaining the improvements after sham interventions and the correlation of endpoints in the active treatment and sham groups. Participants' perception of whether they received active treatment or sham has been shown to contribute more to clinical improvement than the biological effects per se.^{32 58}

Non-specific factors

The role of non-specific factors, primarily spontaneous remission or statistical regression-to-the-mean, in placebo-controlled studies is controversial.⁵⁹ A recent meta-analysis analysing 202 trials with an untreated group, spanning 60 different clinical conditions, found rather small differences between placebo and no treatment, with effect sizes in the range of 0.2 to 0.3.⁶⁰ Apart from acupuncture trials (mean ES 0.68), the authors did not include trials reporting the effectiveness of invasive procedures. Another meta-analysis studied the placebo effect of a range of treatments (pharmacological, non-pharmacological and surgical) for osteoarthritis of the hand, hip and knee.⁶¹ Of 198 included trials fourteen had a no-treatment arm. The mean ES in the placebo groups was about 0.5, while it was only slightly above zero in the no-treatment groups. The difference between the placebo and no-treatment groups was larger than the difference between the placebo and active treatment groups. Trials using injections, acupuncture and surgery had the largest

1
2
3
4
5
6
7 placebo effects, and the effects were larger for subjective than
8 objective endpoints. The authors concluded that there is a
9 significant placebo effect on pain, stiffness and function in
10 symptomatic osteoarthritis.

11
12 Because the trials in the present study did not include a no-
13 treatment arm (i.e. waiting list), we cannot rule out that the
14 changes appearing during the trial period also reflect non-
15 specific factors, i.e. spontaneous improvement or regression to
16 the mean. Such mechanisms would be expected to be most
17 prominent in trials with brief illness duration before inclusion
18 and with longer time to follow-up, while improvements in
19 chronic, unremitting conditions such as Parkinson's disease
20 would be more likely attributed to placebo. Interestingly, in
21 three of the four included Parkinson trials, there were
22 moderate to large improvements in the sham groups even at
23 one-year follow-up.⁴⁹⁻⁵¹ Other authors have also found
24 improvements several years after sham surgery,
25 indistinguishable from conventional surgery.^{32 62} This is in
26 agreement with recent insights into the neurobiological effects
27 of placebo and their relation to underlying psychological
28 mechanisms, principally expectation and conditioning.⁶³

29 **Are ethical objections to sham justified?**

30 The use of sham in controlled surgical trials is a divisive issue,
31 with scepticism, even frank opposition, being voiced by both
32 ethics committees, involved surgeons and anaesthetists, and
33 potential patients.⁶⁴ Ethical arguments include the inherent
34 risks of sham procedures combined with the lack of obvious
35 benefits to the participants. Barriers related primarily to
36 feasibility include problems with patient and assessor blinding,
37 differing technical expertise, the heterogeneity of the
38 interventional techniques and variable outcome specifications,
39 making standardization difficult to achieve. Existing ethical
40 guidelines accept the role of placebo-controlled trials when
41 certain conditions are met.⁶⁵ There must be genuine equipoise,
42 i.e. conflicting or weak evidence of the effectiveness of a
43 procedure. Blinding of both participants and assessors must be
44 assured, and participants must freely consent to suspend
45 knowledge of whether they are receiving sham or conventional
46 treatment. The health risks and consequences of placebo or
47 delayed treatment must be minimal, and outweighed by the
48 societal importance of establishing the clinical utility of the
49 intervention in question.^{66 67}

50 The selected trials gave a detailed description of adverse
51 events in both active and sham-treated groups (table 1). The
52 safety concerns frequently raised as an argument against the
53 use of sham were generally not supported. Major adverse
54 events related to the sham procedure were reported in only
55 one of the trials⁵³ and they were short-lived and not life
56 threatening. Minor adverse events were more frequent, but
57
58
59
60

1
2
3
4
5
6
7 also of limited duration. Positive placebo-induced effects
8 generally outweighed adverse events, thus weakening ethical
9 arguments against the use of sham interventions. In our
10 opinion, the consequences of the continued use of unproven
11 invasive procedures are of a different magnitude. In the light
12 of studies supporting the beneficial effects of sham
13 procedures, at least for pain and Parkinson symptoms,
14 research ethics committees should consider such factors in
15 their risk-benefit assessments of planned sham controlled
16 trials.^{68 69}

17 **Clinical implications.**

18 The present results are pertinent to the ongoing discussion
19 about wasteful and unproven medical practices, and
20 underscore the necessity for a continual assessment of existing
21 or novel unproven procedures. Minimally invasive techniques
22 have lowered the threshold for interventions, and led to their
23 application to a wider clinical spectrum (indication creep)
24 without an ongoing evaluation of effectiveness or safety.⁴ The
25 last two decades have seen dramatic increases in the use of
26 several of the described procedures, as well as interventions
27 we have not investigated, such as acromioplasty, percutaneous
28 coronary intervention and, more recently, robotic surgery.⁷⁰⁻⁷⁵
29 In light of the results in the present study, placebo effects
30 might well explain a large part of the purported effects of such
31 procedures. When clinicians and regulators are faced with
32 claims of large treatment effects for insufficiently tested
33 procedures, their default mode should be watchful scepticism.
34 The standards of the evaluation process before approval and
35 reimbursement of devices and procedures need to be
36 strengthened, and economic or regulatory incentives that
37 perpetuate the use of undocumented or harmful procedures
38 should be abrogated.

39 **CONCLUSION**

40 Sham-controlled trials are unique in their ability to
41 discriminate between true treatment effects and non-specific
42 effects. The results of the present study suggest that placebo
43 and other non-specific effects explain a large part of their
44 purported benefits. Further, results indicate that the risks of
45 adverse events in sham-controlled trials are overrated and
46 could be considered acceptable in view of the potential
47 personal harm and societal costs associated with unproven
48 minimally invasive interventions.

49 **Figure legends**

50 Figure 1. [Flow chart of study selection in the present meta-](#)
51 [analysis.](#)

52 [Figure 2.](#) Effect sizes of active treatment and sham, primary
53 endpoints.
54
55
56
57
58
59
60

Figure 23. Differences in effect size between active treatment and sham.

Figure 34. Association between effect sizes of primary endpoints in active treatment and sham arms. Linear regression, 95% confidence intervals. N=21.

Figure 45. Association between effect sizes of pooled secondary endpoints in active treatment and sham arms. Linear regression, 95% confidence intervals. N=19.

References

1. Prasad V, Vandross A, Toomey C et al. A decade of reversal: an analysis of 146 contradicted medical practices. *Mayo Clin Proc* 2013;**88**:790-8.
2. Tiago V, Pereira TV, Horwitz RI et al. Empirical Evaluation of Very Large Treatment Effects of Medical Interventions. *JAMA* 2012;**308**:1676-84.
3. Roberts AL, Kewman DG, Mercier L et al. The power of nonspecific effects in healing: implications for psychosocial and biological treatments. *Clin Psychol Rev* 1993;**13**:375-91.
4. Garner S, Littlejohns P. Disinvestment from low value clinical interventions: NICEly done? *BMJ* 2011;**343**:d4519.
5. Scott IA, Elshaug AG. Foregoing low-value care: how much evidence is needed to change beliefs? *Intern Med J* 2013;**43**:107-9.
6. Obremsky WT, Pappas N, Attallah-Wasif E et al. Level of evidence in orthopaedic journals. *J Bone Joint Surg Am* 2005;**87**:2632-8.

7. Reeves B. Health-technology assessment in surgery.
Lancet 1999;**353**:Suppl 1:S13-S15;
8. Wenner DM, Brody BA, Jarman AF et al. Do surgical trials meet the scientific standards for clinical trials? *J Am Coll Surg* 2012;**215**:722-30.
9. Ezekiel JE, Miller FG. The Ethics of Placebo-Controlled Trials — A Middle Ground. *N Engl J Med* 2001;**345**:915-9.
10. Campbell MK, Entwistle VA, Cuthbertson BH et al. Developing a placebo-controlled trial in surgery: issues of design, acceptability and feasibility. *Trials* 2011;**12**:50
11. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0.
<http://handbook.cochrane.org>; (11.11.2014)
12. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009;**339**:b2700.
13. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.
14. Durlak JA. How to Select, Calculate, and Interpret Effect Sizes. *J Pediatr Psychol* 2009; **34**: 917-28.

- 1
2
3
4
5
6
7 15. MedCalc Software bvba, Ostend, Belgium;
8 <http://www.medcalc.org>; (08.03.2014).
9
- 10 16. Nath S, Nath CA, Pettersson K et al. Percutaneous
11 [lumbar zygapophysial \(Facet\) joint neurotomy using](#)
12 [radiofrequency current, in the management of chronic](#)
13 [low back pain: a randomized double-blind trial.](#) *Spine*
14 [2008;33:1291-7.](#)
15
- 16 17. Patel N, Gross A, Brown L et al. A randomized, placebo-
17 [controlled study to assess the efficacy of lateral branch](#)
18 [neurotomy for chronic sacroiliac joint pain.](#) *Pain Med*
19 [2012;13:383-398.](#)
20
- 21 18. Cohen SP, Hurley RW, Buckenmaier CC et al.
22 [Randomized placebo-controlled study evaluating](#)
23 [lateral branch radiofrequency denervation for](#)
24 [sacroiliac joint pain.](#) *Anesthesiology* 2008;**109**:279-88.
25
- 26 19. Tekin I, Mirzai H, Ok G et al. A comparison of
27 [conventional and pulsed radiofrequency denervation](#)
28 [in the treatment of chronic facet joint pain.](#) *Clin J*
29 [Pain 2007;**23**:524-9.
30](#)
- 31 20. Leclaire R, Fortin L, Lambert R et al. Radiofrequency
32 [facet joint denervation in the treatment of low back](#)
33 [pain: a placebo-controlled clinical trial to assess](#)
34 [efficacy.](#) *Spine* 2001;**26**:1411-6.
35
- 36 21. van Wijk RM, Geurts JW, Wynne HJ et al.
37 [Radiofrequency denervation of lumbar facet joints in](#)
38 [the treatment of chronic low back pain: a randomized,](#)
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

double-blind, sham lesion-controlled trial. *Clin J*

Pain 2005 ;21:335-44.

~~16.22.~~ Rutjes AWS, Jünl P, da Costa BR et al.

Viscosupplementation for Osteoarthritis of the Knee. A Systematic Review and Meta-analysis. *Ann Intern Med* 2012;**157**:180-91.

~~17.23.~~ Pinto RZ, Maher CG, Ferreira ML et al.

Epidural corticosteroid injections in the management of sciatica: a systematic review and meta-analysis. *Ann Intern Med* 2012;**157**:865-77.

~~18.24.~~ McGillion M, Cook A, Victor JC et al.

Effectiveness of percutaneous laser revascularization therapy for refractory angina. *Vasc Health Risk Manag* 2010;**6**:735-47.

~~19.25.~~ Helm S II, Deer TR, Manchikanti L et al.

Effectiveness of thermal annular procedures in treating discogenic low back pain. *Pain Physician* 2012;**15**:E279-E304.

~~20.26.~~ Shi MM, Cai XZ, Lin T et al. Is there really no

benefit of vertebroplasty for osteoporotic vertebral fractures? A meta-analysis. *Clin Orthop Relat Res* 2012;**470**:2785-99.

~~21.27.~~ Petrella RJ, Cogliano A, Decaria J.

Combining two hyaluronic acids in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. *Clin Rheumatol* 2008;**27**:975-81.

1
2
3
4
5
6
7 22-28. [Lundsgaard C](#), Dufour N, Fallentin E et al.

8 Intra-articular sodium hyaluronate 2 mL versus
9 physiological saline 20 mL versus physiological saline 2
10 mL for painful knee osteoarthritis: a randomized
11 clinical trial. *Scand J Rheumatol* 2008 ;**37**:142-50.

12
13
14
15
16 23-29. [Karppinen J](#), Malmivaara A, Kurunlahti M et

17 al. Periradicular infiltration for sciatica: a randomized
18 controlled trial. *Spine* 2001; **26**:1059-67.

19
20
21 24-30. [Freed CR](#), Greene PE, Breeze RE et

22 al. Transplantation of embryonic dopamine neurons for
23 severe Parkinson's disease. *N Engl J Med*
24 2001;**344**:710-9.

25
26
27 25-31. [Gordon PH](#), Yu Q, Qualls C et al. Reaction

28 time and movement time after embryonic cell
29 implantation in Parkinson disease. *Arch Neurol*
30 2004;**61**:858-61.

31
32
33 26-32. [McRae C](#), Cherin E, Yamazaki TG et al.

34 Effects of perceived treatment on quality of life and
35 medical outcomes in a double-blind placebo surgery
36 trial. *Arch Gen Psychiatry* 2004; **61**: 412-20.

37
38
39 27-33. [Salem M](#), Rotevatn S, Stavnes S et al.

40 Usefulness and safety of percutaneous myocardial
41 laser revascularization for refractory angina pectoris.
42 *Am J Cardiol* 2004;**93**:1086-91.

43
44
45 28-34. [Leon MB](#), Kornowski R, Downey WE et al. A

46 blinded, randomized, placebo-controlled trial of
47
48
49
50
51
52
53
54
55
56
57
58
59
60

percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. *J Am Coll Cardiol* 2005;**46**:1812-9.

~~29~~35. Moseley JB, O'Malley K, Petersen NJ et al. A

controlled trial of arthroscopic surgery for osteoarthritis of the knee. *N Engl J Med* 2002;**347**:81-8.

~~30~~36. Sihvonen R, Paavola M, Malmivaara A et al.

Arthroscopic partial meniscectomy versus sham surgery for a degenerative meniscal tear. *N Engl J Med* 2013;**369**:2515-24.

~~31~~37. Pham T, Le Henanff A, Ravaud P et al.

Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis. *Ann Rheum Dis* 2004;**63**:1611-7.

~~32~~38. Altman RD, Akermark C, Beaulieu AD et al.

Efficacy and safety of a single intra-articular injection of non-animal stabilized hyaluronic acid (NASHA) in patients with osteoarthritis of the knee. *Osteoarthritis Cartilage* 2004;**12**:642-9.

~~33~~39. Chevalier X, Jerosch J, Goupille P et al.

Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial. *Ann Rheum Dis* 2010;**69**:113-9.

1
2
3
4
5
6
7 **34-40.** Kallmes DF, Comstock BA, Heagerty PJ et

8 al. A randomized trial of vertebroplasty for
9 osteoporotic spinal fractures. *N Engl J Med*
10
11 2009;**361**:569-79.

12
13
14 **35-41.** Buchbinder R, Osborne RH, Ebeling PR et

15 al. A randomized trial of vertebroplasty for painful
16 osteoporotic vertebral fractures. *N Engl J Med*
17
18 2009;**361**:557-68.

19
20
21 **36-42.** Iversen T, Solberg TK, Romner B et al.

22 Effect of caudal epidural steroid or saline injection in
23 chronic lumbar radiculopathy: multicentre, blinded,
24 randomised controlled trial. *BMJ* 2011;**343**:d5278.

25
26
27 **37-43.** Cohen SP, White RL, Kurihara C et al.

28 Epidural steroids, etanercept, or saline in subacute
29 sciatica: a multicenter, randomized trial. *Ann Intern*
30
31 *Med* 2012;**156**:551-9.

32
33
34 **38-44.** Arden NK, Price C, Reading I et al. A

35 multicentre randomized controlled trial
36 of epidural corticosteroid injections for sciatica: the
37
38 WEST study. *Rheumatology* 2005;**44**:1399-406.

39
40
41 **39-45.** Valat JP, Giraudeau B, Rozenberg S et

42 al. Epidural corticosteroid injections for sciatica: a
43
44 randomised, double blind, controlled clinical trial. *Ann*
45
46 *Rheum Dis* 2003;**62**:639-43.

47
48
49 **40-46.** Pauza KJ, Howell S, Dreyfuss P et al. A

50
51
52 randomized, placebo-controlled trial of intradiscal
53
54
55
56
57
58
59
60

electrothermal therapy for the treatment of discogenic low back pain. *Spine J* 2004;**4**:27-35.

41-47. Freeman BJ, Fraser RD, Cain CM et al. A randomized, double-blind, controlled trial: intradiscal electrothermal therapy versus placebo for the treatment of chronic discogenic low back pain. *Spine* 2005;**30**:2369-77.

42-48. Kvarstein G, Måwe L, Indahl A et al. A randomized double-blind controlled trial of intra-annular radiofrequency thermal disc therapy--a 12-month follow-up. *Pain* 2009;**145**:279-86.

43-49. Olanow CW, Goetz CG, Kordower JH et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. *Ann Neurol* 2003;**54**:403-14.

44-50. Marks WJ Jr, Bartus RT, Siffert J et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. *Lancet Neurol* 2010;**9**:1164-72.

45-51. Gross RE, Watts RL, Hauser RA et al. Intrastratial transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial. *Lancet Neurol* 2011;**10**:509-19.

1
2
3
4
5
6
7 46-52. LeWitt PA, Rezai AR, Leehey MA et al.

8
9 AAV2-GAD gene therapy for advanced Parkinson's
10 disease: a double-blind, sham-surgery controlled,
11 randomised trial. *Lancet Neurol* 2011;**10**:309-19.
12
13

14 47-53. Dowson A, Mullen MJ, Peatfield R et al.

15
16 Migraine Intervention With STARFlex Technology
17 (MIST) trial: a prospective, multicenter, double-blind,
18 sham-controlled trial to evaluate the effectiveness of
19 patent foramen ovale closure with STARFlex septal
20 repair implant to resolve refractory migraine
21 headache. *Circulation* 2008;**117**:1397-404.
22
23
24
25
26

27 48-54. Hannink G, Gooszen HG, Rovers MM.

28
29 Comparison of registered and published primary
30 outcomes in randomized clinical trials of surgical
31 interventions. *Ann Surg* 2013;**257**:818-23.
32
33
34

35 49-55. Birch S. A review and analysis of placebo

36 treatments, placebo effects, and placebo controls in
37 trials of medical procedures when sham is not inert. *J*
38 *Altern Complement Med* 2006;**12**:303-10.
39
40
41

42 50-56. Bicket MC, Gupta A, Brown CH 4th et al.

43
44 Epidural injections for spinal pain: a systematic review
45 and meta-analysis evaluating the "control" injections
46 in randomized controlled trials.
47
48
49
50 *Anesthesiology*. 2013;**119**:907-31.
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 ~~51-57.~~ Kaptchuk TJ, Goldman P, Stone DA et al. Do
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
medical devices have enhanced placebo effects? *J Clin Epidemiol* 2000;**53**:786-92.

~~52-58.~~ Einvik G, Tjomsland O, Kvernebo K et al.
Preoperative expectations and clinical outcome of
transmyocardial laser treatment in patients with
angina pectoris. *Tidsskr Nor Laegeforen* 2002;**122**:2102-4.

~~53-59.~~ Turner JA, Deyo RA, Loeser JD et al. The
importance of placebo effects in pain treatment and
research. *JAMA* 1994;**271**:1609-14.

~~54-60.~~ Hróbjartsson A, Gøtzsche PC. Placebo
interventions for all clinical conditions. *Cochrane Database Syst Rev* 2010; CD003974.

~~55-61.~~ Zhang W, Robertson J, Jones AC et al. The
placebo effect and its determinants in osteoarthritis:
meta-analysis of randomised controlled trials. *Ann Rheum Dis* 2008;**67**:1716-23.

~~56-62.~~ Marchand S, Kupers RC, Bushnell MC et al.
Analgesic and placebo effects of thalamic stimulation.
Pain 2003;**105**:481-8.

~~57-63.~~ Finniss DG, Kaptchuk TJ, Miller F et al.
Biological, clinical, and ethical advances of placebo
effects. *Lancet* 2010;**375**:686-95.

~~58-64.~~ Campbell MK, Entwistle VA, Cuthbertson
BH et al. Developing a placebo-controlled trial in

surgery: issues of design, acceptability and feasibility.

Trials 2011;**12**:50. doi: 10.1186/1745-6215-12-50.

59-65. Snyder L. Review of the American College of Physicians Ethics Manual, Sixth Edition. *Ann Intern Med* 2012;**156**(1_Part_2):73-104.

60-66. Flum DR. Interpreting surgical trials with subjective outcomes: avoiding UnSPORTsmanlike conduct. *JAMA* 2006;**296**:2483-5.

61-67. Heckerling PS. Placebo surgery research: a blinding imperative. *J Clin Epidemiol* 2006;**59**:876-80.

62-68. Brim RL, Miller FG. The potential benefit of the placebo effect in sham-controlled trials: implications for risk-benefit assessments and informed consent. *J Med Ethics* 2013;**39**:703-7.

63-69. Redberg RF. Sham controls in medical device trials. *N Engl J Med* 2014;**371**:892-3.

64-70. Haahr JP, Østergaard S, Dalsgaard J et al. Exercises versus arthroscopic decompression in patients with subacromial impingement: a randomised, controlled study in 90 cases with a one year follow up. *Ann Rheum Dis* 2005;**64**:760-4.

65-71. Ketola S, Lehtinen J, Rousi T et al. No evidence of long-term benefits of arthroscopic acromioplasty in the treatment of shoulder impingement syndrome: Five-year results of a

randomised controlled trial. *Bone Joint Res* 2013;**2**:132-9.

66-72. Herrlin S, Hållander M, Wange P et al. Arthroscopic or conservative treatment of degenerative medial meniscal tears: a prospective randomised trial. *Knee Surg Sports Traumatol Arthrosc* 2007;**15**:393-401.

67-73. Yu E, Cil A, Harmsen WS et al. Arthroscopy and the dramatic increase in frequency of anterior acromioplasty from 1980 to 2005: an epidemiologic study. *Arthroscopy* 2010;**26**,Supplement:S142-7.

68-74. Vitale MA, Arons RR, Hurwitz S et al. The rising incidence of acromioplasty. *J Bone Joint Surg Am* 2010;**92**:1842-50.

69-75. Brox JI, Staff PH, Ljunggren AE et al. Arthroscopic surgery compared with supervised exercises in patients with rotator cuff disease (stage II impingement syndrome). *BMJ* 1993;**307**:899-903.

Contributors: RH initiated and planned the project and searched databases. JIB and OT assisted in developing search strategies. Article screening and data extraction was carried out by RH. Quality of data extraction and checking was carried out by JIB and OT. Statistical analysis was undertaken by RH, who also wrote the draft. OT and JIB reviewed the draft and contributed to manuscript revisions. RH is the guarantor for this study.

Funding sources: None.

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: Ethical approval was not required for this work.

Data sharing: Dataset can be obtained from Robin Holtedahl (robi-hol@online.no).

The lead author affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.




Figure 1 Flow chart of study selection in the present meta-analysis. SR = systematic review
254x190mm (300 x 300 DPI)

Review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2 Effect sizes of active treatment and sham, primary endpoints.
250x216mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3 Differences in effect size between active treatment and sham.
221x173mm (300 x 300 DPI)

ew only




Figure 4 Association between effect sizes of primary endpoints in active treatment and sham arms. Linear regression, 95% confidence intervals. N=21. 67x50mm (300 x 300 DPI)

ew only




Figure 5. Association between effect sizes of pooled secondary endpoints in active treatment and sham arms. Linear regression, 95% confidence intervals. N=19.
67x50mm (300 x 300 DPI)

ew only

Appendix table 1. Indications, postulated mechanisms and history of selected interventions

Invasive procedure / indication	Postulated mechanism	History	References
Percutaneous myocardial laser revascularization / intractable angina pectoris	Increasing the delivery of oxygenated blood to poorly perfused myocardium by creating channels	Introduced in the 1980s, initially transmyocardial route, later percutaneous route, now mostly abandoned	Schofield PM, McNab D. NICE evaluation of transmyocardial laser revascularisation and percutaneous laser revascularisation for refractory angina. <i>Heart</i> 2010;96:312-3.
Patent foramen ovale closure with STARFlex Septal Repair Implant / migraine	Improvement of migraine headache, believed to block the formation of microembolies to the brain	Developed in the 1990s for the prevention of stroke, later thought to cure migraine, never in clinical use for this indication	Gornall J. A very public break-up. <i>BMJ</i> 2010;340:c110
Arthroscopic debridement / Knee osteoarthritis	Unclear, no documented effect on arthritic process, but about 50% report relief of pain (Mosely)	Annually about 650.000 procedures in the USA in the mid-nineteens, but 39% decrease between 2000 and 2008.	Holmes R, Moschetti W, Martin B, Tomek I, Finlayson S. Effect of evidence and changes in reimbursement on the rate of arthroscopy for osteoarthritis. <i>Am J Sports Med</i> 2013;41:1039-43.
Arthroscopic meniscectomy / degenerative meniscal lesions	Unclear, relief of symptoms attributed to trimming damaged meniscus down to viable meniscus and removing fragments.	The most common orthopedic procedure in the United States, 700.000 per year, up 50% last 15 years	Kim S, Bosque J, Meehan JP, Jamali A, Marder R. Increase in outpatient knee arthroscopy in the United States: a comparison of National Surveys of Ambulatory Surgery, 1996 and 2006. <i>J Bone Joint Surg Am</i> 2011;93:994-1000. Rutjes 2012 (15)
Viscosupplementation with hyaluronic acid / Knee osteoarthritis	Improve joint lubrication by increasing HA levels in joint, in spite of short half-lives (Marshall 2000)	Many positive reports since late 1980s, including sham-controlled trials. Still widely in use	
Percutaneous vertebroplasty with PMMA cement injection / vertebral compression fracture	Increase the strength of the damaged bone and alleviate pain by preventing microfractures	Numerous observational studies and single-blind trials reported substantial clinical benefits. Slight reduction of procedure since 2009	Manchikanti L, Pampati V, Hirsch JA. Analysis of utilization patterns of vertebroplasty and kyphoplasty in the Medicare population. <i>J Neurointerv Surg</i> 2013;5:467-72.
Epidural injection of corticosteroids / Sciatica	Dampen inflammatory reaction in nerve root sheaths caused by mechanical compression	Routinely used for sciatica since the 1950s (Pinto 2012). Since 2000 the number of injections increased by about 130% in the United States and 50% in the United Kingdom	Manchikanti L, Falco FJ, Singh V, Pampati V, Parr AT, Benyamin RM, Fellows B, Hirsch JA. Utilization of interventional techniques in managing chronic pain in the Medicare population: analysis of growth patterns from 2000 to 2011. <i>Pain Physician</i> 2012;15:E969-82

1			
2			
3	Percutaneous intradiscal radiofrequency and thermocoagulation (PIRFT and IDET) / discogenic low back pain	Placement of a electrode or RF-probe into the annulus and applying heat or current to destruct nociceptors/annulus	Introduced in 1996 (IDET), later mostly abandoned
4			Helm 2012 (18)
5			
6			
7			
8	Fetal nigral transplantation / Parkinson's disease		-
9			
10			
11			
12	Gene delivery of AAV2-Neurturin / Parkinson's disease		
13		Restoration of dopamin levels in basal ganglia through injection of growth factors, GAD gene or nigral dopamine neurons	Based on animal models and a few small observational trials from about 2000. None in routine clinical use due to insufficient evidence
14			
15			
16	Transplantation of human retinal pigmental cells / Parkinson's disease		
17			
18			
19			
20			
21			
22	Insertion of AAV-GAD gene into subthalamic nucleus / Parkinson's disease		
23			
24			
25			
26			
27			
28			
29			
30			
31			
32			
33			
34			
35			
36			
37			
38			
39			
40			
41			
42			
43			
44			
45			
46			
47			
48			
49			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			

Appendix table 2. Search phrases, no of eligible studies and reasons for exclusion

Procedure	Search phrase MEDLINE	Source	Eligible studies	Excluded, ES not calculatable	Excluded, risk of bias	Included studies
PMLR	Percutaneous myocardial laser revascularization	McGillion 2010 (17)	3	-	1	Salem 2004, Leon 2005
PIRFT /IDET	Intradiscal OR annular AND thermal AND "low back pain"	Helm 2012 (18)	3	-	-	Kvarstein, 2009
Epidural injection corticosteroids	Epidural AND corticosteroid* AND sciatica	Pinto 2012 (16)	6	Karppinen 2001	1	Iversen 2011, Valat 2002, Arden 2005, Cohen 2012
Intraarticular hyaluronic acid for osteoarthritis knee	Hyaluron* OR viscosuppl* AND knee AND osteoarthritis	Rutjes 2012 (15)	48	Lundsgaard 2008, Petrella 2008	41	Petrella 2006, Chevalier 2010, Altman 2004, Pham 2004
Vertebroplasty	vertebroplast*	Shi 2012 (19)	2	-	-	Kallmes 2009, Buchbinder 2009
Invasive treatment of Parkinson's disease	transplantation OR gene OR "stem cell" AND Parkinson*	MEDLINE	6	Freed 2001, Gordon 2004, McRae 2004	-	Marks 2010, Olanow 2003, Gross 2011, LeWitt 2011
Arthroscopic debridement knee osteoarthritis	debridement AND lavage AND knee AND osteoarthr*	MEDLINE	1	-	-	Moseley 2002
Menisectomy knee	menisectomy AND knee	MEDLINE	1	-	-	Sihvonen 2013
Foramen ovale closure for migraine	"foramen ovale" AND migraine	MEDLINE	1	-	-	Dowson 2008
Number of trials			71	6	43	22

Appendix table 3. Included and excluded secondary endpoints.

Author	Included secondary endpoints	Excluded secondary endpoints (means not reported, or irrelevant)
Leon 2005		
	Time to onset angina	Improvement in angina class
	Time to onset ST depression	Radioisotope imaging
	Overall health	
	Frequency angina	
	Stability angina	
	Physical functioning	
	Disease perception	
	Treatment satisfaction	
	PCS	
	MCS	
Salem 2004		
		Proportion improved CCS angina class
		Medication usage
		Seattle Angina Questionnaire
		Left EF
		Angina stability
		Angina frequency
		Physical limitation
		Treatment satisfactioin
		Disease perception
Sihvonen 2013	WOMET score	-
	Knee pain at rest	
	Knee pain after exercise	
	15D score	
Moseley 2002		
	Arthritis Impact Scale	-
	Physical functioning Scale	
	Walking-bending	
	SF-36 Pain	
	SF-36 Physical functioning	
Pham 2004		
	Lequesne's algofunctional index	-
	Global assessment	
	% painful days	
Chevalier 2010		
	Womac C function	-
Altman 2004		
	Womac stiffness	-
	Womac physical	
Kallmes 2009		
	Pain Intensity	Opioid use

	SF-36 PCS	
	SF-36 MCS	
	Pain Frequency Index	
	Pain Bothersomeness Index	
	EQ-SD Index	
	SOF-ADL	
Buchbinder 2009		
	Roland-Morris Disability Questionnaire	-
	Life Questionnaire of the European Foundation	
	European Quality of Life-5 Dimensions	
Cohen 2012		
	Oswestry Disability Index	-
	Back pain	
Arden 2005		
	Leg pain	Analgesic use
	Back pain	
Valat 2002		
	Roland-Morris Disability Questionnaire	Dallas Pain Questionnaire
	Straight leg raising	
	Schober's test	
Iversen 2011		
		VAS back and leg pain, European Quality of Life scale
Freeman 2005		
	Modifiede Somatic Perception Questionnaire	SF-36 Mental, Role Physical/ Mental, Social Function
	Low Back Pain Outcome Score	
	SF-36 Physical Function	
	SF-36 Pain	
	SF-36 General Health	
	SF-36 Vitality	
Pauza 2003		
	VAS Pain	-
	SF-36 Physical Function	
	SF-36 Pain	
Kvarstein 2009		
	SF-36 Bodily pain	SF-36 Mental, Role Physical/ Mental, Social Function
	SF-36 Physical function	
	Oswestry Disability Index	
	SF-36 General health	
	SF-36 Vitality	
Olanow 2003		
	UPDRS motor on	Mean L-dopa dose equivalents
	UPDRS ADL off	
	UPDRS ADL on	

	% Off time day	
	% On time without dyskinesia	
Marks 2010		
	UPDRS OFF 1	Mean L-dopa dose equivalents
	UPDRS OFF 2	
	UPDRS ON 1	
	UPDRS ON 2	
	UPDRS ON 3	
	On without dyskinesia	
	On with dyskinesia	
Gross 2011		
	UPDRS ON	Mean L-dopa dose equivalents
	UPDRS ADL	
LeWitt 2011		
	UPDRS 1	Timed walking
	UPDRS2	BPRS other than taps
	UPDRS4	Dyskinesia rating scale
	Schwab and England ADL scale	Patient's diary
	BPRS taps 60 s	Clinical global impression
	Hoehan and Yahr stage	
	PDQ-39 total	
Dowson 2008		
	Headache Impact Test	-



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5, Appendix table 1
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5-6, appendix table 2
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	5-6
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2 for each meta-analysis).	6



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	5-6
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	7, fig. 1
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	7-13
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	7,9
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	10-13, fig 2,3
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	10-13
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	7,10
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	14, Fig. 4, 5
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14,15
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	15-17
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	19
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	31

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

Page 2 of 2